PRELIMINARY PROGRAMME

Type: Meet the expert session

Channel 2

09:45 – 10:45

Capacity building and civil society engagement to close policy implementation gaps - A country perspective!

Chair: Ingrid Schoeman (Johannesburg, South Africa)

The aim of a Meet the Expert session is to provide a forum for professional colleagues to discuss the state of the science and/or best practices of programmatic implementation in lung health. The session is intended to allow participants to interact with experts and gain new insights.

The presentation will focus on the development of close cooperation between different stakeholders to ensure the implementation programme and provide services to key Populations. It will also highlight why it is very important to work in different levels that help to cover all stakeholders and demonstrate capacity building in the different operational and policy level.

The following topics of capacity building will be covered for discussion:

- DOT support
- General training on centred-person approach
- Include Universal health coverage (UHC) on the agenda
- Parliament Platform to Fight Tuberculosis

What level we do it:

- City level
- National level - MOH stakeholders
- Policy level - Parliament Platform, procurement training supporting TB supply system, supply management system for PHC

09:45 – 09:50

Live introduction

Speaker: Ingrid Schoeman (Johannesburg, South Africa)

09:50 – 10:05

Capacity building and civil society engagement to close policy implementation gaps - A country perspective!

Speaker: Zahedul Islam (Kyiv, Ukraine)

10:05 – 10:45

Live Q&A
Type: Meet the expert session

Channel 3

09:45 – 10:45  
Are PLWH more prone to relapse?

Chair: Palwasha Khan (United Kingdom)

The aim of a Meet the Expert session is to provide a forum for professional colleagues to discuss the state of the science and/or best practices of programmatic implementation in lung health. The session is intended to allow participants to interact with experts and gain new insights.

Recurrent TB disease, for which HIV co-infection is a risk factor, is due to either relapse or reinfection. Distinguishing between relapse and reinfection requires a comparison of \textit{M.tuberculosis} strains isolated during the first and recurrent TB episodes using molecular-based DNA fingerprinting techniques. The limited published literature together with the association of HIV co-infection with relapse will be discussed.

09:45 – 09:50  
Live introduction

Speaker: Palwasha Khan (United Kingdom)

09:50 – 10:05  
Are PLWH more prone to relapse?

Speaker: Marian Loveday (Pretoria, South Africa)

10:05 – 10:45  
Live Q&A

Track: B3: Clinical trials and operational research for new treatments for TB (for adults and children)

Type: Symposium
Clinical experience from BPaL operational research in Asia, Africa and EEC

Chair: Salah Foraida (United States)

TB Alliance’s Nix-TB and ZeNix trials have shown that the three-drug, all-oral, 6-month BPaL regimen (bedaquiline, pretomanid and linezolid) can significantly improve success rates for highly drug-resistant TB while simplifying treatment. Following WHO guidelines to implement BPaL under operational research conditions in June 2020, at least 12 countries across Africa, Asia and Europe have commenced operational research or similar programmes. Participants of the symposium will learn about preliminary clinical experience of efficacy, safety and management of adverse events in these countries and discuss how clinical trial findings translate into field experience.

Live introduction

South Africa’s experience: Clinical experience of BPaL across Nix-TB, ZeNix and BPaL Clinical Access Program

Speaker: Pauline Howell (Johannesburg, South Africa)

Clinical experience on use of Pretomanid in modified BPaL trial in India

Speaker: Vikas Oswal (Mumbai, India)

Clinical experience from BPaL OR leading up to scale-up in Kyrgyzstan

Speaker: Atyrkul Toktogonova (Bishkek, Kyrgyzstan)

Clinical experience from BPaL OR in the Philippines

Speaker: Irene Flores (San Fernando, Pampanga, Philippines)

Clinical experience of BPaL observed in the OR in Ghana and Ecuador

Speaker: Corinne Merle (Geneva, Switzerland)

Live Q&A

Track: E2: Key affected populations: behavioural, social, and cultural issues and contexts

Type: Symposium
Towards TB-sensitive social protection programmes: understanding barriers and formulating solutions

Chair: Tauhid Islam (Philippines)
Chair: Delia Boccia (Italy)

Social protection is a key component of the WHO End TB Strategy, and of the multi-sectoral approach to ending TB. Operational evidence is uncommon and countries are just now beginning to get guidance on how to establish synergies across TB and social protection sectors. In 2022, the WHO Global Tuberculosis Programme launched the first guidance on social protection for people affected by TB to fill these knowledge and operational gaps. Building upon this guidance, a generic protocol was developed for the assessment of social protection needs and barriers experienced by TB patients. This symposium aims to provide an overview of the evidence and lessons gathered from the implementation of this protocol in a number of countries of the Western Pacific and South East Asia WHO regions. The symposium will promote the roll-out of similar initiatives in other settings and will inform actions to make social protection programmes more TB-sensitive.

11:00 – 11:05 Live introduction
11:05 – 11:17 WHO's guidance on social protection for people affected by TB
Speaker: Debora Pedrazzoli (Geneva, Switzerland)

11:17 – 11:29 Assessing the TB-sensitivity of social protection programs: a generic study protocol
Speaker: Daniel J Carter (London, United Kingdom)

11:29 – 11:41 Enhancing access to social protection for TB patients: challenges and opportunities in the Western Pacific Region
Speaker: Kalpeshsinh Rahevar (Manila, Philippines)

11:41 – 11:53 TB vulnerability assessment and scope for linkages with social protection programs: experience from Timor-Leste
Speaker: Constantino Lopes (Dili, East Timor)

11:53 – 12:20 Live Q&A
<table>
<thead>
<tr>
<th>Time</th>
<th>Channel</th>
<th>Title</th>
<th>Oral Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 12:10</td>
<td>OA-01</td>
<td>Digital innovations to improve TB control</td>
<td>Chair: Dennis Falzon (Geneva, Switzerland)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chair: Rachel Powers (Netherlands)</td>
</tr>
<tr>
<td>11:00 – 11:05</td>
<td></td>
<td>Live introduction</td>
<td></td>
</tr>
<tr>
<td>11:13 – 11:21</td>
<td>OA01-201-08</td>
<td>Transporting sputum specimen using a digitally fluent ‘Riders for Health’ software by community-based riders to ensure quality TB diagnosis in Pakistan</td>
<td>Oral Presenter: Adeel Tahir (Islamabad, Pakistan)</td>
</tr>
<tr>
<td>11:37 – 11:45</td>
<td>OA01-204-08</td>
<td>Sensitivity and specificity of computer-aided detection for presumptive TB identification by chest X-ray during active case finding activities in the Philippines</td>
<td>Oral Presenter: Nichel Marquez (Makati City, Philippines)</td>
</tr>
<tr>
<td>11:45 – 11:53</td>
<td>OA01-205-08</td>
<td>Piloting interactive voice response system-based communication with TB patients to improve bank account seeding for direct benefit transfers</td>
<td>Oral Presenter: Pranati Das (Patna, India)</td>
</tr>
<tr>
<td>12:01 – 12:09</td>
<td>OA01-207-08</td>
<td>Feasibility and quality of digital chest radiography for childhood TB diagnosis at the district level in high TB burden, low-income countries</td>
<td>Oral Presenter: Bernard Melingui (Montpellier, France)</td>
</tr>
<tr>
<td>12:09 – 12:20</td>
<td></td>
<td>Live Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
Track: C8: Global and local policies and politics, including funding and accountability

Type: Oral Abstract session

Channel 4

11:00 – 12:20  **OA-02**  
**Strengthening national-and global policies: lessons learnt**

Chair: Grania Brigden (Geneva, France)

Chair: Zahedul Islam (Kyiv, Ukraine)

11:00 – 11:05  
**Live introduction**

11:05 – 11:13  **OA02-208-08**  
**Analysis of Global Fund COVID-19 Response Mechanism 2021 (C19RM 2021) investments supporting TB activities in 20 countries**

Oral Presenter: Grania Brigden (Geneva, France)

11:13 – 11:21  **OA02-209-08**  
**Towards universal health coverage in Vietnam: lessons from the enrolment of people with TB in the National Social Health Insurance scheme**

Oral Presenter: Rachel Forse (Ha Noi, Vietnam)

11:21 – 11:29  **OA02-210-08**  
**Can effective and sustained advocacy to government increase domestic funding for TB control? Experience from Nigeria**

Oral Presenter: Sani Useni (FCT, Nigeria)

11:29 – 11:37  **OA02-211-08**  
**Integration of TB and HIV control with national AMR plans: findings of the 2021 Global Tripartite Survey**

Oral Presenter: Melvin Agbogbatey (Kumasi, Ghana)

11:37 – 11:45  **OA02-212-08**  
**A global survey of national TB programmes: policies, practices and challenges of systematic screening for TB disease**

Oral Presenter: Liana Macpherson (London, United Kingdom)

11:45 – 11:53  **OA02-213-08**  
**The “Tibay ng Dibdib” strategy: an intersectoral dialogue to engage and empower local leaders in achieving TB elimination in Tarlac, The Philippines**

Oral Presenter: Mark Darren Cacanindin (Makati, Philippines)

11:53 – 12:01  **OA02-214-08**  
**Civil society advocacy interventions to ensure sustainable funding for comprehensive TB care package in Ukraine**
Oral Presenter: Svitlana Okromeshko (Kyiv, Ukraine)

12:01 – 12:09 OA02-215-08  
Resilient community structures: cornerstone of improved TB treatment success rate despite the pandemic

Oral Presenter: Nicholas Kirirabwa (Kampala, Uganda)

12:09 – 12:20  
Live Q&A

Track: D7: HIV-TB and other HIV-related lung health

Type: Symposium

Channel 5

11:00 – 12:20 SP-03  
Advancing the TB-HIV response by addressing advanced HIV disease

Chair: Marco Vitoria (Switzerland)

Chair: Riitta Dlodlo (Zimbabwe)

Despite impressive scale-up of antiretroviral therapy and TB preventive treatment, TB still accounts for a third of all HIV deaths. The mortality rate among people with HIV on TB treatment was 11% in 2020, compared with 4% for all people with TB. People with advanced HIV disease are at a greater risk of mortality due to TB, followed by cryptococcal disease and other opportunistic infections. The WHO recommends a package of care for individuals with advanced HIV disease, which includes tools such as TB LF-LAM test and the cryptococcal antigen test, the uptake of which is critical for reducing both morbidity and mortality among people with HIV. This symposium will explore the current global data and policy for TB-HIV and advanced HIV disease and will discuss critical needs, strategies and research needs for supporting a broad, sector-wide response for reducing TB deaths among people with HIV, including those with advanced HIV disease.

11:00 – 11:05  
Live introduction

11:05 – 11:15  
Update on global TB/HIV burden and policy

Speaker: Annabel Baddeley (Geneva, Switzerland)

11:15 – 11:25  
Perspective from a survivor of advanced HIV disease and TB

Speaker: Stephen Watiti (KAMPALA, Uganda)

11:25 – 11:35  
Understanding high TB mortalities through death audits; a perspective from Siaya county, Kenya
Integration of the AHD package into TB/HIV care; case study from Malawi

Speaker: Paul Nyasulu (Lilongwe, Malawi)

Living with HIV but dying from TB: What do we need to do to get to zero deaths?

Speaker: Helen Ayles (Lusaka, Zambia)

Live Q&A

Track: B1: TB diagnostics – Operational and clinical studies
Type: Symposium
Channel 1

12:30 – 13:50  SP-04  Stool-based diagnostics: a game-changer for hard-to-diagnose populations?

Chair: Elisa Lopez-Varela (Spain)
Chair: Sabine Hermans (Netherlands)

TB diagnosis is more difficult in certain populations, mainly those with sputum paucibacillary disease such as children and people living with HIV. In order to close the case detection gap, it is important to identify approaches that provide equitable access to diagnosis. Stool-based diagnostics have gained more attention over the last few years and offer promising solutions in these populations.

The objective of this symposium is to provide the audience with a summary of the opportunities, challenges and limitations offered by stool-based TB diagnostics, and to give an overview of the recent advances in this field. Preliminary results of several ongoing studies on diagnostic stool-based techniques will be presented, along with the latest stool processing methods. The symposium will conclude with a session on future directions of stool- and other non-sputum based TB diagnostics. This will be followed by an interactive Q&A session.

12:30 – 12:35  Live introduction
12:35 – 12:45  The landscape of stool-based diagnostics and results of stool-processing studies.
Speaker: Morten Ruhwald (Geneva, Switzerland)

12:45 – 12:55
The Global Laboratory Initiative practical manual for stool testing using Xpert Ultra and lessons learned for implementation of stool testing in children and PLHIV.

Speaker: Petra de Haas (The Hague, Netherlands)

12:55 – 13:05
TB-Speed results of using stool samples for diagnosis of tuberculosis in vulnerable children.

Speaker: Maryline Bonnet (MONTPELLIER, France)

13:05 – 13:15
A novel stool DNA isolation technique for diagnosing TB disease by qPCR and M tuberculosis drug resistance by targeted sequencing.

Speaker: Alexander Kay (Houston, United States)

13:15 – 13:25
Future directions of non-sputum based TB diagnosis.

Speaker: Christoph Lange (Borstel, Germany)

13:25 – 13:50
Live Q&A

Track: TRACK A: BASIC AND TRANSLATIONAL RESEARCH
Type: Oral Abstract session
Channel 2

12:30 – 13:50
OA-03
Management of DR-TB

Chair: Kwame Shanaube (Lusaka, Zambia)

Chair: Mansa Mbenga (The Hague, Netherlands)

12:30 – 12:35
Live introduction

12:35 – 12:43
OA03-216-08
Active screening and management of adverse events during multidrug-resistant TB treatment in Dharavi, India

Oral Presenter: Varsha Puri (Mumbai, India)

12:43 – 12:51
OA03-217-08
Barriers to achieving treatment success in drug-resistant TB patients in India

Oral Presenter: Tulip Jhaveri (Jackson, United States)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session No</th>
<th>Title</th>
<th>Oral Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:51 – 12:59</td>
<td>OA03-218-08</td>
<td>High prevalence of bedaquiline resistance in difficult to treat drug-resistant TB patients in a MSF Clinic in Mumbai, India</td>
<td>Samsuddin Khan (Mumbai, India)</td>
</tr>
<tr>
<td>12:59 – 13:07</td>
<td>OA03-219-08</td>
<td>Antimicrobial and synergistic effects of MMV Pathogen Box compounds on resistant strains of M. tuberculosis</td>
<td>Eric Mensah (Pretoria, South Africa)</td>
</tr>
<tr>
<td>13:07 – 13:15</td>
<td>OA03-220-08</td>
<td>Health-related quality of life and psychological distress among TB patients after treatment for drug-susceptible TB in four African countries</td>
<td>Tembeka Sineke (Johannesburg, South Africa)</td>
</tr>
<tr>
<td>13:23 – 13:31</td>
<td>OA03-222-08</td>
<td>Treatment outcomes of longer WHO-recommended all-oral, multidrug-resistant TB regimens</td>
<td>Michael Rich (Boston, United States)</td>
</tr>
<tr>
<td>13:39 – 13:50</td>
<td></td>
<td>Live Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

Track: TRACK A: BASIC AND TRANSLATIONAL RESEARCH
Type: Oral Abstract session
Channel 3

12:30 – 13:50 **OA-04** Integrated care - how it helps in improving access
Chair: Wim Vandevelde (Cape Town, South Africa)
Chair: Mary Rosary Santiago (Makati, Philippines)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Oral Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 – 12:35</td>
<td>Live intro</td>
<td>Live introduction</td>
<td></td>
</tr>
<tr>
<td>12:35 – 12:43</td>
<td>OA04-224-08</td>
<td>Integrating TB screening and testing in COVID-19 health facilities in the city of Manila, The Philippines</td>
<td>Mary Rosary Santiago (Makati, Philippines)</td>
</tr>
<tr>
<td>12:43 – 12:51</td>
<td>OA04-225-08</td>
<td>Trends in private sector notifications in India: experience from the Joint Effort for Elimination of Tuberculosis project</td>
<td>Aakshi Kalra (Delhi, India)</td>
</tr>
<tr>
<td>12:51 – 12:59</td>
<td>OA04-226-08</td>
<td>Stakeholder engagement improved uptake and turnaround time of GeneXpert test results in Ethiopia</td>
<td>Gudeta Tibesso (Addis Ababa, Ethiopia)</td>
</tr>
<tr>
<td>13:15 – 13:23</td>
<td>OA04-229-08</td>
<td>Scale-up of 99DOTS for TB treatment supervision: intervention reach and treatment outcomes</td>
<td>Rebecca Crowder (San Francisco, United States)</td>
</tr>
<tr>
<td>13:23 – 13:31</td>
<td>OA04-230-08</td>
<td>Digital adherence monitoring of TB treatment in Ukraine: analysis of adherence levels and patient-provider communication before and during the war in Ukraine</td>
<td>Natasha Deyanova (Kyiv, Ukraine)</td>
</tr>
<tr>
<td>13:31 – 13:50</td>
<td>Live Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Track:** C7: Access to quality TB care and services  
**Type:** Oral Abstract session  
**Channel:** 4
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Oral Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 – 12:35</td>
<td>Live introduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:35 – 12:43</td>
<td>OA05-231-08</td>
<td>A combined holistic approach to increase TB case detection in Cambodia: programme monitoring data results in 2022</td>
<td>Sovannary Tuot (Phnom Penh, Cambodia)</td>
</tr>
<tr>
<td>12:51 – 12:59</td>
<td>OA05-233-08</td>
<td>Bridge TB Care: preliminary evaluation of a cross-border TB patient referral programme in Japan</td>
<td>Akihiro Ohkado (Kiyose, Japan)</td>
</tr>
<tr>
<td>12:59 – 13:07</td>
<td>OA05-234-08</td>
<td>The MOVE IT Model: increasing access to TB diagnostics for private sector patients in Tarlac City, Philippines</td>
<td>Rhodora Cruz (Makati, Philippines)</td>
</tr>
<tr>
<td>13:07 – 13:15</td>
<td>OA05-235-08</td>
<td>Convergence and divergence of TB treatment support services between TB health facilities and people with TB in two East African countries</td>
<td>Kolawole Oyediran (Arlington, United States)</td>
</tr>
<tr>
<td>13:23 – 13:31</td>
<td>OA05-237-08</td>
<td>Improving private sector access to high-quality TB diagnostic services in Gresik, East Java Province, Indonesia</td>
<td>Rini Palup (Jakarta, Indonesia)</td>
</tr>
<tr>
<td>13:31 – 13:42</td>
<td></td>
<td>Live Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
Track: B6: Active case finding and contact investigation for TB

Type: Oral Abstract session

Channel 1

15:00 – 16:20  OA-06  How could we improve contact investigation?

Chair: Nicole Salazar-Austin (Baltimore, United States)

Chair: Corinne Merle (Geneva, Switzerland)

15:00 – 15:05  Live introduction

15:05 – 15:12  OA06-239-08  Evaluation of three computer-aided diagnostic packages in household contacts for the detection of microbiologically confirmed prevalent TB, incident TB and asymptomatic disease using FDG-PET/CT

Oral Presenter: Liana Macpherson (London, United Kingdom)

15:12 – 15:19  OA06-240-08  Artificial intelligence-based chest X-ray screening to support TB case detection in the Yangon Region, Myanmar

Oral Presenter: Thet Naing Maung (Yangon, Myanmar)

15:19 – 15:26  OA06-241-08  Impacts of stool-based testing on childhood TB case notification in Kano State, northwestern Nigeria

Oral Presenter: Chinenye Igwetu (FCT, Nigeria)

15:26 – 15:33  OA06-242-08  A systematic review of the number needed to screen to detect active TB among children

Oral Presenter: Katherine Robsky (Baltimore, United States)

15:33 – 15:40  OA06-243-08  TB yield among contacts of non-pulmonary bacteriologically confirmed index patients in an urban setting of Central Uganda

Oral Presenter: Herbert Kisamba (Kampala, Uganda)

15:40 – 15:47  OA06-244-08  TB screening by mobile proprietary patent medicine vendors: impact on case-finding in high-burden areas in Osun State, Nigeria

Oral Presenter: Christian Anyomi (Osogbo, Nigeria)

15:47 – 15:54  OA06-245-08  Case yield from household contact screening of TB index patients in Karachi, Pakistan

Oral Presenter: Maria Jaswal (Karachi, Pakistan)
Mapping the relationship between tuberculosis burden and case notifications in Uganda
Speaker: Nathaniel Henry (Seattle, United States)

Live Q&A

Track: C11: Cost-effectiveness of TB and lung health interventions
Type: Oral Abstract session
Channel 2

15:00 – 16:20

OA-07 Cost and cost-effectiveness of TB interventions
Chair: Alice Zwerling (Ottawa, Canada)

15:00 – 15:05 Live introduction

15:05 – 15:13 OA07-246-08 Cost-effectiveness of decentralising paediatric TB diagnosis services in seven low-income, high TB burden countries
Oral Presenter: Marc D’Elbée (Bordeaux, France)

15:13 – 15:21 OA07-247-08 An integrated macroeconomic-health model for estimating the economic impact of TB
Oral Presenter: Tom Sumner (London, United Kingdom)

Oral Presenter: Yuli Lily Hsieh (Cambridge, United States)

15:29 – 15:37 OA07-249-08 Cost-utility analysis of artificial intelligence-powered, intensified case screening and finding strategies in two urban centres in Mega Manila, the Philippines
Oral Presenter: Jason Alacapa (Makati City, Philippines)

15:37 – 15:45 OA07-250-08 Patient-incurred costs for digital adherence technologies to support TB treatment adherence: findings from the ASCENT multi-country study
Oral Presenter: Nicola Foster (London, United Kingdom)

15:45 – 15:53 OA07-251-08 Costs incurred by individuals undergoing TB care in low-, middle- and high-income settings
Oral Presenter: Olivia D’Silva (Ottawa, Canada)

15:53 – 16:01  OA07-252-08  
Do catastrophic costs due to TB predict unfavourable TB treatment outcomes? A systematic review and meta-analysis

Oral Presenter: Paula P. Carballo-Jimenez (London, United Kingdom)

16:01 – 16:20  
Live Q&A

Track: C2: Care and treatment of TB (drug-sensitive and drug-resistant TB)

Type: Oral Abstract session

Channel 3

15:00 – 16:20  OA-08  
Causes and effects of DR-TB

Chair: Peter Ngo’la Owiti (Nairobi, Kenya)

Chair: Thi Anh Mai Pham (Stockholm, Sweden)

15:00 – 15:05  
Live introduction

15:05 – 15:13  OA08-253-08  
Determinants of catastrophic cost incurrence in households impacted by MDR-TB in Ho Chi Minh City, Viet Nam

Oral Presenter: Thi Anh Mai Pham (Stockholm, Sweden)

15:13 – 15:21  OA08-254-08  
Care for patients with multidrug-resistant TB and alcohol use disorders during the COVID pandemic

Oral Presenter: Rebecca E. Harrison (Minsk, Belarus)

15:21 – 15:29  OA08-255-08  
Burden of rifampicin-resistant TB on total TB treatment regimen costs in WHO European Region countries

Oral Presenter: Gunar Günther (Bern, Switzerland)

15:29 – 15:37  OA08-256-08  
The effect of malnutrition on sputum culture conversion and treatment outcomes among people with multidrug-resistant TB

Oral Presenter: Fasil Wagnew (Canberra, Australia)

15:37 – 15:45  OA08-257-08  
Emergence of resistance to bedaquiline in Karakalpakstan, Uzbekistan
Oral Presenter: Soe Moe (Nukus, Uzbekistan)

15:45 – 15:53 OA08-258-08 Coverage, timeliness and effectiveness of conditional cash transfers for people with drug-resistant TB in Zimbabwe

Oral Presenter: Collins Timire (London, United Kingdom)

15:53 – 16:01 OA08-259-08 The effectiveness and safety of an all-oral ultra-short regimen in China: preliminary results from the TB-TRUST study

Oral Presenter: Wenhong Zhang (Shanghai, China)

16:01 – 16:09 OA08-260-08 Can T-wave morphology abnormalities identify patients at risk of clinically relevant QT prolongation during drug-resistant TB treatment?

Oral Presenter: Gareth Hughes (London, United Kingdom)

16:09 – 16:20 Live Q&A

Track: C6: Person-centred care
Type: Symposium
Channel 4

15:00 – 16:20 SP-05 What will it take to eliminate TB stigma? Engaging communities in implementation research to develop person-centred TB stigma interventions

Chair: Ruvandhi Nathavitharana (United States)

Chair: Graeme Hoddinott (South Africa)

TB-related stigma is a critical barrier to the delivery of high-quality TB care. Despite its impact at each step of the care cascade, meaningful progress to eliminate TB stigma has been limited, in part due to the lack of person-centred approaches led by TB survivors and communities. This symposium will synthesise evidence and perspectives from diverse settings to uncover neglected drivers of stigma, and spearhead innovative actions led by key community and health worker actors supporting stigma elimination. Given the wide heterogeneity in the approaches to implementing and evaluating stigma interventions, we will learn about tools for stigma evaluation to inform implementation and scale-up. We will present insights from TB survivor peer research associates conducting community-based stigma assessments in South Africa, perspectives on empowering treatment and multi-pronged stigma interventions in Cameroon and Vietnam, and explore the intersections between stigma, caste and racism as they affect rural families in India.
15:00 – 15:05  
Live introduction

15:05 – 15:15  
Considerations for the design and evaluation of TB stigma reduction interventions  
Speaker: Amrita Daftary (York, Canada)

15:15 – 15:25  
Developing TB survivors as peer research associates for stigma research  
Speaker: Phumeza Tisile (Cape Town, South Africa)

15:25 – 15:35  
The Roots and Impacts of TB Stigma and the protective effects of Empowering treatment  
Speaker: Myriam Baiguerel (Ngaoundere, Cameroon)

15:35 – 15:45  
Stigma measurement and the evaluation of “From the Inside Out” - a self-stigma management toolkit among people with TB and MDR-TB in Vietnam  
Speaker: Lisa Redwood (Sydney, Australia)

15:45 – 15:55  
Exploring the intersections between stigma, caste and racism as they relate to TB policy and practice  
Speaker: Andrew McDowell (New Orleans, United States)

15:55 – 16:20  
Live Q&A

Track: B3: Clinical trials and operational research for new treatments for TB (for adults and children)  
Type: Symposium  
Channel 5

15:00 – 16:20  
**Evaluation of a standardised TB treatment regimen in patients with multidrug-resistant tuberculosis: STREAM Stage 2 final results**

Chair: Ya Diul Mukadi (United States)  
Chair: Oxana Rucsineanu (Moldova)

STREAM (Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-Resistant) is the first large-scale, multi-country clinical trial to examine shortened regimens for multidrug-resistant TB. Stage 1 of STREAM compared a 9-month short regimen to the then locally used long regimen (approximately 20-month) and showed that the short regimen was non-inferior to the long regimen. STREAM Stage 2
evaluated two additional regimens containing bedaquiline (one of the newest TB drugs), including a 9-month all oral regimen. This symposium will present results of the Stage 2 trial, including efficacy, safety and health economics. Presentations will be followed by a panel discussion on the results and their potential programmatic implications.

15:00 – 15:05
Live introduction

15:05 – 15:15
Overview of STREAM Stage 2 trial design and implementation
Speaker: Narendran Gopalan (Chennai, India)

15:15 – 15:25
Efficacy Results from STREAM Stage 2
Speaker: Ruth Goodall (London, United Kingdom)

15:25 – 15:35
Safety Results from STREAM Stage 2 trial
Speaker: Bruce J. Kirenga (Kampala, Uganda)

15:35 – 15:45
Health Economics Analyses
Speaker: Laura ROSU (Liverpool, United Kingdom)

15:45 – 15:55
STREAM Stage 2 Results Dissemination
Speaker: Maia Kipiani (Tbilisi, Georgia)

15:55 – 16:20
Live Q&A

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments
Type: E-posters
Channel: E-posters (accessible on-demand)

15:00 – 16:00
**EP-06**
**TB and MDR-TB treatment outcomes**

15:00 – 15:08
EP-06-651
Treatment outcomes in young children with rifampicin-resistant TB regimens including bedaquiline and delamanid: a global individual patient data meta-analysis
Oral Presenter: Maria Garcia-Cremades (San Francisco, United States)

15:08 – 15:16
EP-06-652
Clinical audit to improve quality of DR-TB treatment in Indonesia
Oral Presenter: Retno Kusuma Dewi (South Jakarta, Indonesia)
Effect of mobile phone access on the uptake of digital adherence technologies in Nigeria

Oral Presenter: Iboro Gordon (Abuja, Nigeria)

Barriers to achieving treatment success in previously treated TB patients in India: a systematic review

Oral Presenter: Tulip Jhaveri (Jackson, United States)

Uptake of 99DOTS Lite vs. video-observed therapy: lessons from the digital adherence technologies pilot study in Nigeria

Oral Presenter: Iboro Gordon (Abuja, Nigeria)

Barriers to achieving treatment success in new bacteriologically confirmed pulmonary TB patients in India: a systematic review

Oral Presenter: Tulip Jhaveri (Jackson, United States)

Impact of decentralised ambulatory drug-resistant TB care on treatment outcomes in Afghanistan

Oral Presenter: Said Mirza Sayedi (Kabul, Afghanistan)

Digital technologies to support adherence and optimise health human resource: the 99DOTS Lite experience in Uttar Pradesh, India

Oral Presenter: Muneer Mammi Kutty (New Delhi, India)

Factors that influence uptake of digital adherence technologies in Nigeria

Oral Presenter: Iboro Gordon (Abuja, Nigeria)

Developing digital adherence tool to improve TB treatment success rate in Papua, Indonesia: tool refinement process

Oral Presenter: Agnes Suyanto (Seattle, United States)

Treatment safety and outcomes in children treated for MDR/RR-TB in Papua New Guinea: a 6-year retrospective cohort

Oral Presenter: Henry Welch (Port Moresby, Papua New Guinea)
Transmission of MTBC strains in human and animal populations

Chair: Liliana Salvador (Athens, United States)
Chair: Osvaldo Frederico Inlamea (Mozambique)

Genomic analysis of Mycobacterium bovis isolates from Baja California, Mexico, and California, USA, to determine zoonotic TB infection patterns
Oral Presenter: Ehsan Suez (Athens, United States)

M. bovis in cattle from Morocco show close phylogenetic relationship to isolates from France, Spain, Portugal and Algeria
Oral Presenter: Hind Yahyaoui Azami (Athens, United States)

Isolation of M. orygis from free ranging spotted deer and blackbuck in Chennai, India
Oral Presenter: Harini Ramanujam (Chennai, India)

African buffalo samples in novel transport medium provides rapid and safe detection of M. bovis in maintenance hosts on Xpert Ultra
Oral Presenter: Wynand Goosen (Cape Town, South Africa)

Genetic profiling of M. tuberculosis complex strains from slaughtered cattle in Chennai, India
Oral Presenter: Kannan Palaniyandi (India, India)

Candidate host-directed therapeutics differentially restrict in-vitro growth of M. tuberculosis complex lineages
Oral Presenter: Leopold Djomkam Tientcheu (Banjul, Gambia)

Integrating surveillance and genomic data to reveal TB transmission clusters in Southern Taiwan
Oral Presenter: Ying-An Chen (Hsinchu, Taiwan)
Treatment of TB infection is critical to prevent progression of infection to disease. TB preventive treatment (TPT) is prioritised among people living with HIV and household contacts of TB patients. Until recently, uptake has been very poor. Recent innovations in TPT offer new pharmacological options, which allows for shorter dosing such as 12 weekly doses of rifapentine and isoniazid (3HP), to be scaled up. The United Nations High-Level Meeting (UNHLM) set ambitious targets for TPT and, with the deadline for reaching the target rapidly approaching, there is great urgency to step up action. Since 2018, the call to scale up TPT has been led by national TB programmes with the cooperation of governments, funders and implementing partners. The symposium will highlight key implementation approaches to catalyse the scale-up of 3HP in high-burden settings. Session participants will be informed of the progress in 3HP scale-up, including studies that will generate key evidence for the feasibility of implementation in high-burden settings.
Speaker: Munyaradzi Paul Mapingure (Harare, Zimbabwe)

17:40 – 17:50  
Panel with a live Q&A

Track: B3: Clinical trials and operational research for new treatments for TB (for adults and children)

Type: Oral Abstract session

Channel 3

16:30 – 17:50  
OA-10  
Clinical trials and operational research for new treatment for TB (adults and Children)

Chair: Rob Aarnoutse (Nijmegen, Netherlands)

Chair: Rovina Ruslami (BANDUNG, Indonesia)

16:30 – 16:35  
Live introduction

16:35 – 16:43  
OA10-268-08  
Pregnancy outcomes in patients treated with new and repurposed drugs for drug-resistant TB

Oral Presenter: Saman Ahmed (Karachi, Pakistan)

16:43 – 16:51  
OA10-269-08  
Monitoring for hepatotoxicity among HIV-positive patients on ART and isoniazid and rifapentine for treatment of TB infection

Oral Presenter: Salome Charalambous (Johannesburg, South Africa)

16:51 – 16:59  
OA10-270-08  
Predictors of treatment outcomes in children with rifampicin-resistant TB

Oral Presenter: Anthony Garcia-Prats (Madison, United States)

16:59 – 17:07  
OA10-271-08  
Treatment outcomes in pre-XDR-TB patients on BPaL under operational research conditions in Ukraine

Oral Presenter: Nataliia Lytvynenko (Ukraine)

17:07 – 17:15  
OA10-272-08  
Validating machine readings of QT interval during STREAM Stage 1 trial monitoring

Oral Presenter: Gareth Hughes (London, United Kingdom)

17:15 – 17:23  
OA10-273-08  
Adverse drug reactions with a novel triple-dose TB retreatment regimen: interim findings of TRIDORE
Oral Presenter: Mahamadou Bassirou Souleymane (Niamey, Niger)

17:23 – 17:31 OA10-274-08  
**Paediatric formulation of delamanid for the treatment of children with rifampicin-resistant TB in Khayelitsha, South Africa**

Oral Presenter: Chloe Maugans (Boston, United States)

17:31 – 17:50  
**Live Q&A**

Track: E2: Key affected populations: behavioural, social, and cultural issues and contexts

Type: Symposium

Channel 4

16:30 – 17:50 SP-08  
**Enabling gender equity in TB: gender-sensitive solutions in TB policy and programme**

Chair: Kerry Millington (United Kingdom)

Chair: Katherine Horton (United Kingdom)

Gender is a key social determinant of TB, affecting the risk of infection and disease, access to prevention and treatment, and social and economic impacts. Enabling gender equity in TB is critical to accelerate progress toward global targets to reduce TB morbidity and mortality and to ensure that no one is left behind. Led by the Union’s Gender Equity in Tuberculosis Working Group, this session highlights lessons learnt through personal experience, explores what gender equity in TB means both conceptually and practically, and presents findings from gender-sensitive solutions implemented in programmatic, research and civil society settings. With a panel of speakers from different sectors, working at local, regional and global levels, this session will build knowledge for an evidence-informed, person-centred response to gender disparities in TB.

16:30 – 16:35  
**Live introduction**

16:35 – 16:45  
**A personal experience with TB and a call for gender-sensitive and identity-conscious approaches to address TB inequities and injustice**

Speaker: Tenzin Kunor (London, United Kingdom)

16:45 – 16:55  
**What gender equity in TB means and could look like**

Speaker: Amrita Daftary (York, Canada)

16:55 – 17:05  
**Solutions to addressing gender inequities to accessing TB care and prevention: Findings from the Stop TB Partnership’s Communities, Rights and Gender assessments**
Speaker: Ani Herna Sari (Surabaya, Indonesia)

17:05 – 17:15

**Development and evaluation of gender-sensitive TB interventions for community settings in Nigeria**

Speaker: Chukwuebuka Ugwu (Karu, Nigeria)

17:15 – 17:25

**Where women lead, change happens: Empowering women to end the tuberculosis epidemic**

Speaker: Maurine Murenga (Nairobi, Kenya)

17:25 – 17:50

**Live Q&A**

Track: C7: Access to quality TB care and services

Type: Symposium

Channel 5

16:30 – 17:50  **SP-09**

**Designing future-ready TB diagnostic systems using diagnostic network optimisation (DNO): uptake and impact of DNO recommendations from country experiences**

Chair: Nazir Ismail (Switzerland)

Chair: Juliet Bryant (Switzerland)

Countries are increasingly applying diagnostic network optimisation (DNO), a geospatial network analytics approach, to inform national strategic planning and investments to improve access to testing and enhance utilisation of available testing capacity while preparing for future challenges. While individual country analyses may vary depending on the local context and priorities, several common use cases for DNO are emerging, such as examining opportunities to integrate testing and sample referral systems, including re-purposing of equipment procured for COVID-19 testing and targeting device procurement and placement where needed, to increase access in the most cost efficient and impactful manner. This session will explore the value of DNO and how to measure the impact of network changes. It will highlight recent initiatives to build regional capacity and experience-sharing among countries, and showcase country examples of DNO use to inform strategic and operational planning and investments in systems strengthening.

16:30 – 16:35

**Live introduction**

16:35 – 16:45

**Value for Money of investments in laboratory systems strengthening - access, efficiency and equity perspectives**
Speaker: Heidi Albert (Cape Town, South Africa)

16:45 – 16:55
Beyond DNO - measuring use of DNO outputs for country decision making and impact on diagnostic systems

Speaker: Nancy Scott (South Africa)

16:55 – 17:05
Scaling up access to molecular testing and implementation of optimal sample referral system towards achieving universal DST in ten Indian states

Speaker: Archana Beri (Delhi, India)

17:05 – 17:15
Embedding data driven decision-making for TB diagnostic systems in Pakistan’s TB National Strategic Planning processes

Speaker: Sabira Tahseen (Islamabad, Pakistan)

17:15 – 17:25
Mapping tuberculosis testing capacity in national laboratory networks of Africa: how can DNO address gaps through the ASLM LabCoP?

Speaker: Marguerite Massinga Loembé (Libreville, Gabon)

17:25 – 17:50
Live Q&A

Type: Meet the expert session

Channel 2

18:15 – 19:45
Respiratory effects of e-cigarette flavoring chemicals

Chair: Elif Dagli (Istanbul, Turkey)

The aim of a Meet the Expert session is to provide a forum for professional colleagues to discuss the state of the science and/or best practices of programmatic implementation in lung health. The session is intended to allow participants to interact with experts and gain new insights.

18:15 – 18:20
Live introduction

Speaker: Elif Dagli (Istanbul, Turkey)

18:20 – 18:35
Respiratory effects of e-cigarette flavoring chemicals

Speaker: Ilona Jaspers (Chapel Hill, United States)
18:35 – 19:15

Live Q&A

Wednesday, November 9, 2022

Type: Meet the expert session

Channel 3

09:45 – 10:45

Challenges in diagnosis and management of children and adolescents with TB

Chair: James Seddon (Cape Town, South Africa)

The aim of a Meet the Expert session is to provide a forum for professional colleagues to discuss the state of the science and/or best practices of programmatic implementation in lung health. The session is intended to allow participants to interact with experts and gain new insights.

Over 1.1 million children (0-14-year age) were affected by TB in 2020 and less than half of these were reported by national programs. The WHO has issued updated guidance and an operational handbook, on management of TB in children and adolescents, which if widely adopted and implemented, will help overcome some of the many challenges in diagnosis and management of children and adolescents, especially in high TB incidence settings.

09:45 – 09:50

Live introduction

Speaker: James Seddon (Cape Town, South Africa)

09:50 – 10:05

Challenges in diagnosis and management of children and adolescents with TB

Speaker: Farhana Amanullah (TBC, Pakistan)

10:05 – 10:45

Live Q&A
Track: B3: Clinical trials and operational research for new treatments for TB (for adults and children)

Type: Symposium

Channel 1

11:00 – 12:20  SP-10  Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis (TRUNCATE-TB Trial)

Chair: Nicholas Paton (Singapore, Singapore)

The TRUNCATE-TB ('Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis') Trial is a randomised controlled trial conducted at 18 sites in five countries (Indonesia, the Philippines, Thailand, India and Uganda) and coordinated from Singapore. The trial investigates a treatment strategy comprising an initial 2-month treatment course (using regimens combining standard and repurposed drugs intended to boost regimen sterilising efficacy), followed by close monitoring and early retreatment of relapses. In this session, we will present key data, as well as practical experiences from implementing the trial to evaluate the impact on future approaches to TB programmatic treatment, as well as on the design of future TB clinical trials.

11:00 – 11:05  Live introduction

11:05 – 11:15  Overview of the TRUNCATE-TB trial design and conduct

Speaker: Erlina Burhan (Jakarta Timur, Indonesia)

11:15 – 11:25  Efficacy and safety results from the treatment strategy

Speaker: Nicholas Paton (Singapore, Singapore)

11:25 – 11:35  Implementation of whole genome sequencing and impact on trial results

Speaker: Celina Suresh (Singapore, Singapore)

11:35 – 11:45  Pharmacokinetics and pharmacodynamics of the trial regimens

Speaker: Christopher Cousins (Singapore, Singapore)

11:45 – 11:55  Feasibility and acceptability of the 2-month treatment strategy

Speaker: Nerissa Donato (Quezon City, Metro Manila, Philippines)

11:55 – 12:20  Live Q&A
Track: TRACK C: POLICIES AND CLINICAL & PROGRAMMATIC IMPLEMENTATION

Type: Oral Abstract session

Channel 2

11:00 – 12:20  **OA-11**  Expanding active case finding in vulnerable populations

Chair: Charles Ohikhuai (Abuja, Nigeria)

Chair: Guy Marks (Sydney, Australia)

11:00 – 11:05  Live introduction

11:05 – 11:13  **OA11-275-09**  The yield from the integration of traditional birth attendants in TB case-finding in Niger State, north-central Nigeria

Oral Presenter: Charles Ohikhuai (Abuja, Nigeria)

11:13 – 11:21  **OA11-276-09**  Expanding contact investigation using the spot to tent approach: the Plateau State experience in Nigeria

Oral Presenter: Gift Lawrence (Jos, Nigeria)

11:21 – 11:29  **OA11-277-09**  Xpert Ultra in pregnancy: implications and complications

Oral Presenter: Neeta Pradhan (Pune, India)

11:29 – 11:37  **OA11-278-09**  Intensified TB case-finding for high-risk groups in Vietnam’s general hospitals using the Double X Strategy

Oral Presenter: Thu Hien Mai (Hanoi, Vietnam)

11:37 – 11:45  **OA11-279-09**  Higher number of community than household contacts among people with drug-resistant TB, South Africa

Oral Presenter: Sarita Shah (Atlanta, United States)

11:45 – 11:53  **OA11-280-09**  Facilitating and inhibiting factors for the introduction of digital adherence tools for TB care: analysis of multi-country, cluster randomised trial data

Oral Presenter: Tanyaradzwa Dube (Johannesburg, South Africa)

11:53 – 12:01  **OA11-281-09**  Engaging local non-government organisations to scale up active TB case-finding

Oral Presenter: Svitlana Okromeshko (Kyiv, Ukraine)

12:01 – 12:09  **OA11-282-09**  Increased childhood case notification through the engagement of orphanages in a hard-to-reach, high TB burden area in Anambra State, south-east Nigeria
Oral Presenter: Ugochukwu Chukwulobelu (Awka, Nigeria)

12:09 – 12:20  
Live Q&A

Track: D8: Modelling, including modelling of COVID-19: the effect of social controls, preparedness and lessons for other infectious diseases.

Type: Oral Abstract session

Channel 3

11:00 – 12:20  OA-12  
Modelling the impact of TB control strategies

Chair: Hojoon Sohn (Seoul, Korea, Republic of)

Chair: Corinne Merle (Geneva, Switzerland)

11:00 – 11:05  
Live introduction

11:05 – 11:13  OA12-283-09  
New TB vaccines in India: possible health and economic impacts of adolescent/adult vaccination with M72/AS01 E-like and BCG revaccination-like vaccines

Oral Presenter: Rebecca Clark (London, United Kingdom)

11:13 – 11:21  OA12-284-09  
The global impact and cost-effectiveness of multidrug- and rifampicin-resistant TB household contact management in children for 2019

Oral Presenter: Christopher Finn McQuaid (London, United Kingdom)

11:21 – 11:29  OA12-285-09  
Impact of reversing M. tuberculosis immunoreactivity tests on the estimated annual risk of infection

Oral Presenter: Alvaro Schwalb (London, United Kingdom)

11:29 – 11:37  OA12-286-09  
Impact and yield of TB infection screening and treatment in immigrant groups in a low-prevalence country

Oral Presenter: Hester Korthals Altes (Bilthoven, Netherlands)

11:37 – 11:45  OA12-287-09  
Improving estimates of social contact patterns for the airborne transmission of M. tuberculosis and other respiratory pathogens

Oral Presenter: Nicky McCreesh (London, United Kingdom)

11:45 – 11:53  OA12-288-09  
Factors for medication adherence among adult TB patients using digital adherence technologies
Oral Presenter: Andrew Mganga (Dar es Salaam, Tanzania)

11:53 – 12:01  OA12-289-09  Accuracy and costs of screening and diagnostic algorithms for early TB detection

Oral Presenter: Saskia Den Boon (Geneva, Switzerland)

12:01 – 12:20  Live Q&A

Track: C7: Access to quality TB care and services
Type: Symposium
Channel 4

11:00 – 12:20  SP-11  Private sector engagement to end TB in Africa

Chair: Monica Dias (Switzerland)
Chair: Azhee Akinrin (Nigeria)

The COVID-19 pandemic has slowed worldwide progress in TB control, and Africa has not been an exception. Africa reported 549,000 TB deaths in 2020. Home to 17 of the 30 high TB burden countries globally, Africa had an estimated 2.5 million cases in 2020—a quarter of the global TB burden. The 2020 milestone seeks a 35% reduction in TB deaths and 20% decline in cases. A WHO scorecard on the 2020 milestone finds that only eight countries—Botswana, Cabo Verde, Eswatini, Ethiopia, Kenya, Namibia, South Africa and Togo—met or exceeded the 20% reduction target.

In this symposium, we review the opportunities to improve access to TB services as part of strengthening the overall health systems, including regulation, financing and private sector engagement with concrete examples of PPM plans and strategies in Nigeria, South Africa, Tanzania, Lesotho, Malawi, Mozambique and Zambia.

11:00 – 11:05  Live introduction

11:05 – 11:15  Private sector engagement in TB control in Southern Africa

Speaker: Chimwemwe Chamdimba (Johannesburg, South Africa)

11:15 – 11:25  Scaling up PPM as part of the national plan to Ending TB in Nigeria

Speaker: Chukwuma Anyaike (Abuja, Nigeria)

11:25 – 11:35  Innovative approaches: Engaging private providers in TB and HIV services in South Africa

Speaker: Refiloe Matji (Pretoria, South Africa)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:35 – 11:45</td>
<td>Providing TB and HIV services to mining populations in northern Tanzania</td>
</tr>
<tr>
<td></td>
<td>Speaker: Rabia Abeid (Kahama Municipal, Shinyanga Region, Tanzania)</td>
</tr>
<tr>
<td>11:45 – 11:55</td>
<td>Access to quality TB care by engaging all healthcare providers in Africa: Investment priorities to End TB</td>
</tr>
<tr>
<td></td>
<td>Speaker: Andre Ndongsioeme (Abidjan, Cote D'Ivoire)</td>
</tr>
<tr>
<td>11:55 – 12:20</td>
<td>Live Q&amp;A</td>
</tr>
</tbody>
</table>

Track: TRACK A: BASIC AND TRANSLATIONAL RESEARCH
Type: Oral Abstract session
Channel 1

12:30 – 13:50  **OA-13**  Transmission dynamics of TB and MDR-TB

- Chair: RD Marte (Thailand)
- Chair: Stefan Niemann (Borstel, Germany)

12:30 – 12:35  Live introduction

12:35 – 12:43  OA13-290-09  Multidrug- and pre-extensively drug-resistant TB in Mozambique

- Oral Presenter: Tatiana Fernando (Maputo, Mozambique)

12:43 – 12:51  OA13-291-09  Uncertainty of hospital or community MDR-TB reinfection in patients on TB treatment in high MDR-TB burden setting

- Oral Presenter: Ecaterina Noroc (Chisinau, Moldova)

12:51 – 12:59  OA13-292-09  Identification of urban areas with high TB incidence using satellite images increases the yield of active case-finding in Kigali, Rwanda

- Oral Presenter: Mauro Faccin (Paris, France)
   Oral Presenter: Meng Li (Shanghai, China)

   Oral Presenter: Mauro Faccin (Paris, France)

   Oral Presenter: Lukas Fenner (Bern, Switzerland)

13:23 – 13:31 OA13-296-09  Longitudinal transmission of multidrug-resistant TB in urban China
   Oral Presenter: Rui Zhang (Shenzhen, China)

   Oral Presenter: Nirupa Misra (Durban, South Africa)

13:39 – 13:50 Live Q&A

Track: D1: TB epidemiology across the life course
Type: Oral Abstract session
Channel 2

12:30 – 13:50 OA-14  Prevalence, risk factors, mortality
   Chair: Nera Kadiri-Eneh (Port Harcourt, Nigeria)
   Chair: Anthony D Harries (Winchester, United Kingdom)

12:30 – 12:35 Live introduction
12:35 – 12:43 OA14-298-09  Prevalence of pulmonary TB among prisons inmates in Port Harcourt Correctional Centre, Rivers State, Nigeria
   Oral Presenter: Nera Kadiri-Eneh (Port Harcourt, Nigeria)

12:43 – 12:51 OA14-299-09  Prevalence of pre-XDR TB and XDR-TB in Indonesia per WHO new definitions
Prevalence of extrapulmonary TB in Africa: a systematic review and meta-analysis
Oral Presenter: Yusie Permata (Jakarta, Indonesia)

Sex differences in TB: disentangling exposure, access to healthcare and biological factors
Oral Presenter: Semira Hailu (Brisbane, Australia)

Predictors of mortality among patients on TB treatment in Botswana: a 10-year retrospective cohort study
Oral Presenter: Hai Nguyen (Ha Noi, Vietnam)

Programmatic data over-estimate deaths due to TB during treatment and under-estimate deaths due to TB after treatment
Oral Presenter: Keatlaretse Siamisang (Gaborone, Botswana)

Sub-clinical TB in a high TB incidence country: another call for attention
Oral Presenter: Nunurai Ruswa (Windhoek, Namibia)

Live Q&A

Digital health technologies for providing person-centred tuberculosis care: country experiences and suggested strategies for scale-up
Chair: Degu Jerene (The Hague, Netherlands)
Chair: Dennis Falzon (Geneva, Switzerland)
Digital health technologies (DHTs) have broad areas of application in TB care, including direct patient care, surveillance and monitoring, and electronic learning. The emergence of the COVID-19 pandemic created a new momentum for adopting DHTs worldwide. Some countries have used digital adherence technologies (DATs) to support treatment adherence as adjuncts to directly observed treatment (DOT) or as alternatives to DOT.
during periods when physical health facility visits were not possible. The current trends highlight the importance of DATs in ensuring person-centredness of TB care. However, there is limited data on the feasibility of the various patient support tools and how these influences patient adherence, patient and health staff satisfaction and ultimately, treatment outcomes. In this session, we will 1) review country experiences with the introduction of DATs and other point-of-care digital interventions in TB care; and 2) suggest strategies for further scale-up of these technologies.

12:30 – 12:35
Live introduction

12:35 – 12:45
Digital Adherence Technologies in TB care: overview of the experience from five countries

Speaker: Kristian van Kalmthout (The Hague, Netherlands)

12:45 – 12:55
Synthesising evidence on the impact of digital adherence technologies on health outcomes and implementation issues of employing adherence technologies, among people being treated for tuberculosis disease

Speaker: Katherine Fielding (London, United Kingdom)

12:55 – 13:05
The use of digital adherence technologies to improve TB treatment outcomes: results from the TB MATE study in South Africa

Speaker: Salome Charalambous (Johannesburg, South Africa)

13:05 – 13:15
How digital adherence technologies helped mitigate the impact of Covid-19 on TB services in Philippines

Speaker: Jason Alacapa (Makati City, Philippines)

13:15 – 13:25
Programmatic Introduction of Digital Adherence Technology in Ethiopia: A stepwise approach towards national scale up

Speaker: Taye Letta (Addis Ababa, Ethiopia)

13:25 – 13:50
Live Q&A

Track: E2: Key affected populations: behavioural, social, and cultural issues and contexts

Type: Symposium

Channel 4

12:30 – 13:50  SP-13
TB and forced migration: what do we know and what should we do?

Chair: Dominik Zenner (London, United Kingdom)
Despite their significant risk of infection and worse outcomes, TB among persons experiencing forced migration is an important, yet largely underexplored topic. This session aims to outline the epidemiology of TB among forced migrants, facilitate learning from frontline experiences among refugees in Ukraine and elsewhere, discuss practical and helpful laboratory tools and outline principles for TB detection and control in these populations.

12:30 – 12:35  
Live introduction

12:35 – 12:45  
What do we know? The epidemiology of TB among forced migrant populations.

Speaker: Dominik Zenner (London, United Kingdom)

12:45 – 12:55  
Lessons from the frontline: TB in first reception centres on the Romanian border

Speaker: Ioana Margineanu (Groningen, Netherlands)

12:55 – 13:05  
Lessons from the frontline: Afghanistan evacuation efforts

Speaker: Drew Posey (United States)

13:05 – 13:15  
Lessons from the frontline: Key challenges for TB control and elimination in the Middle East—TB in refugees, migrants and internally displaced populations

Speaker: Saiful Qayyum (Lebanon)
Speaker: Nevin Wilson (Amman, Jordan)

13:15 – 13:25  
Whizzy gadgets – the combined COVID and TB testing among refugees in Moldova and the Middle East – reporting from a joint IOM/FIND project

Speaker: Christopher Gilpin (Geneva, Switzerland)

13:25 – 13:50  
Live Q&A
Chair: Bertrand H Mbatchou Nga’hane (Douala, Cameroon)

12:30 – 12:35  Live introduction

12:35 – 12:43  LBCOV-2053-09  Evaluating the clinical impact of Nitazoxanide in patients with mild to moderate COVID-19: a randomised controlled trial (the C3-RCT)
Oral Presenter: Suzette Oelofse (Cape Town, South Africa)

Oral Presenter: Alexandra Sanchez (Rio de Janeiro, Brazil)

12:51 – 12:59  LBCOV-2080-09  Predictors of SARS-CoV-2 culture-conversion in a university-based cohort
Oral Presenter: Genevieve Dupuis (Boston, United States)

12:59 – 13:07  LBCOV-2002-09  Global opinions on SARS-CoV-2 Ag RDT self-testing policy and implementation: A cross-sectional survey
Oral Presenter: Melody Sakala (Blantyre, Malawi)

Oral Presenter: Adi Mor (Tel Aviv, Israel)

Oral Presenter: Neerja Arora (New Delhi, India)

Oral Presenter: Yana Terleeva (Kyiv, Ukraine)

13:31 – 13:50  Live Q&A

Track: G3: MPOWER for tobacco control
**Type:** Symposium

**Channel 1**

15:00 – 16:20  **SP-14**  
**Contemplating tobacco endgame in low- and middle-income countries through sustenance of tobacco control policies**

Chair: Sonu Goel (Chandigarh, India)

Chair: Gustavo Sóñora (Uruguay)

The 2021 Global Progress in Implementation of the WHO FCTC reports that progress in the implementation of the treaty was sub-optimal, especially in low- and middle-income countries. The most frequently implemented articles were those focused on reducing demand for tobacco products, such as Articles 8, 11 and 12, although even this had fallen behind the minimum targets. There are opportunities to close these gaps; however, challenges in effective implementation and enforcement of tobacco control policies remain. Tobacco endgame is a strategy for achieving the ultimate agenda of moving beyond controlling tobacco toward a tobacco-free future. This symposium will bring together global experts to share their experiences on the sustainability of tobacco control policies while arguing why it may be the right time to work towards the tobacco endgame in low- and middle-income countries.

15:00 – 15:05  
**Live introduction**

15:05 – 15:15  
**Global leadership for tobacco endgame- lessons learnt**

Speaker: Ruth Malone (United States)

15:15 – 15:25  
**Status on uptake of WHO FCTC in South-East Asia Region**

Speaker: Jagdish Kaur (New Delhi, India)

15:25 – 15:35  
**Tobacco Free Generation (TFG) End Game Strategy in Philippines- a case study**

Speaker: Heng Nung Koong (Singapore, Singapore)

15:35 – 15:45  
**Establishing Tobacco Endgame Hub: Experiences from Australia & India**

Speaker: Anne Jones (Sydney, Australia)

15:45 – 15:55  
**Establishing Tobacco Endgame Hub: Experiences from Australia & India**

Speaker: Sonu Goel (Chandigarh, India)

15:55 – 16:20  
**Live Q&A**
Track: B3: Clinical trials and operational research for new treatments for TB (for adults and children)

Type: Oral Abstract session

Channel 2

15:00 – 16:20 **OA-15** Pharmacokinetic studies for better patient care

Chair: Paolo Denti (Cape Town, South Africa)
Chair: Elin Svensson (Uppsala, Sweden)

15:00 – 15:05 Live introduction


Oral Presenter: Noha Abdelgawad (Cape Town, South Africa)

15:13 – 15:21 OA15-306-09 Pharmacokinetics of isoniazid, rifampicin and pyrazinamide in Tanzanian children on WHO-recommended dosages

Oral Presenter: Hadija Semvua (Moshi, Tanzania)

15:21 – 15:29 OA15-307-09 Pharmacokinetics of bedaquiline and delamanid in drug-resistant TB patients in India

Oral Presenter: B Jeyadeepa (Chennai, India)


Oral Presenter: Lisa Aaron (Boston, United States)

15:37 – 15:45 OA15-309-09 Pharmacokinetics of efavirenz co-administered with isoniazid and rifapentine in HIV-infected individuals

Oral Presenter: Qingluan Yang (Shanghai, China)

15:45 – 15:53 OA15-310-09 Urine colorimetry for the evaluation of isoniazid and pyrazinamide pharmacokinetics

Oral Presenter: Prakruti Rao (Charlottesville, United States)

15:53 – 16:01 OA15-311-09 Systematic assessment of clinical and bacteriological TB markers for treatment response monitoring reveals discordance and inaccuracy of symptom-based diagnosis

Oral Presenter: Bariki Mtafya (Mbeya, Tanzania)

16:01 – 16:09 OA15-312-09 The first cohort of TB patients on the BPaL regimen under operational research conditions in the Kyrgyz Republic
Tackling barriers in access to rapid molecular TB testing in remote areas: the Truenat experience

Chair: Amy Piatek (United States)
Chair: Charles Sandy (Zimbabwe)

The first-in-class near-POC rapid molecular diagnostic tool for the detection of TB and rifampicin resistance, Truenat, was recommended by the WHO in 2020 and has been widely adopted in India. Introducing New Tools Project (iNTP), a collaboration between the Stop TB Partnership and the United States Agency for International Development (USAID), is now introducing Truenat in nine additional high TB burden countries. USAID’s Infectious Disease Detection and Surveillance (IDDS) Project has been making available a package of support for its effective implementation. From the experience that will be shared by countries in the symposium, Truenat has been used in hard-to-reach areas and in community active case-finding coupled with digital chest X-ray screening. In India, the equipment has been used to test for both TB and COVID-19. The symposium will discuss the impact of Truenat testing on the diagnosis of TB and rifampicin resistance and lessons learnt in the initial implementation.

15:00 – 15:05
Live introduction

15:05 – 15:15
Truenat roll-out under the Stop TB/USAID introducing New Tools Project: filling gaps in access to testing in hard-to-reach places

Speaker: Lucy Mupfumi (Geneva, Switzerland)

15:15 – 15:25
Support package for the Truenat assay implementation at the peripheral level

Speaker: Erik Reisdorf (Rockville, MD, United States)

15:25 – 15:35
Early experience of Nigeria in implementing Truenat in peripheral health care settings and in active case-finding activities

Speaker: Nkiru Nwokoye (Abuja, Nigeria)

15:35 – 15:45
Improving patient-centered primary care in the Philippines: early experience implementing Truenat
15:45 – 15:55
Impact of the simultaneous, integrated approach to testing for TB and COVID-19 using the Truenat technology in India
Speaker: Nishant Kumar (NEW DELHI, India)

15:55 – 16:20
Live Q&A

Track: C3: Maternal and child TB
Type: Symposium
Channel 4

15:00 – 16:20
Child contact case management: promising strategies and models of care to close the policy–practice gap
Chair: Martina Casenghi (Italy)
Chair: Farhana Amanullah (TBC, Pakistan)

Progress in addressing the paediatric TB detection gap and TB preventive treatment (TPT) coverage among child and adolescent contacts has been slow. Despite supportive global- and national-level policies, as well as compelling evidence demonstrating that contact investigation interventions are a key gateway to both case-finding and identification of those in need of TPT, effective prioritisation and scale-up of contact case management approaches remains challenging in TB-endemic countries. This session will review and discuss implementation of promising strategies, adapted for delivery in high-burden settings, including experiences on decentralised and family-centred models of care recommended by the recently released WHO paediatric TB guidelines.

15:00 – 15:05
Live introduction

15:05 – 15:17
Designing Decentralized Pediatric TB Prevention Services Using a Task-sharing Approach between the TB clinic and the Health Extension Worker in Ethiopia: a qualitative study
Speaker: Nicole Salazar-Austin (Baltimore, United States)

15:17 – 15:29
Decentralized model of care for child contact investigation and TPT management in Cameroon and Uganda: CONTACT study results
Speaker: Maryline Bonnet (MONTPELLIER, France)

15:29 – 15:41
Family-centered approaches for child contact management: experiences from Brazil
Speaker: Anete Trajman (Rio de Janeiro, Brazil)

15:41 – 15:53  Supporting national roll-out of contact investigation interventions targeting families and children in Vietnam: reflections on planning, budgeting and monitoring requirements for successful implementation

Speaker: Anh Innes (Bangkok, Thailand)

15:53 – 16:20  Live Q&A

Track: E2: Key affected populations: behavioural, social, and cultural issues and contexts
Type: Symposium
Channel 5

15:00 – 16:20  SP-17  Systemic neglect of tuberculosis in indigenous peoples, the hidden pandemic

Chair: Madison Bangert (United States)
Chair: Latha Rajan (United States)

The ongoing neglect of indigenous populations throughout the world has given rise to a silent TB epidemic driven mostly by socio-economic and political issues. Even though little is known about TB in indigenous communities, it is obvious that the discrepancies between indigenous and non-indigenous populations are astounding and clear. Without clear and deliberate efforts to specifically address the failures in improving access, data collection and programme implementation, this pandemic will continue to plague our most vulnerable populations. This symposium hopes to provoke discussion about the determinants driving TB disease burden, the current state of affairs and potential solutions for TB in indigenous populations. The symposium features speakers of native descent.

15:00 – 15:05  Live introduction
15:05 – 15:15  Combating TB within Canada’s First Nation communities through culturally competent practices

Speaker: Tina Campbell (Prince Albert, Canada)

15:15 – 15:25  Addressing inequities in tuberculosis care of indigenous Venezuelans

Speaker: Julian Villalba (Rochester, United States)

15:25 – 15:35  Prevalence of pulmonary tuberculosis among the tribal populations in India
Speaker: Beena Thomas (Chennai, India)

15:35 – 15:55  Participatory Action Research to develop a better understanding of tuberculosis with Aboriginal communities in northern New South Wales, Australia, for health system change

Speaker: Sue Devlin (Lismore, Australia)

Speaker: Richard “Uncle Richard” Widders (coffs harbour, Australia)

15:55 – 16:20  Live Q&A

Track: C1: Implementation of TPT

Type: Oral Abstract session

Channel 1

16:30 – 17:50  OA-16  Implementation of TPT

Chair: Anete Trajman (Rio de Janeiro, Brazil)

Chair: Jonathon Campbell (Montreal, Canada)

16:30 – 16:35  Live introduction

16:35 – 16:43  OA16-313-09  Process and contextual factors influencing acceptance and completion of isoniazid-rifapentine (3HP) regimen for TB prevention by people living with HIV in Uganda

Oral Presenter: Joan Ritar Kasidi (Kampala, Uganda)

16:43 – 16:51  OA16-314-09  Scale-up of short-course TB preventive treatment (3HP) in high TB burden countries: the IMPAACT4TB Project

Oral Presenter: Lindiwe Tsope (Johannesburg, South Africa)

16:51 – 16:59  OA16-315-09  Evaluation of community-based latent TB detection using Mantoux tuberculin skin testing and a interferon-gamma release assay (QFT-Plus) in Vietnam
Oral Presenter: Victoria Lebrun (Hanoi, Vietnam)

16:59 – 17:07  OA16-316-09  Completion of IPT among people living with HIV on ART across differentiated service delivery models in Uganda

Oral Presenter: Levicatus Mugenyi (Kampala, Uganda)


Oral Presenter: Jinsoo Min (Seoul, Korea, Republic of)

17:15 – 17:23  OA16-318-09  Uptake and completion of TB preventive therapy in people living with HIV: a comprehensive systematic review

Oral Presenter: Svetlana Degtyareva (Moscow, Russian Federation)

17:23 – 17:31  OA16-319-09  High completion rates of 3HP among household contacts despite COVID-19 in Indonesia

Oral Presenter: Jhon Sugiharto (Jakarta, Indonesia)


Oral Presenter: Anete Trajman (Rio de Janeiro, Brazil)

17:39 – 17:50  Live Q&A

Track: B6: Active case finding and contact investigation for TB

Type: Oral Abstract session

Channel 2

16:30 – 17:50  OA-17  Active case finding: Impact and Yield

Chair: Lily Telisinghe (London, United Kingdom)

Chair: John Paul Dongo (Kampala, Uganda)

16:30 – 16:35  Live introduction

16:35 – 16:43  OA17-321-09  The effect of community-wide TB screening and HIV testing with linkage to care on TB case notification rates at the Zambian HPTN 071 trial sites
The yield of community-based TB services vs. facility-based TB services targeting high-risk groups in the Gaza and Inhambane Provinces, Mozambique, in 2021

Evaluation of integrating TB screening into the government's COVID-19 vaccination campaigns in Vietnam

Impact of active TB case-finding on case notifications in Blantyre, Malawi: a community-based cluster-randomised trial (SCALE)

Effect of community active case-finding strategies for TB detection in Cambodia

Impact of self-reported availability on potential yield of household-based TB contact investigation

Application of digital chest X-ray for TB screening tool in the Ehlanzeni and Tambo Districts, South Africa

One-stop shop TB diagnostic package for community active case-finding: a pilot intervention during the 2022 World TB Day celebrations in Nigeria

Live Q&A
Chair: Kevin Schwartzman (Montreal, Canada)
Chair: Simon Tiberi (London, United Kingdom)

16:30 – 16:35
Live introduction

16:35 – 16:43 OA18-329-09 Differences in IGRA positivity rates among close contacts exposed to M. tuberculosis lineage 1 and lineage 2 in Thailand
Oral Presenter: Reiko Miyahara (Tokyo, Japan)

16:43 – 16:51 OA18-330-09 Management of TB infection in people experiencing homelessness: a pilot study
Oral Presenter: Adam Gray (London, United Kingdom)

16:51 – 16:59 OA18-331-09 Short-course rifapentine and isoniazid preventive treatment among PLHIV in low and middle-income countries is safe and associated with high treatment completion rates
Oral Presenter: Violet Chihota (Parktown, Johannesburg, South Africa)

16:59 – 17:07 OA18-332-09 Long-term follow-up for TB prevention in contacts on 6-month isoniazid or 9-month isoniazid: an observation cohort study for effectiveness
Oral Presenter: Pei-Chun Chan (Taipei city, Taiwan)

17:07 – 17:15 OA18-333-09 A systematic review and meta-analysis of tuberculous preventive therapy adverse events
Oral Presenter: Luca Melnychuk (Montreal, Canada)

17:15 – 17:23 OA18-334-09 Determinants of losses in the TB infection cascade of care among children and adolescent contacts of pulmonary TB cases in Brazil
Oral Presenter: María Arriaga Gutiérrez (Salvador BR, Peru)

17:23 – 17:31 OA18-335-09 Household costs incurred under two TB preventive therapy service-delivery models for children in Cameroon and Uganda
Oral Presenter: Nyashadzaise Mafirakureva (Sheffield, United Kingdom)

17:31 – 17:50 Live Q&A

Track: C8: Global and local policies and politics, including funding and accountability
Type: Symposium
What the pandemic taught us: TB programming during COVID-19 and beyond

Chair: Kathy Fiekert (United Kingdom)
Chair: Farai Mavhunga (Switzerland)

The COVID-19 pandemic had a detrimental impact on health service delivery worldwide, as large parts if not all service and human resource capacity were redirected to the COVID-19 response, leaving little room for other essential services. We know that this will not be easily mitigated by simply trying to increase spending, especially as the health workforce in many places has been stretched beyond breaking point and is in no position to accommodate any further increase in workload to make up for the loss or even sustain current commitment levels, even if the money is available. As countries slowly emerge from the pandemic, country-led, evidence-based, holistic and people-centred approaches to planning and programming are more important than ever. This session will share country experiences and lessons learnt from navigating the pandemic and introduce principles and guidance for planning, including different tools to strengthen and future-proof TB strategic programming.

16:30 – 16:35 Live introduction

16:35 – 16:45 Navigating the impact of COVID-19 on TB programming – how a change in approach to information turned a pandemic into success

Speaker: Patrick Lungu (Lusaka, Zambia)

16:45 – 16:55 National TB Control Program Adaptive Plan: Experience and challenges

Speaker: Allan Fabella (Marikina City, Philippines)

16:55 – 17:05 Principles and guidance for planning a resilient TB programme - WHO tools & guidelines to support the planning process

Speaker: Soleil Labelle (Geneva, Switzerland)

17:05 – 17:15 User-experience-design & co-creation approaches to develop tailor made tools and approaches to facilitate evidence-based, country-led planning & decision making

Speaker: Egwuma Efo (The Hague, Netherlands)

17:15 – 17:25 Using the People-Centred Framework for TB programming to plan our way out of the pandemic – introducing the PCF Knowledge Hub & toolkit

Speaker: Degu Jerene (The Hague, Netherlands)

17:25 – 17:50 Live Q&A
16:30 – 17:50 SP-19

**Advancing the science of TB education and counselling to improve patient-centred TB care in low- and middle-income countries**

Chair: Rhea Lobo (Denmark)

Chair: Sheela Shenoi (United States)

The 2017 revision of the WHO TB treatment guidelines included, for the first time, a strong recommendation for health education and counselling on TB disease and treatment adherence as patient-centred strategies for enhancing treatment outcomes, albeit based on a low-to-moderate certainty of evidence. To advance the End TB pillars of patient-centred care and research, this session will draw upon behavioural science and the expertise of people living with TB to set a forward-looking agenda for TB education and counselling, with the overall goal of improving outcomes of TB treatment, including patient well-being.

16:30 – 16:35

**Live introduction**

16:35 – 16:45

**The Community Perspective: What and why we need to know?**

Speaker: Rhea Lobo (Denmark)

16:45 – 16:55

**Steps toward a patient-centered framework for TB treatment literacy interventions**

Speaker: Courtney Yuen (Boston, MA, United States)

16:55 – 17:05

**Peer Navigation to Enhance TB Education and Counseling for Individuals Diagnosed with TB and HIV-TB in Uganda**

Speaker: J. Lucian (Luke) Davis (New Haven, United States)

17:05 – 17:15

**Counselling and peer support to improve outcomes for people with DRTB/HIV in South Africa: Staff training, patient experiences, and lessons for future practice**

Speaker: Boitumelo Seepamore (Durban, South Africa)

17:15 – 17:25

**Patient education and counselling for people affected by TB: lessons learned from COVID-19 and HIV and the path forward for TB**

Speaker: Amrita Daftary (York, Canada)

17:25 – 17:50

**Live Q&A**
Thursday, November 10, 2022

Type: Meet the expert session

Channel 3

09:45 – 10:45  Non communicable respiratory diseases in children
The aim of a Meet the Expert session is to provide a forum for professional colleagues to discuss the state of the science and/or best practices of programmatic implementation in lung health. The session is intended to allow participants to interact with experts and gain new insights.

09:45 – 09:50  Live introduction

09:50 – 10:05  Non communicable respiratory diseases in children
Speaker: Adaeze Ayuk (Nigeria)

10:05 – 10:45  Live Q&A

Track: A1: Immunology - research into diagnostics and immunity

Type: Oral Abstract session
11:00 – 12:20  **OA-19** Application of the GeneXpert platform new developments

Chair: Pradeep Suri (India)

Chair: Praharshinie Rupasinghe (Antwerp, Belgium)

11:00 – 11:05  Live introduction

11:05 – 11:13  **OA19-336-10** Using Xpert MTB/XDR to facilitate conclusive, rapid fluoroquinolone resistance test results to inform MDR/RR-TB treatment

Oral Presenter: Praharshinie Rupasinghe (Antwerp, Belgium)

11:13 – 11:21  **OA19-337-10** Performance assessment of four stool processing methods using Xpert Ultra to detect TB in children

Oral Presenter: Manon Lounnas (Montpellier, France)

11:21 – 11:29  **OA19-338-10** Pooling sputum samples to extend reagent availability for Xpert MTB/RIF and Xpert Ultra testing for TB in Cameroon

Oral Presenter: Comfort Vuchas (Bamenda, Cameroon)

11:29 – 11:37  **OA19-339-10** Diagnostic accuracy of the Simple One-Step stool processing method with Xpert MTB/RIF Ultra testing of children with pulmonary TB in Ethiopia

Oral Presenter: Bazezew Yenew (Addis Ababa, Ethiopia)

11:37 – 11:45  **OA19-340-10** Using Xpert MTB/RIF Ultra for rapid and improved diagnosis of extrapulmonary TB in a clinical setting

Oral Presenter: Rumana Nasrin (Dhaka, Bangladesh)

11:45 – 11:53  **OA19-341-10** The accuracy of molecular bacterial load assay, the Xpert MTB/RIF Ultra test, smear microscopy and culture in monitoring TB treatment response

Oral Presenter: Wilber Sabiiti (St Andrews, United Kingdom)

11:53 – 12:01  **OA19-342-10** Discrepant genotypic/phenotypic rifampicin resistance results in patients tested using Xpert MTB/RIF at the Singapore TB Control Unit

Oral Presenter: Caroline Choong (Singapore, Singapore)

12:01 – 12:09  **OA19-343-10** Improving uptake of stool-based Xpert testing for childhood TB diagnosis in Imo State, Nigeria

Oral Presenter: Golibe Ugochukwu (Owerri, Nigeria)
The current definition of TB disease is still based on the presence of symptoms and bacterial detection. We know from TB prevalence surveys that roughly half of all bacteriologically confirmed TB cases have detectable disease on chest X-ray, but are asymptomatic, which does not encourage healthcare seeking. We also routinely identify ‘clinically diagnosed’ TB where bacteria cannot be detected, but the X-ray and symptoms indicate TB. Physiologically, pathology is a prerequisite for bacterial detection; by enabling airway access, it triggers symptom onset, and is the cause of post-TB sequelae. This symposium will provide new insights obtained from historical and contemporary data into how early pathology develops into classic clinical TB disease and the complexity of using symptoms as a threshold. The symposium will also address the question of treating culture-negative TB disease, both from the clinical and patient perspectives.
**What patients want: Discrete Choice Experiments for treatment of symptomatic culture negative individuals**

Speaker: Wala Kamchedzera (Blantyre, Malawi)

**Live Q&A**

**Innovative approaches and tools to find and treat missing people with TB**

Chair: Eliud Wandwalo (Switzerland)

Chair: Christian Gunneberg (Switzerland)

TB is one of the most infectious diseases, with a very high mortality. Innovative approaches have been developed and implemented in countries to address gaps and improve TB care among marginalised and vulnerable populations. Digital technological innovations have been used to create platforms and address programmatic gaps along the TB care cascade while enhancing accountability to improve access to TB services. This symposium will highlight innovative tools that have been developed and share lessons learnt from countries. These tools have helped in addressing existing barriers through TB prevention and meaningful engagement with communities through community-led monitoring. These would further enable impactful and effective TB programming to achieve global End TB targets and UN High-Level Meeting TB targets.

**Global Fund TB strategic Initiative : Finding Missing people with TB and supporting innovative approaches in countries**

Speaker: Daisy Lekharu (Geneva, Switzerland)

**Country adaptation and use of WHO Prevent TB application: Philippines' End TB App Suite**

Speaker: Ma. Clarice A. Salido (Manila, Philippines)

**Country adaptation and use of WHO Prevent TB application: experience from India and future plans**

Speaker: Ravinder Kumar (NEW DELHI, India)
11:35 – 11:45  
**OneImpact Community-led Monitoring – Innovation for action, advocacy and accountability in TB.**

Speaker: Caoimhe Smyth (Geneva, Switzerland)

11:45 – 11:55  
**OneImpact CLM Mozambique – Key Successes and Lessons Learnt**

Speaker: Helen Hallstrom (Maputo, Mozambique)

11:55 – 12:20  
**Live Q&A**

Track: C3: Maternal and child TB  
Type: Symposium  
Channel 5

11:00 – 12:20  
**SP-22 Updated WHO guidelines on the management of TB in children and adolescents**

Chair: Stephen Graham (Australia)  
Chair: Sabine Verkuijl (Switzerland)

In March 2022, the World Health Organization released new consolidated guidelines on the management of TB in children and adolescents. The guidelines include recommendations that cover the entire pathway of TB infection and disease in children and adolescents and the interface with and retention across sequential stages of care (the care cascade). This session provides background data and implementation considerations for the new recommendations on integrated treatment decision algorithms, shorter treatment for children with non-severe drug-susceptible TB, a short intensive treatment regimen for TB meningitis, and decentralised and family-centred, integrated models of care for TB case detection and prevention in children and adolescents.

11:00 – 11:05  
**Live introduction**

11:05 – 11:15  
**Development and validation of treatment-decision algorithms for children being evaluated for pulmonary tuberculosis: an individual participant data meta-analysis**

Speaker: Kenneth Gunasekera (New Haven, United States)

11:15 – 11:25  
**Assessing severity of disease to determine treatment duration for children and adolescents with drug-susceptible TB, experiences from the SHINE trial**

Speaker: Chishala Chabala (Lusaka, Zambia)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:25 – 11:35 | Experiences with the short intensive treatment regimen for children with TB meningitis  
Speaker: Regan Solomons (Cape Town, South Africa) |
| 11:35 – 11:45 | Implementing decentralized and integrated TB services for children under 5 years: evidence and lessons learned generated by the INPUT study in Cameroon  
Speaker: Boris Tchounga (Yaoundé, Cameroon) |
| 11:45 – 11:55 | Civil society perspectives on implementation of the new recommendations on child and adolescent TB  
Speaker: Amir Khan (Islamabad, Pakistan) |
| 11:55 – 12:20 | Live Q&A                                                                 |

Track: A4: Imaging and image analysis for diagnostics  
Type: Oral Abstract session  
Channel 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:30 – 13:50 | OA-20 Developments in tuberculosis imaging  
Chair: Veronique Suttels (Lausanne, Switzerland) |
| 12:30 – 12:35 | Live introduction |
Oral Presenter: Veronique Suttels (Lausanne, Switzerland) |
| 12:43 – 12:51 | OA20-345-10 Clinical outcomes over time in TB prevalence survey participants with a high CAD score but no microbiologically confirmed TB in Zambia and South Africa  
Oral Presenter: Maria Ruperez (London, United Kingdom) |
| 12:51 – 12:59 | OA20-346-10 Pulmonary TB screening based on radiological signs on chest X-ray using Deep models  
Oral Presenter: Geoffrey Raposo (Martigny-Ville, Switzerland) |
In recent years, the tobacco industry has invested in COVID vaccine development, medicinal cannabis plants and respiratory technology. The industry openly announced its pharmaceutical transformation, claiming to be an expert in respiratory delivery systems. While still causing the death of millions through deadly tobacco products, the industry demands to take part in political decision-making as members of the pharmaceutical sector. As classical cigarettes are no longer popular among the new generation, the industry is in the process of developing cannabis products both for medical and recreational use. The public health community needs to solve the ethical and legal aspects of this transformation. The session will discuss a) new cannabis and nicotine products, b) the pharmaceutical transformation of the industry, c) the response of medical organisations, and d) the need for consensus on a code of conduct.
12:30 – 12:35  Live introduction

12:35 – 12:47  The “changing face” of the tobacco industry  
Speaker: Debby Sy (Bkk, Thailand)

12:47 – 12:59  Vaping: Tobacco Industry is destroying the future of children  
Speaker: Andrew Bush (London, United Kingdom)

12:59 – 13:11  Can the industry turn into a medical company?  
Speaker: Elif Dagli (Istanbul, Turkey)

13:11 – 13:23  Healthwashing; the role of medical societies

13:23 – 13:50  Live Q&A

Track: C2: Care and treatment of TB (drug-sensitive and drug-resistant TB)  
Type: Symposium  
Channel 4

12:30 – 13:50  SP-24  
Practical considerations for implementing and scaling up a new DR-TB regimen: experience from early BPaL-adopting countries  
Chair: Suvanand Sahu (Switzerland)  
Chair: Corinne Merle (Geneva, Switzerland)

Following WHO Guidelines to implement the BPaL regimen (bedaquiline, pretomanid and linezolid) under operations research (OR) conditions in June 2020, several countries began implementing the regimen and scaling up access. As a three-drug, all-oral, 6-month treatment, the BPaL regimen simplifies therapy compared to the longer 18-month, 7–9 drug treatments for pre-extensively drug-resistant TB. Implementing BPaL required countries to prepare and execute plans deliberately and systematically. The first OR commenced within 5 months of the WHO guidelines, with several others following shortly thereafter. There are currently more than 12 ORs underway and three countries have developed sufficient experience to begin scaling up the BPaL regimen under OR conditions. Additionally, since 2019, a vast majority of DR-TB caseload in the United States has been treated with BPaL following US FDA approval. Symposium participants will learn from implementation experience of early BPaL adopters about best practices for rapidly and effectively deploying novel DR-TB regimens.

12:30 – 12:35  Live introduction
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:35 – 12:45| A practical implementation guide for programmatic introduction of the BPaL regimen  
Speaker: Suzanne Staples (Durban, South Africa) |
| 12:45 – 12:55| Paving the way: Learnings from Ukraine, the first country to implement BPaL outside clinical trials and proceed to scale-up  
Speaker: Yuriy Gamazin (Ukraine) |
| 12:55 – 13:05| BPaL introduction and scale-up plans for Tajikistan  
Speaker: Azamova Shahnoza (Tajikistan) |
| 13:05 – 13:15| Implementing a novel regimen in a large country with diverse settings and considerations: learnings from South Africa  
Speaker: Norbert Ndjeka (Pretoria, South Africa) |
Speaker: Connie Haley (Gainesville, United States) |
| 13:25 – 13:50| Live Q&A |

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments  
Type: Oral Abstract session  
Channel 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:30 – 13:50| **OA-21** Susceptibility resistance  
12:30 – 12:35 Live introduction  
12:35 – 12:43 OA21-351-10 The thin-layer agar method allows a rapid determination of the minimal inhibitory concentration for bedaquiline  
Oral Presenter: Isabel Cuella-Martin (Antwerp, Belgium) |
| 12:43 – 12:51| OA21-352-10 Phenotypic DST profile, genetic determinants of drug resistance and treatment outcomes of newly diagnosed pulmonary TB patients in two TB centres, Myanmar  
Oral Presenter: Wah Wah Aung (Yangon, Myanmar) |
12:51 – 12:59  OA21-353-10  Evaluation of Meltpro® MTB/PZA to detect pyrazinamide susceptibility among patients with rifampicin-resistant TB
Oral Presenter: Feng Sun (Shanghai, China)

12:59 – 13:07  OA21-354-10  Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance
Oral Presenter: Senamile Ngema (Durban, South Africa)

Oral Presenter: Linrui Tang (New York, United States)

Oral Presenter: Yohannes Babo (Addis Ababa, Ethiopia)

13:23 – 13:31  OA21-357-10  Implementation and comprehensive molecular drug resistance profile analysis derived from whole-genome sequencing of M. tuberculosis in Kazakhstan
Oral Presenter: Nurlan Takenov (Almaty, Kazakhstan)

13:31 – 13:50  Live Q&A

Track: DS: Infection prevention and control of TB (and other airborne diseases affecting lung health e.g. SARS CoV-2)
Type: Symposium
Channel 1

15:00 – 16:20  SP-25  Airborne infection prevention and control: the key to preventing the next pandemic
Chair: Sujata Baveja (India)
Chair: Yuhong Liu (China)
Healthcare workers continue to be at greater risk of developing TB and COVID-19 than the general population. In several countries, healthcare facilities have become TB and COVID-19 transmission zones because of inadequate airborne infection prevention and control (IPC) practices. Airborne IPC practices alone are not enough to limit the transmission of TB and COVID-19 in health settings; however, implementing these results in safer outcomes to protect healthcare workers without excessive costs. In resource-limited settings, using simple workable strategies will produce safer work environments for healthcare workers.

In this session, we will focus on workplace risks of infections to healthcare workers in the area of TB and COVID-19; show how to prevent transmission of airborne pathogens; address risks, and provide practical implementable solutions to reduce risk and disease transmission; improve surveillance, provide the logistics required and implement behaviour change needed to better protect the health of healthcare workers.

15:00 – 15:05  
Live introduction

15:05 – 15:15  
IPC the convergence for TB and COVID-19: an overview  
Speaker: Lindiwe Mvusi (Pretoria, South Africa)

15:15 – 15:25  
Prioritizing & managing IPC risks in health facilities in the era of TB & COVID-19  
Speaker: Anita Rani Kansal (New Delhi, India)

15:25 – 15:35  
Engineering considerations for TB and COVID-19: theory and practice  
Speaker: Isabel Ochoa (Peru)

15:35 – 15:45  
Commodities supply & management for a successful IPC programme  
Speaker: Gidado Mustapha (The Hague, Netherlands)

15:45 – 15:55  
Airborne IPC interventions based on rapid turnaround time for COVID-19 and TB diagnosis to reduce transmission  
Speaker: Grigory Volchenkov (Vladimir, Russian Federation)

15:55 – 16:20  
Live Q&A

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: Oral Abstract session

Channel 2

15:00 – 16:20  
OA-22  
Tuberculosis sequencing and resistance
Chair: Paolo Miotto (Milano, Italy)

Chair: Juliano Timm (New York, United States)

15:00 – 15:05  Live introduction

15:05 – 15:13  OA22-358-10  Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four pretomanid-containing clinical trials
Oral Presenter: Juliano Timm (New York, United States)

15:13 – 15:21  OA22-359-10  Identification and drug resistance prediction of M. tuberculosis directly from sputum samples
Oral Presenter: Michelle Wuzinski (Winnipeg, Canada)

15:21 – 15:29  OA22-360-10  A bioinformatics and artificial intelligence algorithm for determining sequencing-based drug resistance of M. tuberculosis
Oral Presenter: Ritu Singhal (New Delhi, India)

Oral Presenter: Sheng-Han Wu (Taipei, Taiwan)

15:37 – 15:45  OA22-362-10  Routine M. tuberculosis drug susceptibility prediction using whole-genome sequencing, supplemented by phenotypic testing
Oral Presenter: Rina de Zwaan (Bilthoven, Netherlands)

15:45 – 15:53  OA22-363-10  Sequencing reveals a high proportion of pyrazinamide resistance among presumed multidrug-resistant TB patients in India
Oral Presenter: Uma Devi Kr (Chennai, India)

15:53 – 16:01  OA22-364-10  Evolution of M. tuberculosis in people with drug-resistant TB who fail treatment
Oral Presenter: Azraa Khan (Durban, South Africa)

16:01 – 16:20  Live Q&A

Track: B1: TB diagnostics – Operational and clinical studies

Type: Oral Abstract session
Channel 3

15:00 – 16:20  **OA-23**  
**Innovation in tuberculosis diagnostics**

Chair: Sanjana Gupta (Palo Alto, United States)
Chair: Tim Rodwell (San Diego, United States)

15:00 – 15:05  
**Live introduction**

15:05 – 15:13   **OA23-365-10**  
*A nine-gene blood-based signature meets the WHO target product profiles for the diagnosis of active TB and prediction of progression from latent to active disease*

Oral Presenter: Sanjana Gupta (Palo Alto, United States)

15:13 – 15:21   **OA23-366-10**  
*Point-of-care C-reactive protein-based TB triage testing for people with and without HIV: a multi-country diagnostic accuracy study*

Oral Presenter: Danaida Marcelo (Dasmariñas City, Philippines)

15:21 – 15:29   **OA23-367-10**  
*Nasopharyngeal aspirate and stool sample collection for the detection of TB in children in six low-income and high TB incidence countries*

Oral Presenter: Guillaume Breton (Paris, France)

15:29 – 15:37   **OA23-368-10**  
*Novel urine specimen processing technology improves the sensitivity of lateral flow urine lipoarabinomannan assay*

Oral Presenter: Andrew Codlin (Ha Noi, Vietnam)

15:37 – 15:45   **OA23-369-10**  
*Identification of host protein biomarker signatures for diagnosis and treatment monitoring of TB infection in Madagascar using a multiplex assay*

Oral Presenter: Mame Diarra Bousso Ndiaye (Antananarivo, Madagascar)

15:45 – 15:53   **OA23-370-10**  
*Yield of bacteriologically confirmed pulmonary TB in the private sector in a high-TB burden district of South Africa*

Oral Presenter: Keeren Lutchminarain (Durban, South Africa)

15:53 – 16:01   **OA23-371-10**  
*Feasibility and performance of the PAANTHER treatment decision algorithm in HIV-infected children with presumptive TB in the TB-Speed HIV study*

Oral Presenter: Clémentine Roucher (Bordeaux, France)

16:01 – 16:20  
**Live Q&A**
Track: C7: Access to quality TB care and services

Type: Symposium

Channel 4

15:00 – 16:20 SP-26  The effect of the COVID-19 pandemic on quality and pathways to TB care in India, Indonesia and Nigeria

Chair: Guy Stallworthy (United States)

Chair: William Wells (United States)

India, Indonesia and Nigeria rank first, third and sixth, respectively, in terms of high TB burden countries worldwide, and in all three countries, the majority of people with TB symptoms seek care with private providers. COVID-19 has reversed years of progress in the TB response due to restrictions, lockdown protocols and healthcare system overload. Since the pandemic, it is unclear how the care-seeking pathway and diagnostic and treatment referral patterns of individuals with TB have changed, and what implications these changes will have for post-pandemic health system recovery.

This symposium will present data from the COVID-19 effect on Tuberculosis (COVET) project, with study sites in Bandung, Indonesia; Mumbai and Patna, India; and Lagos and Kano, Nigeria. Multiple surveys were used to investigate the TB care pathways of individuals newly diagnosed with TB and the providers’ perspectives using a standardised patient study.

15:00 – 15:05  Live introduction

15:05 – 15:17  Quality of care for individuals with chest symptoms in Patna before and during the COVID-19 pandemic in India

Speaker: Benjamin Daniels (Washington, United States)

15:17 – 15:29  Are individuals with TB symptoms having more complex pathways to care in Indonesia since the pandemic

Speaker: Lavanya Huria (Montreal, Canada)


Speaker: Charity Oga-Omenka (Waterloo, Ontario, Canada)

15:41 – 15:53  Implications and recommendations for TB care

Speaker: Bony Wiem Lestari (Bandung, Indonesia)

15:53 – 16:20  Live Q&A
Track: E2: Key affected populations: behavioural, social, and cultural issues and contexts

Type: Symposium

Channel 5

15:00 – 16:20  **SP-27 Mobilising communities against TB**

Chair: Robert Horsburgh (United States)

Chair: Ingrid Schoeman (Johannesburg, South Africa)

TB not only affects individuals, but also communities. In order to reduce the TB burden in a community, it is essential to engage community leaders and mobilise the entire population in the effort to reduce the TB burden. Important initiatives include stigma reduction, identification and engagement of key opinion leaders and devising convenient and acceptable strategies for finding and treating community members affected with TB. Successful programmes are those that enlist community help in the effort to become TB-free. In such situations, community members become invested in the goal, and participation becomes a desirable activity that is rewarded with public approval.

15:00 – 15:05  **Live introduction**

15:05 – 15:17  **Community Programs to reduce TB Stigma in India**

Speaker: Chapal Mehra (India)

15:17 – 15:29  **Where does the community stand in the collective effort to combat TB in high burden settings?**

Speaker: Thu Anh (Hanoi, Vietnam)

15:29 – 15:41  **Community engagement for implementation research in Lima, Peru**

Speaker: Daniela Puma (Lima, Peru)

15:41 – 15:53  **Educating My Community**

Speaker: Goodman Makanda (Western cape, South Africa)

15:53 – 16:20  **Live Q&A**

Track: late-breaker
Type: Oral Abstract session

Union live

15:00 – 16:20  LBST  RIT/JATA student late-breaker on lung health

Chair: Carrie Tudor (United States)
Chair: Norio Yamada (Japan)

15:00 – 15:05  Live introduction
15:05 – 15:20  LB02-2050-10  How well the asthma knowledge among outpatient Bangladeshi asthmatics?
Oral Presenter: Nahlah Elkudssiah Ismail (Puchong, Malaysia)

15:20 – 15:35  LB02-1700-10  Identifying best practices for offering telephonic adherence support to people on treatment for TB or HIV and/or TPT: A scoping review
Oral Presenter: Zinhle Mtwane (Durban, South Africa)

15:35 – 15:50  LB02-1737-10  Age-associated tissue-specific amino acid and immune cell dysregulation in Mycobacterium tuberculosis-infected C57BL/6 mice
Oral Presenter: Falak Pahwa (New Delhi, India)

15:50 – 16:05  LB02-1841-10  Development of a costing and cost-effectiveness framework for comparing use of TST and IGRA among high TB-burden populations
Oral Presenter: Jade Tso (Sacramento, United States)

16:05 – 16:20  Live Q&A

Track: C6: Person-centred care
Type: Oral Abstract session
Channel 1

16:30 – 17:50  OA-24  Person-centred care: how new technologies can support
16:30 – 16:35 Live introduction

16:35 – 16:43 OA24-372-10 Client-centred interventions to reach persons at high risk of TB: lessons from Kampala, Uganda
Oral Presenter: Mwikiriize Mubarak (Kampala, Uganda)

16:43 – 16:51 OA24-373-10 Improved TB treatment outcomes by buddying TB patients with community-based volunteers in 24 high TB burden districts, Zambia
Oral Presenter: Lisa Mueller (United States)

16:51 – 16:59 OA24-374-10 Designing for diversity in patient preferences for digital adherence products across urban and rural India
Oral Presenter: Devika Kapadia (Mumbai, India)

16:59 – 17:07 OA24-375-10 Decentralisation of ECG monitoring using a mobile device (KardiaMobile-6L) for patients on drug-resistant TB treatment in an outpatient setting
Oral Presenter: Mansa Mbenga (The Hague, Netherlands)

17:07 – 17:15 OA24-376-10 Patient acceptability of using medication monitors and experience of a differentiated care approach for TB treatment adherence in South Africa
Oral Presenter: Rachel Mukora (Johannesburg, South Africa)

17:15 – 17:23 OA24-377-10 Developing a method to incorporate multidimensional wealth indices into analysis of TB patient cost surveys
Oral Presenter: Anna Carlqvist (Stockholm, Sweden)

17:23 – 17:31 OA24-378-10 Integrated management of childhood illness: a potential platform to identify the missing under-five children with TB in Bangladesh
Oral Presenter: Senjuti Kabir (Dhaka, Bangladesh)

17:31 – 17:50 Live Q&A

Track: D8: Modelling, including modelling of COVID-19: the effect of social controls, preparedness and lessons for other infectious diseases.

Type: Symposium
Full value assessment of novel TB vaccines: combating pandemics today and tomorrow

Chair: Matteo Zignol (Italy)
Chair: Rhea Lobo (Denmark)

Novel TB vaccines are urgently needed. However, their development is expensive and time-consuming, and there is a lack of market incentives for diseases affecting LMICs. This symposium will present critical new data on the broader health and economic impacts of novel TB vaccines, and how this evidence supports Indian, South African and global-level TB vaccine financing and introduction. This evidence can be used by governments, multinational partners and advocates to make the case for quicker development, adoption and implementation of novel TB vaccines. This symposium is closely in line with the conference theme: “Combating pandemics: today and tomorrow”. Vaccines are one of the most impactful and cost-effective health technologies, and TB can only be combatted successfully with new, safe and effective TB vaccines.

16:30 – 16:35 Live introduction

16:35 – 16:45 Health impacts of novel TB vaccines in low- and middle-income countries

Speaker: Rebecca Clark (London, United Kingdom)

16:45 – 16:55 Economic and broader impacts of novel TB vaccines in low- and middle-income countries: a modelling study

Speaker: Allison Portnoy (Boston, United States)

16:55 – 17:05 How will the Full Value Assessment of Novel TB Vaccines support Indian country level decision making?

Speaker: Kirankumar Rade (Delhi, India)

17:05 – 17:15 Implications of the Full Value Assessment of Novel TB Vaccines for South African country level decision making

Speaker: Salome Charalambous (Johannesburg, South Africa)

17:15 – 17:25 Implications of the Full Value Assessment of Novel TB Vaccines for global level TB vaccine decision making

Speaker: Marta Tufet (Geneva, Switzerland)

17:25 – 17:50 Live Q&A
Track: A1: Immunology - research into diagnostics and immunity

Type: Oral Abstract session

Channel 3

16:30 – 17:50  OA-25  Models and TB immunity

Chair: Carlton Evans (Peru)
Chair: Yiran Liu (Stanford, United States)

16:30 – 16:35  Live introduction
16:35 – 16:43  OA25-379-10  Blood transcriptional correlates of vaccine-induced protection against TB in macaques
Oral Presenter: Yiran Liu (Stanford, United States)

16:43 – 16:51  OA25-380-10  Harnessing machine learning to eliminate TB (HaMLET)
Oral Presenter: Scott Lee (Atlanta, United States)

16:51 – 16:59  OA25-381-10  TIGIT marks potent effector CD8+ T-cells in patients with active TB
Oral Presenter: Jingyu Zhou (Shanghai, China)

16:59 – 17:07  OA25-382-10  The presence of indoleamine 2,3-dioxygenase in an aerosol-mediated infant rhesus macaque TB model
Oral Presenter: Katherine Turnbull (Covington, United States)

17:07 – 17:15  OA25-383-10  M. tuberculosis infection among children and adolescent contacts of pulmonary TB cases in Brazil
Oral Presenter: María Arriaga Gutiérrez (Salvador BR, Peru)

17:15 – 17:23  OA25-384-10  Pre-diagnosis and pre-treatment loss to follow-up of presumptive TB patients presenting at selected health facilities in Uganda
Oral Presenter: Rebecca Nuwematsiko (Kampala, Uganda)

17:23 – 17:31  OA25-385-10  Improving clients’ satisfaction by reducing intra-laboratory turnaround time at the TB Reference Laboratory in Douala, Cameroon, March–April, 2022
Oral Presenter: Teyim Pride Mbuh (Douala, Cameroon)

17:31 – 17:50  Live Q&A
**COPD among Non-smokers: A distinct endotype?**

The aim of a Meet the Expert session is to provide a forum for professional colleagues to discuss the state of the science and/or best practices of programmatic implementation in lung health. The session is intended to allow participants to interact with experts and gain new insights.

**18:15 – 18:20**
*Live introduction*

**18:20 – 18:35**
*COPD among non-smokers: a distinct endotype?*

Speaker: Siddharthan Trishul (Miami, United States)

**18:35 – 19:15**
*Live Q&A*

---

**The importance of nutrition support during TB treatment**

Chair: Niesje Jansen (The Hague, Netherlands)

The aim of a Meet the Expert session is to provide a forum for professional colleagues to discuss the state of the science and/or best practices of programmatic implementation in lung health. The session is intended to allow participants to interact with experts and gain new insights.

**18:15 – 18:20**
*Live introduction*

Speaker: Niesje Jansen (The Hague, Netherlands)
18:20 – 18:35  The importance of nutrition support during TB treatment - 1
Speaker: Ingrid Schoeman (Johannesburg, South Africa)

18:35 – 18:50  The importance of nutrition support during TB treatment - 2
Speaker: Pranay Sinha (Boston, United States)

18:50 – 19:15  Live Q&A

Type: Meet the expert session
Channel 2

09:45 – 09:50  Live introduction
Speaker: Rovina Ruslami (BANDUNG, Indonesia)

09:45 – 10:45  Clinical management of TB meningitis and other manifestations of CNS tuberculosis
Chair: Rovina Ruslami (BANDUNG, Indonesia)

The aim of a Meet the Expert session is to provide a forum for professional colleagues to discuss the state of the science and/or best practices of programmatic implementation in lung health. The session is intended to allow participants to interact with experts and gain new insights.

09:45 – 09:50  Live introduction
Speaker: Rovina Ruslami (BANDUNG, Indonesia)

09:50 – 10:05  Clinical management of TB meningitis and other manifestations of CNS tuberculosis
Speaker: Reinout van Crevel (Netherlands)
10:05 – 10:45
Live Q&A

Track: D6: Health and well-being post TB
Type: Oral Abstract session
Channel 1

11:00 – 12:20
OA-26 Life after TB

Chair: Toyin Togun (Fajara, Gambia)
Chair: Sumona Datta (Liverpool, United Kingdom)

11:00 – 11:05
Live introduction

11:05 – 11:13
OA26-386-11 Life events and TB

Oral Presenter: Sumona Datta (Liverpool, United Kingdom)

11:13 – 11:21
OA26-387-11 Economic burden of TB during treatment and after treatment in India

Oral Presenter: Susmita Chatterjee (New Delhi, India)

11:21 – 11:29
OA26-388-11 Respiratory impairment and disability after successful treatment of pulmonary TB: a systematic review and meta-analysis

Oral Presenter: Josh Taylor (Montreal, Canada)

11:29 – 11:37
OA26-389-11 Tracking of lung function during anti-TB treatment in adolescents with pulmonary TB

Oral Presenter: Marieke M. van der Zalm (Cape Town, South Africa)

11:37 – 11:45
OA26-390-11 One year on: the impact of COVID-19 and government restrictions on healthcare-seeking behaviour, financial security and mental health of TB survivors

Oral Presenter: Nelly Jinga (Johannesburg, South Africa)

11:45 – 11:53
OA26-391-11 Risk of TB recurrence and mortality associated with smoking among people with TB: a systematic review and meta-analysis
Oral Presenter: Aishwarya Vidyasagaraj (York, United Kingdom)

11:53 – 12:01 OA26-392-11 Tele-pulmonary rehabilitation experiences of post-COVID patients
Oral Presenter: Asli Gorek Dilektasli (Turkey)

12:01 – 12:20 Live Q&A

Track: C10: COVID-19: policies and clinical implementation
Type: Oral Abstract session
Channel 2

11:00 – 12:20 OA-27 Impact of Covid-19 on TB and other health services
Chair: Flor Lucia Gonzalez (Basel/Luzern, Switzerland)
Chair: David Dowdy (Baltimore, United States)

11:05 – 11:13 Live introduction
11:05 – 11:13 OA27-393-11 Integrated SARS-CoV-2, TB and HIV testing during 2 years of pandemic: a pragmatic care model in two rural districts in Lesotho
Oral Presenter: Flor Lucia Gonzalez (Basel/Luzern, Switzerland)

11:13 – 11:21 OA27-394-11 Post-COVID, a risk group for targeted TB case-finding: programmatic experience from Tamil Nadu, India
Oral Presenter: Raghavan Parthasarathy (Chennai, India)

Oral Presenter: Rajendra Basnet (Kathmandu, Nepal)

Oral Presenter: Vivian Ibeziako (Enugu, Nigeria)

11:37 – 11:45 OA27-397-11 Effectiveness of vaccination in preventing COVID-19 reinfection: a retrospective, population-based cohort study
Oral Presenter: Huong Chu (Providence, United States)
11:45 – 11:53  OA27-398-11  COVID measures to curb emerging trends of tobacco use: case study from Chandigarh, India
Oral Presenter: Opinder Preet Kaur Gill (Mohali, India)

11:53 – 12:01  OA27-399-11  Previous TB as a predictor of mortality among mine workers diagnosed with COVID-19
Oral Presenter: Batsirai Murapa (Johannesburg, South Africa)

12:01 – 12:09  OA27-400-11  Effectiveness and durability of protection from infection-acquired immunity and vaccination against Omicron infection, hospitalisation and death in Ontario, Canada
Oral Presenter: Shishi Wu (Toronto, Canada)

12:09 – 12:20  Live Q&A

Track: C6: Person-centred care
Type: Oral Abstract session
Channel 3

11:00 – 12:20  OA-28  Find and treat; the hurdles and how to overcome
Chair: Affolabi Dissou (Cotonou, Benin)
Chair: Joseph Omame (Bauchi, Nigeria)

11:00 – 11:05  Live introduction

11:05 – 11:13  OA28-401-11  Changing the narrative in public-private mix (PPM) case-finding: impact of intensified sensitisation and demand creation by PPM providers in Bauchi, Nigeria
Oral Presenter: Joseph Omame (Bauchi, Nigeria)

11:13 – 11:21  OA28-402-11  Screening for TB, COVID-19 and mental health conditions in juvenile detention centres in Lima, Peru
Oral Presenter: Daniela Vanesa Puma Abarca (Lima, Peru)

Oral Presenter: Nikki Davis (Arlington, United States)

11:29 – 11:37  OA28-404-11  “You’re mistaken. I didn’t default, I’m just not well”: insights from a qualitative study on community-based TB stigma in South Africa
11:37 – 11:45 OA28-405-11 Impact of interventions to reduce TB-related stigma: a structured literature review, quality appraisal and conceptual framework
Oral Presenter: Ahmad Fuady (Jakarta, Indonesia)

11:45 – 11:53 OA28-406-11 Continuation of active TB case-finding among at-risk populations during the hostilities in Ukraine
Oral Presenter: Evgenia Geliukh (Kyiv, Ukraine)

11:53 – 12:01 OA28-407-11 TB yield from targeted community-based active TB case-finding activities: implications for end TB programmes in Uganda
Oral Presenter: Kenneth Mutesasira (Kampala, Uganda)

12:01 – 12:09 OA28-408-11 Discordant TB knowledge, attitudes and practices among pharmacy professionals in Vietnam
Oral Presenter: Trang Thi Thu Le (Hanoi, Vietnam)

12:09 – 12:20 Live Q&A

Track: C3: Maternal and child TB
Type: Symposium
Channel 5

11:00 – 12:20 SP-29 Use of diagnostic algorithms to improve tuberculosis diagnosis in children
Chair: Hilda Mujuru (Zimbabwe)
Chair: Olivier Marcy (France)

Childhood TB remains largely undiagnosed globally. Due to the limitations of microbiological TB diagnosis in children, comprehensive approaches combining clinical features, contact history, chest radiography and other imagery/biomarkers are needed to tackle underdiagnosis. The WHO recently recommended the use of algorithms for TB diagnosis in low- and middle-income countries (LMICs), but there is no evidence so far on the performance of these algorithms. Children living with HIV (CLHIV) and those with severe acute malnutrition (SAM) are particularly prone to underdiagnosis and may require specific diagnostic approaches. This symposium will review current recommendations on TB treatment decision algorithms for children, updated evidence
on their use and performance in CLHIV and children with SAM, and perspectives for further improving their diagnostic accuracy.

11:00 – 11:05
Live introduction

11:05 – 11:15
Development and validation of a TB treatment decision algorithm for children in low- and middle-income countries – an individual patient data meta-analysis
Speaker: James Seddon (Cape Town, South Africa)

11:15 – 11:25
Feasibility and performance of specific diagnostic algorithms for highly vulnerable groups: children living with HIV and children with severe acute malnutrition
Speaker: Chishala Chabala (Lusaka, Zambia)

11:25 – 11:35
Cost effectiveness of using different tuberculosis diagnostic algorithms in highly vulnerable groups: children living with HIV and children with severe acute malnutrition
Speaker: Marc D’Elbée (Bordeaux, France)

11:35 – 11:45
Integrating TB diagnostic algorithms into IMCI (Integrated Management of Childhood Illness) approaches for children in primary healthcare
Speaker: Celso Khosa (Maputo, Mozambique)

11:45 – 11:55
Role of new biomarkers for future TB diagnostic algorithms in children
Speaker: Laura Olbrich (Munich, Germany)

11:55 – 12:20
Live Q&A

Track: C7: Access to quality TB care and services
Type: Symposium
Channel 1

12:30 – 13:50
SP-30
*Is digital X-ray and CAD/AI a game-changer in the fight against TB?*
In line with WHO recommendations for the use of computer-aided detection (CAD) and of ultra-portable digital X-ray, this symposium aims at facilitating the digital transformation of TB screening in an effort to boost the effectiveness and reach of TB case-finding in the context of COVID-19. This section starts with a presentation of the global resources for large-scale implementation and a cost-effectiveness analysis, followed by three country case studies that showcase the lessons learnt from Vietnam, Nigeria and South Africa, concluding with a Q&A session.

12:30 – 12:35
Live introduction

12:35 – 12:45
Resources for the implementation of AI-based digital X-ray for TB detection and results from a qualitative study of pilot project users

Speaker: Zhi Zhen Qin (Geneva, Switzerland)

12:45 – 12:55
Is mainstreaming chest X-ray screening using artificial intelligence-powered computer-aided tuberculosis detection cost-effective in public health facilities?

Speaker: Ruth Francisco (Quezon City, Philippines)

12:55 – 13:05
Scaling up the use of digital X-ray with CAD for active TB case-finding in Nigeria: implementation experience from mobile units to ultra-portable systems

Speaker: Austin Ihesie (Abuja, Nigeria)

13:05 – 13:15
Evaluating the use of ultraportable X-rays and CAD software for TB screening during the COVID-19 pandemic in Viet Nam

Speaker: Lan Nguyen (Hanoi, Vietnam)

13:15 – 13:25
Using mobile CAD system for digital chest X-ray in four KwaZulu Natal districts, South Africa

Speaker: Lynette Duckworth (Durban, South Africa)

13:25 – 13:50
Live Q&A

Track: TRACK E: POLITICS, CIVIL SOCIETY AND HUMAN RIGHTS
Type: Oral Abstract session
Channel 2
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>OA-29</td>
<td><strong>Innovative responses to airborne pandemics</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Nicholas Stewart (Washington DC, United States)</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Live introduction</td>
<td></td>
</tr>
<tr>
<td>12:35</td>
<td>OA29-409-11</td>
<td>Using SMS reminders to promote care-seeking behaviour and improve active TB case-finding in Chennai, India</td>
</tr>
<tr>
<td></td>
<td>Oral Presenter: Nicholas Stewart (Washington DC, United States)</td>
<td></td>
</tr>
<tr>
<td>12:43</td>
<td>OA29-410-11</td>
<td>Mitigating the impact of COVID-19 through tele-counselling support by trained TB survivors: lessons learnt from India</td>
</tr>
<tr>
<td></td>
<td>Oral Presenter: Anupama Srinivasan (Chennai, India)</td>
<td></td>
</tr>
<tr>
<td>12:51</td>
<td>OA29-411-11</td>
<td>Addressing COVID-19 vaccine hesitancy in Nigeria through an integrated TB/COVID-19 community social and behaviour change approach</td>
</tr>
<tr>
<td></td>
<td>Oral Presenter: Olatunde Toluwase (Abuja, Nigeria)</td>
<td></td>
</tr>
<tr>
<td>12:59</td>
<td>OA29-412-11</td>
<td>Boosting TB awareness in Ukraine by synergising TV and web-based TB interventions amid COVID-19 recovery</td>
</tr>
<tr>
<td></td>
<td>Oral Presenter: Olga Pavlova (Kyiv, Ukraine)</td>
<td></td>
</tr>
<tr>
<td>13:07</td>
<td>OA29-413-11</td>
<td>Pioneering a social enterprise model to notify people with TB through private pharmacies</td>
</tr>
<tr>
<td></td>
<td>Oral Presenter: Kinz ul Eman (Islamabad, Pakistan)</td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td>OA29-414-11</td>
<td>Channelising the power of youth, creative communication and digital technology in creating awareness towards TB</td>
</tr>
<tr>
<td></td>
<td>Oral Presenter: Niraj Sharma (New Delhi, India)</td>
<td></td>
</tr>
<tr>
<td>13:23</td>
<td>OA29-415-11</td>
<td>Asmara TBC application: efforts to revive TB contact investigation during the COVID-19 pandemic in Tangerang City, Indonesia</td>
</tr>
<tr>
<td></td>
<td>Oral Presenter: Tristi Dwi Veronita (Tangerang, Indonesia)</td>
<td></td>
</tr>
<tr>
<td>13:31</td>
<td>OA29-416-11</td>
<td>Shifting focus on to community empowerment through by engaging TB champions: the journey so far</td>
</tr>
<tr>
<td></td>
<td>Oral Presenter: Smrity Kumar (Delhi, India)</td>
<td></td>
</tr>
<tr>
<td>13:39</td>
<td>Live Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
Track: G2: Tobacco control and tobacco industry interference

Type: Oral Abstract session

Channel 3

12:30 – 13:50  **OA-30  Tobacco Industry Interference**

Chair: Elif Dagli (Istanbul, Turkey)
Chair: Asli Gorek Dilektasli (Turkey)

12:30 – 12:35  Live introduction

12:35 – 12:43 OA30-417-11  How does tobacco industry bypass the menthol ban?
Oral Presenter: Elif Dagli (Istanbul, Turkey)

12:43 – 12:51 OA30-418-11  Pricing strategies and cigarette affordability in Taiwan have the opposite effect of increased taxation and economic growth
Oral Presenter: Mattia Sanna (Taipei, Taiwan)

Oral Presenter: Nidhi Jaswal (Chandigarh, India)

Oral Presenter: Paramita Bhattacharya (Kolkata, India)

Oral Presenter: Sejal Saraf (Baltimore, United States)

13:15 – 13:23 OA30-422-11  Exploring the challenges faced by bidi workers and their readiness to shift to alternative livelihoods
Oral Presenter: Divyarajprabhakar Subramani (Chennai, India)

13:23 – 13:31 OA30-423-11  Effective implementation of ban on smoking in public places and exposure to second-hand smoke: compliance assessment for COTPA Section 4 in Karnataka, India
Oral Presenter: Mahantesh B U (Gokak Taluk, India)

13:31 – 13:50  Live Q&A
Track: C6: Person-centred care
Type: Symposium
Channel 4

12:30 – 13:50  **SP-31**  
**Joining forces for integrated, people-centred care for TB and comorbidities**

Chair: Kerri Viney (Geneva, Switzerland)
Chair: Jeff Acaba (Philippines)

Key risk factors such as HIV, diabetes, undernutrition, tobacco and alcohol use disorders accounted for 45% of the global TB epidemic in 2020. People with TB frequently experience other comorbidities, including mental health disorders. All of these conditions are risk factors for poorer TB treatment outcomes. Integrated patient-centred care and TB prevention, including HIV-associated TB and other comorbidities, are key components of Pillar One of the End TB Strategy. Although global guidance on interventions to address TB and comorbidities exists, its uptake has been variable. This symposium will discuss the barriers and enablers to integrated care for people with TB and comorbidities, both from the perspective of the programmes and that of TB survivors, and will present WHO’s *Framework for collaborative action on TB and comorbidities*, which aims to support countries in the introduction and scale-up of people-centred services for TB and comorbidities.

12:30 – 12:35  
**Live introduction**

12:35 – 12:45  
**An introduction to the WHO Framework for collaborative action on TB and comorbidities**

Speaker: Annabel Baddeley (Geneva, Switzerland)

12:45 – 12:55  
**The syndemicity of TB comorbidities: interviews with survivors from 11 high-burden countries**

Speaker: Amrita Daftary (York, Canada)

12:55 – 13:05  
**Integrating tuberculosis screening and testing in COVID-19 health facilities in the City of Manila, Philippines**

Speaker: Mary Rosary Santiago (Makati, Philippines)

13:05 – 13:15  
**Case study from India: Introducing and scaling up TB-HIV interventions in a concentrated HIV epidemic setting**

Speaker: Sanjay Kumar Mattoo (Delhi, India)
13:15 – 13:25  Case study from Madagascar: introducing and scaling up assessment, counselling and management of undernutrition in TB patients

Speaker: Nonhlanhla Xaba (Johannesburg, South Africa)

13:25 – 13:50  Live Q&A

Track: B3: Clinical trials and operational research for new treatments for TB (for adults and children)

Type: Symposium

Channel 5

12:30 – 13:50  SP-32  TB-PRACTECAL: final trial results and the case for programmatic roll-out

Chair: Charlotte Batts (United Kingdom)

Chair: Philipp du Cros (Australia)

TB-PRACTECAL is an ambitious phase II/III adaptive, open label, non-inferiority, randomised controlled trial examining 24-week treatments for rifampicin-resistant TB (RR-TB) sponsored by Médecins Sans Frontières. Following its termination in March 2021, interim data were assessed by the WHO Guideline Development Group and the May 2022 rapid communication recommended BPaLM for programmatic use in multidrug-resistant/RR-TB. We report the final trial results following the completion of >99% of follow-up visits and will discuss how we can accelerate the roll out of BPaL-based regimens.

12:30 – 12:35  Live introduction

12:35 – 12:45  TB-PRACTECAL Trial results

Speaker: Catherine Berry (Newcastle, Australia)

12:45 – 12:55  TB-PRACTECAL regimens: key safety aspects for clinicians

Speaker: Ilaria Motta (Turin, Italy)

12:55 – 13:05  TB-PRACTECAL: the economic case for 24-week BPaL-based treatments for drug-resistant TB

Speaker: Sedona Sweeney (London, United Kingdom)

13:05 – 13:15  Capturing patient-reported experiences and quality of life outcomes in the TB-PRACTECAL clinical trial (PRACTECAL-PRO)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15 – 13:25</td>
<td><strong>The case for programmatic roll out of BPaLM</strong></td>
<td>Beverley Stringer (London, United Kingdom)</td>
</tr>
<tr>
<td>13:25 – 13:50</td>
<td>Live Q&amp;A</td>
<td>Bern-Thomas Nyang’wa (Amsterdam, Netherlands)</td>
</tr>
</tbody>
</table>

Track: TRACK A: BASIC AND TRANSLATIONAL RESEARCH  
Type: Oral Abstract session  
Channel 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 – 16:20</td>
<td><strong>Community-centred, rights-based and gender responsive TB care</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Rachel Powers (Netherlands)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Sanskriti Goel (New Delhi, India)</td>
</tr>
<tr>
<td>15:00 – 15:05</td>
<td><strong>Live introduction</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 15:05 – 15:13| **OA31-424-11**  
MHealth campaign to drive TB care-seeking among employed men in Chennai, India | Oral Presenter: Sanskriti Goel (New Delhi, India)     |
| 15:13 – 15:21| **OA31-425-11**  
Assessing the use of a stigma scale among people with drug-susceptible TB in Vietnam | Oral Presenter: Thi Hoang Yen Phan (Ha Noi, Vietnam) |
| 15:21 – 15:29| **OA31-426-11**  
Developing a TB Champion Empowerment Index to measure power, agency and empowerment among TB-affected communities in India | Oral Presenter: Ramya Ananthakrishnan (Chennai, India) |
| 15:29 – 15:37| **OA31-427-11**  
The impact of civil society organisations in finding missed persons with TB disease among urban populations in Central Uganda | Oral Presenter: Nicholas Kirirabwa Sebuliba (Kampala, Uganda) |
Oral Presenter: Onyinye Kene-Eneh (Abuja, Nigeria)

15:45 – 15:53 OA31-429-11 Engaging local organisations improved community TB care and can help with sustainability in Ethiopia
Oral Presenter: Wogayehu G Tafesse (Addis Ababa, Ethiopia)

15:53 – 16:01 OA31-430-11 Engaging elected representatives for the TB-Free Village Initiative by TB Champions in Tamil Nadu, India
Oral Presenter: K. Balasubramanian (Chennnai, India)

16:01 – 16:09 OA31-431-11 Quantifying TB-related stigma: results from a community-based survey implemented by TB champions using the Stop TB Stigma Assessment Tool
Oral Presenter: Abhijith Njarattil Parameswaran (New Delhi, India)

16:09 – 16:20 Live Q&A

Track: C2: Care and treatment of TB (drug-sensitive and drug-resistant TB)

Type: Symposium

Channel 2

15:00 – 16:20 SP-33 Evidence and research gaps identified during the development of policy guidelines for tuberculosis

Chair: Matteo Zignol (Italy)
Chair: Ya Diul Mukadi (United States)

The development of global TB policy guidance continues to be challenged by a shortage of good-quality evidence, including on aspects such as acceptability, feasibility, equity and cost-effectiveness. Evidence from well-designed, large-scale, multidisciplinary studies with robust testing of interventions is necessary to improve the quality and scope of future guidance. This session will discuss research gaps and technology needs identified in recent update of WHO TB guidelines, with a view to steering innovation towards public health impact.

15:00 – 15:05 Live introduction

15:05 – 15:15 Compilation of research gaps from recent WHO policy guidelines
15:00 – 16:20 **SP-34** Providing TB care in conflict settings: an overview of global guidance and lessons from Afghanistan, Ethiopia and Ukraine

Chair: Pedro Suarez (United States)

Chair: Degu Jerene (The Hague, Netherlands)

Building resilient health systems is critical to withstand shocks from conflicts and other external pressures. A shock can weaken the national health system directly (e.g., due to looting and the destruction of health facilities), by modifying community-level service supply and demand (e.g., due to the increase in water-borne diseases, TB, malnutrition), and by impacting the social determinants of health. The impact of such shocks is particularly visible on programmes with measurable indicators of change such as national TB programmes. Over the last few years, a combination of natural disasters, COVID-19 and conflicts have impacted the national health systems of many countries worldwide; however, the impact was more devastating in some countries, while others performed well despite multiple shocks. In this session, we will 1) review the existing global guidance on how to provide TB services in humanitarian settings; and 2) share lessons from countries that have been affected by conflicts and other shocks.
15:00 – 15:05  Live introduction

15:05 – 15:15  New WHO guidance on TB prevention and care among refugees and other populations in humanitarian settings

Speaker: Kerri Viney (Geneva, Switzerland)

15:15 – 15:25  Afghanistan’s experience in strengthening TB care in a conflict environment

Speaker: Basir Maseed (Kabul, Afghanistan)

15:25 – 15:35  Ethiopia’s resilient health system under the multiple shocks of conflict and COVID-19

Speaker: Daniel Datiko (Addis Ababa, Ethiopia)

15:35 – 15:45  Challenges faced by the Ukrainian TB programme during the recent war

Speaker: Natasha Deyanova (Kyiv, Ukraine)


Speaker: Sandra Harlass (Geneva, Switzerland)

15:55 – 16:20  Live Q&A

Track: B8: TB and comorbidities: including HIV and diabetes

Type: Oral Abstract session

Channel 4

15:00 – 16:20  OA-32  HIV and co-morbidities and interaction with TB

Chair: Limakatso Lebina (Durban, South Africa)

Chair: Oni Tolullah (Cambridge, United Kingdom)

15:00 – 15:05  Live introduction

15:05 – 15:13  OA32-432-11  HIV remains responsible for most TB in Blantyre, Malawi, despite successful antiretroviral therapy scale-up

Oral Presenter: Hannah M. Rickman (London, United Kingdom)
15:13 – 15:21  OA32-433-11  Exploring the impact of participant-related factors on side effect profile and adherence to TB treatment
  Oral Presenter: Christine Tzelios (Boston, United States)

15:21 – 15:29  OA32-434-11  Double trouble! Cardiac dysfunction in active pulmonary TB patients
  Oral Presenter: Shital Patil (Latur, India)

  Oral Presenter: Mikhail Khaitov (New York City, United States)

15:37 – 15:45  OA32-436-11  HIV viral suppression at RR-TB treatment initiation: factors driving the need for enhanced adherence support and viral load monitoring in South Africa
  Oral Presenter: Keri Geiger (Baltimore, United States)

15:45 – 15:53  OA32-437-11  Mortality and associated factors in HIV-infected children with TB assessed using the PAANTHER TB treatment decision score
  Oral Presenter: Gae Mundundu (Lusaka, Zambia)

15:53 – 16:01  OA32-438-11  HbA1c trajectories and their association with treatment outcomes among new pulmonary TB cases in Pune, India
  Oral Presenter: Geeta Pardeshi (Pune, India)

16:01 – 16:20  Live Q&A

Track: C8: Global and local policies and politics, including funding and accountability
Type: Symposium
Channel 5

15:00 – 16:20  SP-35  From domestic resource mobilisation to global policy-making: how can TB get its ‘fair share’ of financing?
  Chair: William Wells (United States)
  Chair: Zina Jarrah (United States)

TB is the second leading infectious killer after COVID-19, and the 13th leading cause of death worldwide. Despite the high burden of disease, and the fact that TB...
disproportionately affects the poorest and the most vulnerable, funding for TB persistently falls short of need. In 2020, less than half—only 41%—of the global funding target for TB was met. Why does TB still not receive its ‘fair share’ of financing, and what can be done to address this problem?

This symposium explores the challenges and opportunities of financing TB sustainably, from incremental national reforms to driving policy change at the global level. The panel will discuss country experiences in domestic resource mobilisation for TB, the use of government funding to contract out TB services, the potential for applying market-based solutions and innovative financing and the importance of engaging Ministries of Finance in health policy decision-making.

15:00 – 15:05  
Live introduction

15:05 – 15:17  
Increasing financial sustainability through domestic resource mobilisation in Ethiopia

Speaker: Taye Letta (Addis Ababa, Ethiopia)

15:17 – 15:29  
Public financing of TB partners: Government outsourcing of TB services in Bangladesh

Speaker: Mohammad Nurul Amin (Dhaka, Bangladesh)

15:29 – 15:41  
India’s experience with blended finance, and potential applications for TB

Speaker: Neeta Rao (Mumbai, India)

15:41 – 15:53  
Creating policy dialogue to support equitable, needs-based, evidence-driven allocation of funding for TB

Speaker: José Antonio González Anaya (Mexico City, Mexico)

15:53 – 16:20  
Live Q&A

16:30 – 17:50  
SP-36  
Laying the groundwork for the success of new TB vaccines

Chair: Shelly Malhotra (United States)
For the first time in 100 years, we are poised to introduce a new vaccine against TB. However, questions remain about how to bridge the gap between the first findings of vaccine efficacy to successful introduction of new TB vaccines into immunisation programmes worldwide. The next several years will be pivotal, as we push through vaccine candidates currently in development in late-stage trials and design implementation strategies that will ensure successful rollout. In this session, we will hear about the latest developments in TB vaccine research, preview the forthcoming WHO roadmap to guide preparations for vaccine introduction, discuss insights to be gained for implementation strategies from upcoming phase III trials and modelling studies, as well as explore the opportunities and challenges of rolling out TB vaccines in India, the country with the highest TB burden in the world.

16:30 – 16:35  
Live introduction

16:35 – 16:45  
Update on the pipeline of late-stage TB vaccines  
Speaker: David Lewinsohn (Portland, United States)

16:45 – 16:55  
TB vaccine efficacy trials: update and implications for scale up  
Speaker: Gavin Churchyard (Parktown, South Africa)

16:55 – 17:05  
The case for TB vaccines  
Speaker: Richard White (London, United Kingdom)

17:05 – 17:15  
Introducing the WHO roadmap for global introduction of new TB vaccines  
Speaker: Birgitte Giersing (Geneva, Switzerland)

17:15 – 17:25  
Vaccine trials in India and lessons learnt for the introduction of adult TB vaccines  
Speaker: Devasahayam Christopher (Vellore, India)

17:25 – 17:50  
Live Q&A
16:30 – 16:35 Live introduction

16:35 – 16:42 LBCDC-2075-11 Pharmacokinetics and optimized dosing of novel dispersible and non-dispersible levofloxacin formulations in children
Oral Presenter: Louvina Elizabeth van der Laan (Cape Town, South Africa)

16:42 – 16:49 LBCDC-1937-11 Optimized delivery of isoniazid-rifapentine for tuberculosis prevention among people living with HIV: the 3HP Options Trial
Oral Presenter: Allan Musinguzi (Kampala, Uganda)

16:49 – 16:56 LBCDC-2070-11 Effects of oral hygiene and food intake on oral swab qPCR results in South African tuberculosis patients
Oral Presenter: Angelique Kany Kany Luabeya (Cape Town, South Africa)

16:56 – 17:03 LBCDC-2077-11 Changes in immune gene expression in rifampicin-susceptible tuberculosis following treatment with GSK3036656
Oral Presenter: Maja Reimann (Borstel, Germany)

17:03 – 17:10 LBCDC-2079-11 Community-based directly observed therapy is effective and results in better treatment outcomes for patients with multi-drug resistant tuberculosis in Uganda
Oral Presenter: Rita Makabayi-Mugabe (Kampala, Uganda)

17:10 – 17:17 LBCDC-2074-11 High rate of successful outcomes treating RR-TB with a delamanid-bedaquiline regimen in BEAT Tuberculosis: an interim analysis
Oral Presenter: Francesca Conradie (Johannesburg, South Africa)

17:17 – 17:24 LBCDC-2078-11 Phase 2a trial of GSK3036656 in rifampicin-susceptible, pulmonary tuberculosis: PET/CT scan results
Oral Presenter: David Barros-Aguirre (London, United Kingdom)

17:24 – 17:31 LBCDC1864 National expenditure on Tuberculosis and Tuberculosis incidence in low- and middle-income countries: an ecological study
Oral Presenter: James O’Connell (Dublin, Ireland)

17:31 – 17:50 Live Q&A

Track: C8: Global and local policies and politics, including funding and accountability
Vulnerability and resilience of TB and COVID-19 care services during military and humanitarian crises: experience of USAID/PATH support for Ukraine

Chair: Kateryna Gamazina (Kyiv, Ukraine)
Chair: Erika Vitek (Atlanta, United States)

Russia’s military intervention in Ukraine came on the heels of several waves of COVID-19, coupled with an ongoing, complex reform of the Ukrainian healthcare system and transformation of TB service delivery. Due to the military crisis and the resulting complex humanitarian emergency, TB and COVID-19 prevention and care services have been drastically affected, and have had to be adapted to address the damage and destruction of infrastructure and systems, health worker shortages, and mass migration and displacement both within and outside of Ukraine. Health systems recovery will involve the intersection of post-pandemic, post-conflict and health reform priorities. Given Ukraine’s unique experience in maintaining the availability of TB services and treatment adherence for people affected by TB under wartime conditions, the lessons learnt and strategies shared in this session can be applied in other settings facing humanitarian crises or conflicts of similar magnitude.

16:30 – 16:35 Live introduction
Speaker: Kateryna Gamazina (Kyiv, Ukraine)

16:35 – 16:45 Overview of TB and COVID-19 prevention and care in Ukraine on the eve of Russia’s military invasion
Speaker: Kateryna Gamazina (Kyiv, Ukraine)

16:45 – 16:55 Principles and priorities of USAID assistance in TB and COVID-19 prevention and care in Ukraine before, during and after Russia’s military invasion.
Speaker: Erika Vitek (Atlanta, United States)

16:55 – 17:05 Response measures to support TB service delivery in territories affected by hostilities and civil crisis in Ukraine
Speaker: Olga Pavlova (Kyiv, Ukraine)

17:05 – 17:15 COVID-19 prevention and control in an environment of wartime mass migration and displacement
Speaker: Roman Rodyna (Kyiv, Ukraine)

Speaker: Gunta Dravniece (Kyiv, Ukraine)
17:25 – 17:50  
Live Q&A

Track: B1: TB diagnostics – Operational and clinical studies
Type: Oral Abstract session
Channel 4

16:30 – 17:50  
**OA-33  Child and host and community**

Chair: Courtney Yuen (Boston, MA, United States)
Chair: Ivor Langley (United Kingdom)

16:30 – 16:35  
Live introduction

16:35 – 16:43  
OA33-439-11  
Acceptability of decentralising childhood TB diagnosis at the district level: experience and perceptions from healthcare workers in sub-Saharan Africa and South-East Asia

Oral Presenter: Basant Joshi (Bordeaux, France)

16:43 – 16:51  
OA33-440-11  
Effects of integrating paediatric TB services into child healthcare on treatment outcomes: results of the INPUT stepped-wedge cluster-randomised study

Oral Presenter: Lise Denoeud-Ndam (Geneva, Switzerland)

16:51 – 16:59  
OA33-441-11  
TB prevalence and clinical characteristics in children under 5 years hospitalised with severe acute malnutrition in Zambia and Uganda

Oral Presenter: Clémentine Roucher (Bordeaux, France)

16:59 – 17:07  
OA33-442-11  
Effect of dysglycaemia on urinary lipid mediator profiles in persons with pulmonary TB

Oral Presenter: María Arriaga Gutiérrez (Salvador BR, Peru)

17:07 – 17:15  
OA33-443-11  
Assessing the variations of M. tuberculosis-induced interferon-γ responses in HIV-negative pregnant women

Oral Presenter: Paulo Ranaivomanana (Antananarivo, Madagascar)

17:15 – 17:23  
OA33-444-11  
Estimating the prevalence of catastrophic costs before and during the treatment of adults with TB in Mozambique

Oral Presenter: Pedroso Nhassengo (Maputo, Mozambique)
17:23 – 17:31  OA33-445-11 Comparing early warning outbreak recognition system (EWORS) and non-EWORS-guided community TB active case-finding in Cross River State, Nigeria
Oral Presenter: Itoro Okon (Calabar Municipality, Nigeria)

Oral Presenter: Brittney van de Water (Chestnut Hill, United States)

17:39 – 17:50  Live Q&A

Track: C3: Maternal and child TB
Type: Oral Abstract session
Channel 5

16:30 – 17:50  OA-34 Important topics in child lung health
Chair: Rebecca Nightingale (United Kingdom)

16:30 – 16:35  Live introduction

16:35 – 16:43  OA34-447-11 Facility-based TB mentors improve childhood TB diagnosis: experience from Eradicate TB Project, Zambia
Oral Presenter: Ibou Thior (United States)

16:43 – 16:51  OA34-448-11 Impact of COVID-19 on TB testing and diagnosis in children and adolescents in the Western Cape Province, South Africa
Oral Presenter: Karen Du Preez (Cape Town, South Africa)

Oral Presenter: Chloe Maugans (Boston, United States)

16:59 – 17:07  OA34-450-11 A prediction score to improve TB treatment decision-making in children
Oral Presenter: Meredith Brooks (Boston, United States)

17:07 – 17:15  OA34-451-11 TB and female sexual and reproductive health in four African countries
Oral Presenter: Olena Ivanova (Munich, Germany)
Oral Presenter: Kerri Viney (Geneva, Switzerland)

17:23 – 17:31 OA34-453-11 The effect of household air pollution on pulmonary function among survivors of childhood pneumonia in Uganda
Oral Presenter: Peter Moschovis (Boston, United States)

17:31 – 17:39 OA34-454-11 Integrating TB screening into the national immunisation programme to improve childhood TB in south-east Nigeria
Oral Presenter: Charles Ohikhua (Abuja, Nigeria)

17:39 – 17:50 Live Q&A

E-poster programme
(Accessible on-demand)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)


EP-01-600 Sub-national impact of COVID-19 on TB notifications and recovery in nine countries
Oral Presenter: Mirjam Bakker (Amsterdam, Netherlands)

EP-01-601 Differences in individual and spatial characteristics of diagnosed drug-resistant TB cases before and after COVID-19 national lockdowns in KwaZulu-Natal, South Africa
Oral Presenter: Kristin Harrington (Atlanta, United States)

Oral Presenter: Abraham Malaza (Durban, South Africa)
EP-01-603 Multi-country calibration of a TB model for the evaluation of the potential impact of new vaccines in low- and middle-income countries
Oral Presenter: Danny Scarponi (London, United Kingdom)

EP-01-604 Quantifying the health impact and cost-effectiveness of new TB vaccines in South Africa
Oral Presenter: Christinah Mukandavire (London, United Kingdom)

EP-01-605 Getting TB case-finding back on track after the COVID-19 pandemic
Oral Presenter: Bamuloba Muzamiru (Kampala, Uganda)

Oral Presenter: Emawayish Tesema (Addis Ababa, Ethiopia)

EP-01-607 Ensuring quality healthcare during the pandemic
Oral Presenter: Sarang Patil (Mumbai, India)

Oral Presenter: Mohammed Fall Dogo (Lomé, Togo)

EP-01-609 Using the continuous quality improvement collaborative approach to address low TB treatment success rates: lessons from Uganda
Oral Presenter: Kenneth Mutesasira (Kampala, Uganda)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters
Channel: E-posters (accessible on-demand)

EP-02 TB and infection control

EP-02-610 Implementation of TB infection control in MDR-TB treatment initiating centres in Amhara and Oromia Regions, Ethiopia
Oral Presenter: Jemal Seid Mohammed (Addis Ababa, Ethiopia)

EP-02-611 Integrating COVID-19 and TB services to help recover TB care and prevention services during the pandemic: results from a multi-country survey
Oral Presenter: Ineke Spruijt (The Hague, Netherlands)

EP-02-612 Improving TB infection prevention and control practices in healthcare facilities, China, 2017–2019

Oral Presenter: Canyou Zhang (Beijing, China)

EP-02-613 Implementation of a novel tool to assess healthcare worker TB screening and management practices in Nigeria

Oral Presenter: Rita Okonkwo (Abuja, Nigeria)

EP-02-614 Treatment efficacy of a novel short-course regimen with isoniazid plus rifapentine for TB infection: preliminary results from a murine model

Oral Presenter: Jingyu Zhou (Shanghai, China)

EP-02-615 Addressing TB and diabetes co-infection in Bangladesh by utilising the diabetic network

Oral Presenter: Md Nadim Reza (Dhaka, Bangladesh)

EP-02-616 Feasibility of linking people with TB symptoms in South Africa’s private sector to timely testing and treatment in the public sector: the Connect TB Study

Oral Presenter: Buyisile Chibi (Durban, South Africa)

EP-02-617 Facility-based active case-finding for early detection and treatment of TB in Bangladesh

Oral Presenter: Arifa Nazneen (Dhaka, Bangladesh)

EP-02-618 Effect of pharmacogenetics on pharmacokinetics of first-line anti-tuberculosis drugs in paediatric TB

Oral Presenter: Nancy Mehra (Chandigarh, India)


Oral Presenter: Nancy Mehra (Chandigarh, India)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters
Channel: E-posters (accessible on-demand)

**EP-03**

**Broader approach for implementation of TB active case finding and preventive strategies**

**EP-03-620** Paradigm shift in the classification of eligible index TB clients for contact investigation: a review of selected tertiary health facilities in Plateau and Nasarawa States, Nigeria

Oral Presenter: Omotayo Salau (FCT Abuja, Nigeria)

**EP-03-621** Assessment of TB knowledge, attitude and practice to engage community pharmacies in TB patient detection in Indonesia

Oral Presenter: Ivan Surya Pradipta (Bandung, Indonesia)

**EP-03-622** Using the door-to-door approach to improve community TB case-finding in Kampala, Wakiso and Mukono Districts, Uganda

Oral Presenter: Priscilla Ajambo (Kampala, Uganda)

**EP-03-623** Integration of HIV testing in a community intervention for TB screening among 5–14-year-old household contacts of TB patients in Cameroon and Uganda

Oral Presenter: Boris Tchakounte Youngui (Yaoundé, Cameroon)

**EP-03-624** Best practices of actively finding childhood TB cases in sub-national public tertiary facilities: programme experience in Oyo State, Nigeria

Oral Presenter: Samuel Akingbesote (Ibadan, Nigeria)

**EP-03-625** Community active case-finding: a mop up strategy for detecting missing TB cases in Cross River State, Nigeria

Oral Presenter: Johnson Diara (Calabar, Nigeria)

**EP-03-626** Optimal strategies to reduce TB diagnostic delays: model for engaging less-than-fully-qualified providers

Oral Presenter: Yogesh Patel (Delhi, India)

**EP-03-627** The role of mass chest radiography screening in TB active case-finding: a re-evaluation of the Kolin study

Oral Presenter: Alvaro Schwalb (London, United Kingdom)

**EP-03-628** Mapping the burden of TB in Ethiopia: a practical approach to develop targeted interventions

Oral Presenter: Nebiyu Hiruy (Addis Ababa, Ethiopia)
EP-03-629 Gender and TB in Nigeria: active household contact investigation as an effective strategy for reaching men

Oral Presenter: Ogoamaka Chukwuogo (Abuja, Nigeria)

EP-03-630 Household TB contact tracing in Tajikistan: active case-finding in a high DR-TB burden setting

Oral Presenter: Aung Aung (Dushanbe, Tajikistan)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

EP-04 TB active case finding: impact, performance and acceptability


Oral Presenter: Chidubem Ogbudebe (Abuja, Nigeria)

EP-04-630 Performance-based financing of community-owned resource persons improves community TB case-finding in a nomadic population: a case in Karamoja Region, Uganda

Oral Presenter: Etwom Alfred (Kampala, Uganda)

EP-04-635 Contact tracing of clinically diagnosed TB cases vs. bacteriologically diagnosed TB cases: an analysis of presumptive and diagnosed TB case yield

Oral Presenter: Golibe Ugochukwu (Owerri, Nigeria)

EP-04-635 The effect of TB screening on TB treatment outcomes: results from the Zambian HPTN 071 intervention sites

Oral Presenter: Lily Telisinghe (London, United Kingdom)


Oral Presenter: Tu Khoa Tran (Ha Noi, Vietnam)
Acceptability and feasibility of household child-contact investigation and preventive therapy management in Cameroon and Uganda

Oral Presenter: Anca Vasiliu (Montpellier, France)

Assessment of paediatric clinical records at a drug-resistant TB hospital in the Eastern Cape, South Africa

Oral Presenter: Razia Gaida (Pretoria, South Africa)

Contact tracing evaluation of bacteriologically confirmed pulmonary TB index cases in Cameroon

Oral Presenter: Albert Kuete Kuate (Yaounde, Cameroon)

Yield from alternative models of contact investigation: the KNCV Nigeria experience

Oral Presenter: Ogoamaka Chukwuogo (Abuja, Nigeria)

Strategies of increasing case-finding in a high TB burden country

Oral Presenter: Obioma Chijioke-Akanire (Abuja, Nigeria)

Clinical trials and operational research for new treatment of TB

Development of a Deep learning model for predicting TB treatment outcomes on time-series CT scans

Oral Presenter: Y.M. Fleming Lure (Shenzhen, China)

Closing the TB adherence gap in Nigeria with digital adherence technologies

Oral Presenter: Iboro Gordon (Abuja, Nigeria)

Strengthening TB drug logistics management using QuanTB for drug quantification and as an early warning system in Uzbekistan

Oral Presenter: Khasan Safaev (Tashkent, Uzbekistan)

Telephonic adherence support for TB treatment: experience from a high TB burden urban setting in South Africa

Oral Presenter: Obioma Chijioke-Akanire (Abuja, Nigeria)
Consecutive missed doses and temporal patterns of non-adherence among TB patients: findings from the ASCENT multi-country study
Oral Presenter: Jason Alacapa (Makati City, Philippines)

Motivating persons with drug-resistant TB to complete treatment: local TB response experience in Zambezia, Mozambique
Oral Presenter: Algy Abdula (Maputo, Mozambique)

The assessment of knowledge, attitude and practice among community pharmacy personnel in TB case detection, drug monitoring and community education
Oral Presenter: Ivan Surya Pradipta (Bandung, Indonesia)

Comprehensive, integrated psychosocial support for people with DR-TB results in improved treatment outcomes in Tajikistan
Oral Presenter: Huriya Hisomova (Dushanbe, Tajikistan)

Sustained costs of 99DOTS following implementation in Uganda
Oral Presenter: Joseph Waswa (Kampala, Uganda)

Role of 99DOTS Lite technology in optimising adherence among TPT beneficiaries under the National TB Elimination Programme India
Oral Presenter: Sanjay Kumar Mattoo (Delhi, India)

Access to quality care; use of new technologies
Exploring the potential of existing artificial intelligence to improve TB case-finding at the Nigeria Correctional Centre Lafia, Nasarawa State, north central Nigeria
Oral Presenter: Daniel Egbule (Lafia, Nigeria)
<table>
<thead>
<tr>
<th>Code</th>
<th>Title</th>
<th>Oral Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP-07-663</td>
<td>Enabling rapid TB triage in prisons using artificial intelligence software for reading digital chest X-rays</td>
<td>John May (North Miami, United States)</td>
</tr>
<tr>
<td>EP-07-664</td>
<td>Digitally enhanced contact investigation to increase TB case-finding in Indonesia</td>
<td>Jhon Sugiharto (Jakarta, Indonesia)</td>
</tr>
<tr>
<td>EP-07-665</td>
<td>The use of artificial intelligence software-aided chest X-ray screening for community active case-finding in Kano, Nigeria</td>
<td>Mamman Bajehson (Kano, Nigeria)</td>
</tr>
<tr>
<td>EP-07-666</td>
<td>Interim result of AI-powered portable CXR in boosting TB case-finding in Katsina State, Nigeria</td>
<td>Muzbau Oyawale (Katsina, Nigeria)</td>
</tr>
<tr>
<td>EP-07-669</td>
<td>“I am not working, even all my dreams are gone”: an exploration of socio-economic consequences associated with TB in rural Tanzania</td>
<td>Stella Kilima (Dar es Salaam, Tanzania)</td>
</tr>
<tr>
<td>EP-07-671</td>
<td>Impact of a digital adherence support intervention on TB treatment outcomes in a nomadic population of Karamoja sub-region, Uganda</td>
<td>Mackline Hope (Kampala, Uganda)</td>
</tr>
</tbody>
</table>

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments
Type: E-posters

Channel: E-posters (accessible on-demand)

**EP-08**

Access to quality care; improvements in case finding and early diagnostics

**EP-08-672**

Role of specimen referral systems on early detection of rifampicin-resistant TB in Afghanistan

Oral Presenter: Del Aqa Safi (Kabul, Afghanistan)

**EP-08-673**

Pre-treatment loss to follow-up in adults with pulmonary TB a qualitative evidence synthesis of patient and healthcare worker perspectives

Oral Presenter: Mercy Mulaku (Nairobi, Kenya)

**EP-08-674**

Implementation of the revised and updated TB contact investigation strategy in the Kyrgyz Republic

Oral Presenter: Sanzharbek Temirbekov (Bishkek, Kyrgyzstan)

**EP-08-675**

Improving bacteriological diagnosis of TB in resource-challenged high-burden primary healthcare centres using Truenat: an early experience in south-south Nigeria

Oral Presenter: Michael Umoren (Abuja, Nigeria)

**EP-08-676**

Improving TB case-finding in hospital outpatient departments: lessons from active TB screening in urban slum areas in Nigeria

Oral Presenter: Chidubem Ogbudebe (Abuja, Nigeria)

**EP-08-677**

Finding missing persons with TB through Monthly Cough Days in Sofala, Mozambique

Oral Presenter: Algy Abdula (Maputo, Mozambique)

**EP-08-678**

TB case detection and notification in three correctional facilities in the Hhohho Region of Eswatini

Oral Presenter: Bongani Ndlangamandla (Mbabane)

**EP-08-679**

Am I TB-free? Changing the future course of TB using a digital self-assessment tool for screening

Oral Presenter: Franz Jared Enriquez (Makati City, Philippines)

**EP-08-680**

Establishing specimen transportation model to ensure access to TB diagnosis in Chernihivska oblast, Ukraine

Oral Presenter: Olga Pavlova (Kyiv, Ukraine)
<table>
<thead>
<tr>
<th>EP-08-681</th>
<th>Strategic planning to expand access to Xpert diagnostic network using laboratory spatial analysis in Vietnam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Presenter: Cuong Duong (Hanoi, Vietnam)</td>
<td></td>
</tr>
</tbody>
</table>

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

<table>
<thead>
<tr>
<th>EP-09</th>
<th>EP-10 TB Access to quality care; the importance of integrated care and the involvement of the private sector</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP-09-682</td>
<td>Engaging indigenous community-based organizations can improve access to TB care services; lessons from the Karamoja sub-region, North Eastern Uganda</td>
</tr>
<tr>
<td>Oral Presenter: William Kasozi (Kampala, Uganda)</td>
<td></td>
</tr>
</tbody>
</table>

| EP-09-683 | Public-private mix for TB faces challenges and opportunities in Ethiopia |
| Oral Presenter: Tilaye Tasew Zewde (Addis Ababa, Ethiopia) |

| Oral Presenter: Stephanie Gande (FCT, Abuja, Nigeria) |

| EP-09-685 | Integrative healthcare approach for vulnerable indigenous communities of southern Mexico: a right to care and education in TB response |
| Oral Presenter: Juan Alberto Garcia (Mexico, Mexico) |

| EP-09-686 | Assessing the key barriers to improving chest radiography testing of people with TB-like symptoms identified by informal providers: RIPEND project experiences |
| Oral Presenter: Vikas Panibatla (Hyderabad, India) |

| EP-09-687 | Acceptability of the Kalinga Health Hub as a TB interface agency among private care providers in Marikina City, The Philippines |
| Oral Presenter: Jason Alacapa (Mandaluyong City, Philippines) |

| EP-09-688 | A public-private mix programme to improve detection of TB in mountainous aboriginal regions in Taiwan |
Oral Presenter: Yin-Yuan Liao (Taipei, Taiwan)

**EP-09-689** Increasing TB notifications among smear-negative, chest-symptomatic individuals through private sector CXR screening under Project Axshya in India

Oral Presenter: Ranjith Babu (New Delhi, India)

**EP-09-690** Baseline assessment of the State TB Training and Demonstration Centres across 17 states in India

Oral Presenter: Neerja Arora (New Delhi, India)

**EP-09-691** Use of the WHO collaborative procedure for accelerated registration to facilitate access to quality-assured TB medicines in Uzbekistan

Oral Presenter: Archil Salakaia (Rockville, United States)

---

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

**Type:** E-posters

**Channel:** E-posters (accessible on-demand)

**EP-10**

**The cost of TB treatment**

**EP-10-692** Two-thirds of TB patients and their families in Ethiopia experienced catastrophic costs

Oral Presenter: Zewdu G Dememew (Addis Ababa, Ethiopia)

**EP-10-693** Provider costs of using medication monitors and a differentiated care approach to improve TB treatment adherence in South Africa

Oral Presenter: Rachel Mukora (Johannesburg, South Africa)

**EP-10-694** Illness, coping and catastrophic costs for TB care in Pune, India

Oral Presenter: Ryan Thompson (Baltimore, United States)

**EP-10-695** An analysis of costs and pathways to care after a negative TB evaluation, August 2021–April 2022

Oral Presenter: Tom Rogers Muyunga-Mukasa (Los Angeles, United States)

**EP-10-696** Impact and cost-effectiveness of TB preventive therapy for household contacts and people with HIV
Oral Presenter: Theresa Ryckman (Baltimore, United States)

EP-10-697 Shortening treatment for TB infection in Canada with 3HP: a cost-effectiveness analysis
Oral Presenter: Suvesh Shrestha (Ottawa, Canada)

EP-10-698 Putting our best cost forward: a comparative analysis of cross-sectional and longitudinal approaches for TB patient costing studies
Oral Presenter: Anchal Thapa (Liverpool, United Kingdom)

EP-10-699 A comparison of outcome and cost-efficiency of community TB active case-finding by local and other volunteers in Cross River State, Nigeria
Oral Presenter: Johnson Diara (Calabar, Nigeria)

EP-10-700 Household costs incurred when seeking and receiving paediatric TB services: a survey in Cameroon and Kenya
Oral Presenter: Nyashadzaishe Mafirakureva (Sheffield, United Kingdom)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments
Type: E-posters
Channel: E-posters (accessible on-demand)

EP-11 Tuberculosis infection and control in a wider context

EP-11-701 Health system strengthening improves national TB preventive therapy coverage among PLHIV in Malawi
Oral Presenter: Paul Nyasulu (Lilongwe, Malawi)

EP-11-702 TB antigen-based skin tests and QFT-Plus® for the diagnosis of M. tuberculosis infection in Brazilian healthcare workers: a cost-effectiveness analysis
Oral Presenter: Ricardo Steffen (Rio de Janeiro, Brazil)

EP-11-703 Closing the science-to-service gap by increasing TB preventive therapy (TPT) uptake using the choice architecture TPT prescriptive stickers
Oral Presenter: Juliet Jokwiro (Harare, Zimbabwe)

Oral Presenter: Yumna Moosa (Durban, South Africa)

**EP-11-705**  
**Resistance to M. tuberculosis infection among highly TB exposed, HIV-infected goldminers in South Africa**

Oral Presenter: Thobani Ntshiqa (Johannesburg, South Africa)

**EP-11-706**  
**The impact of the COVID-19 pandemic on TB preventive treatment in Brazil: a retrospective cohort study**

Oral Presenter: Layana Costa Alves (Salvador, Brazil)

**EP-11-707**  
**Behaviour change intervention promotes uptake and completion rates of IPT among HIV-infected adults initiating antiretroviral therapy at a tertiary referral hospital in Johannesburg, South Africa**

Oral Presenter: Denise Evans (Johannesburg, South Africa)

**EP-11-708**  
**Patients’ experiences with video-observed TB treatment in Kampala, Uganda**

Oral Presenter: Adenike McDonald (Athens, United States)

**EP-11-709**  
**A qualitative inquiry into barriers against the public-private mix for TB control in Ghana**

Oral Presenter: Melvin Agbogbatey (Kumasi, Ghana)

**EP-11-710**  
**Increased child contact investigation and TB preventive treatment management through a community-based intervention in Cameroon and Uganda**

Oral Presenter: Maryline Bonnet (MONTPELLIER, France)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

**Type:** E-posters  

**Channel:** E-posters (accessible on-demand)

**EP-12**  
**TB and vulnerable population**

**EP-12-711**  
**Pregnancy outcomes among South African women with TB in the context of HIV**

Oral Presenter: Sue-Ann Meehan (Cape Town, South Africa)

**EP-12-712**  
**Treatment outcomes of pregnant women with multidrug-resistant TB**

Oral Presenter: Kefyalew Addis Alene (Perth, Australia)
Increasing trend of bacteriologically confirmed TB cases among paediatric TB cases in Ethiopia

Oral Presenter: Nebiyu Hiruy (Addis Ababa, Ethiopia)

Spiritual holy water sites: unrecognised congregate settings for pulmonary TB transmission in Ethiopia

Oral Presenter: Melese Abate Reta (Pretoria, South Africa)

Genetic diversity and drug resistance patterns of M. tuberculosis strains isolated from pulmonary TB symptomatic individuals attending spiritual holy water sites in the Amhara Region, Ethiopia

Oral Presenter: Melese Abate Reta (Pretoria, South Africa)

Alcohol exposure group classification using self-reported and biomarker measures in a South African cohort of persons with TB: a latent class analysis

Oral Presenter: Samantha Malatesta (Boston, United States)

Interventions to address the global underreporting of paediatric and adolescent TB: a systematic review

Oral Presenter: Alexandra Linn (Philadelphia, United States)

Where are the missing people affected by TB? Patient-pathway and cascades of care analyses to optimise TB care in Cambodia

Oral Presenter: Sovannary Tuot (Phnom Penh, Cambodia)

Access to TB care services among vulnerable populations in the Kampala, Mukono and Wakiso Districts in Uganda

Oral Presenter: Rita Makabayi-Mugabe (Kampala, Uganda)

TB case-finding and treatment of missing cases among women in Sind, Pakistan, through improved access of rural women to TB care services

Oral Presenter: Dr. Sharaf Ali Shah (Karachi, Pakistan)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters
### EP-13 TB and COVID

**EP-13-721**  
'It’s like they didn’t come at all', health worker perspectives on TB care during the COVID-19 pandemic in the Western Cape, South Africa  
Oral Presenter: Matthew O’Bryan (Boston, United Kingdom)

**EP-13-722**  
Drug-susceptible and drug-resistant TB care cascades prior to and during the COVID-19 pandemic in Lima, Peru  
Oral Presenter: Lena Faust (Montreal, Canada)

**EP-13-723**  
Sustaining gains in TB awareness and infection prevention in a post-pandemic world: the KNCV Nigeria experience  
Oral Presenter: Hauwa Usman Garba (Katsina, Nigeria)

**EP-13-724**  
Internally displaced people and COVID-19 patients are emerging vulnerable populations for TB in Ethiopia  
Oral Presenter: Zewdu G Dememew (Addis Ababa, Ethiopia)

**EP-13-725**  
Mental health among COVID-19 healthcare workers  
Oral Presenter: Ineke Spruijt (The Hague, Netherlands)

**EP-13-726**  
Inequalities in the impact of COVID-19-associated disruptions on TB diagnosis by age and sex in 49 high burden countries  
Oral Presenter: Christopher Finn McQuaid (London, United Kingdom)

**EP-13-727**  
Sequential infection between M. tuberculosis and SARS-CoV-2 in East Java, Indonesia  
Oral Presenter: Satiti Palupi (Surabaya, Indonesia)

**EP-13-728**  
A quarterly trend analysis of TB case-finding in Liberia before and after the COVID-19 pandemic  
Oral Presenter: Victor Falokun (Monrovia, Liberia)

**EP-13-729**  
COVID-19 lockdowns resulting in decline in household income for people with TB in Ho Chi Minh City, Vietnam  
Oral Presenter: Anja Wiemers (Stockholm, Sweden)

**EP-13-730**  
The long-term effect of BCG vaccination on the risk of COVID-19 infection and the severity of symptoms
Oral Presenter: Sanne Luxemburg (The Hague, Netherlands)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters
Channel: E-posters (accessible on-demand)

**EP-14**  
**Epidemiology of TB and DR-TB**

**EP-14-731**  
Subclinical TB: whether or not it is infectious  
Oral Presenter: Hai Nguyen (Ha Noi, Vietnam)

**EP-14-732**  
Quantifying incidence and pathways across TB disease states following M. tuberculosis infection  
Oral Presenter: Katherine Horton (London, United Kingdom)

**EP-14-733**  
Molecular epidemiology and drug resistance pattern of M. tuberculosis isolates from the Amhara, Gambella and Benishangul-Gumuz Regions of Ethiopia  
Oral Presenter: Bazezew Yenew (Addis Ababa, Ethiopia)

**EP-14-734**  
Incidence and epidemiology of active TB in a healthy, HIV vaccine trial cohort in South Africa  
Oral Presenter: E. Chandler Church (Seattle, United States)

**EP-14-735**  
Resistance sniffer: prediction of drug resistance patterns of M. tuberculosis isolates using next-generation sequencing data  
Oral Presenter: Awelani Mutshembele (Pretoria, South Africa)

**EP-14-736**  
Treatment outcomes in rifampicin-resistant TB patients treated with all-oral regimens in Uganda  
Oral Presenter: John Paul Otuba (Kampala, Uganda)

**EP-14-737**  
Implementation of active drug safety and monitoring in the programmatic management of drug-resistant TB: early learnings from Uganda  
Oral Presenter: Enock Kizito (Kampala, Uganda)

**EP-14-738**  
No association between HIV status and MDR-TB treatment outcomes in Lesotho  
Oral Presenter: Lawrence Oyewusi (Maseru, Lesotho)
<table>
<thead>
<tr>
<th>Type</th>
<th>Title</th>
<th>Oral Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP-14</td>
<td>Addressing loss to follow-up and mortality among patients receiving treatment for drug-resistant TB: lessons from Uganda</td>
<td>Kenneth Mutesasira (Kampala, Uganda)</td>
<td>Kampala, Uganda</td>
</tr>
</tbody>
</table>

**Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments**

**Type: E-posters**

**Channel: E-posters (accessible on-demand)**

<table>
<thead>
<tr>
<th>EP-15</th>
<th>Access to quality TB care and services</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EP-15</td>
<td>Effects of zinc and vitamin A supplementation on TB treatment outcomes and its prognostic markers</td>
<td>Fasil Wagnew (Canberra, Australia)</td>
</tr>
<tr>
<td>EP-15</td>
<td>Acceptability and feasibility of integrating TB services into paediatric care in Cameroon and Kenya</td>
<td>Muhamed Mbunka Awolu (Yaounde, Cameroon)</td>
</tr>
<tr>
<td>EP-15</td>
<td>Improving sputum follow-up and TB cure rate using quality improvement approaches: lessons from Namutumba District, Nigeria</td>
<td>Michael Abwot (Kampala, Uganda)</td>
</tr>
<tr>
<td>EP-15</td>
<td>Training peripheral health staff and monitoring quality of chest X-ray interpretation for TB diagnosis in children</td>
<td>Pierre-Yves Norval (Autichamp, France)</td>
</tr>
<tr>
<td>EP-15</td>
<td>Interventions to improve adolescent and young adult TB service provision from the perspectives of adolescents, healthcare workers and policy stakeholders</td>
<td>Patricia Moscibrodzki (Calgary, Canada)</td>
</tr>
</tbody>
</table>
Oral Presenter: Lawrence Udoudoh (Makurdi, Nigeria)

Oral Presenter: Jeanne Chauffour (Arlington, United States)

Oral Presenter: Azizullah Hamim (Kabul, Afghanistan)

Oral Presenter: Ahmed Ali (Riyadh, Saudi Arabia)
Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

**EP-16**  
**Treatment selection and patient support opportunities to improve treatment outcomes**

**EP-16-751**  
Feasibility and acceptability of a peer-led socio-economic intervention for TB-affected households in Peru: feedback from the CRESIPT trial

Oral Presenter: Matthew J. Saunders (London, United Kingdom)

**EP-16-752**  
Rethinking how we define treatment effects for TB trials using estimands

Oral Presenter: Tra My Pham (London, United Kingdom)

**EP-16-753**  
Favourable outcomes of new treatment regiments in an operational research context in Tajikistan

Oral Presenter: Saodat Qosimova (Dushanbe, Tajikistan)

**EP-16-754**  
Effectiveness of using bedaquiline, linezolid, clofazimine as core drugs when fluoroquinolones are unlikely to be active

Oral Presenter: Chengbo Zeng (Boston, United States)

**EP-16-755**  
Safety and tolerability of increased-dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis

Oral Presenter: Angharad Davis (London, United Kingdom)

**EP-16-756**  
Risk factors for unfavourable outcomes of MDR-TB regimens using bedaquiline, linezolid and clofazimine in Peru

Oral Presenter: Sara Perea (Lima, Peru)

**EP-16-757**  
Effectiveness and safety of bedaquiline-based, modified shorter treatment regimen for rifampicin-resistant TB in Vietnam

Oral Presenter: Thi Mai Phuong Nguyen (Hanoi, Vietnam)

**EP-16-758**  
Linezolid resistance among MDR-TB patients from metropolitan cities of Pune and Mumbai, Western Maharashtra, India

Oral Presenter: Dwaragesh Natarajan (Pune, India)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP-16-759</td>
<td><strong>All-oral short-course MDR-TB regimens in China: a multi-centre, open-labelled, non-randomised controlled trial</strong></td>
<td>Oral Presenter: Liang Fu (Shenzhen, China)</td>
</tr>
<tr>
<td>EP-16-760</td>
<td><strong>Impact of a mobile phone-based interactive voice response software on TB treatment outcomes at public facilities in Uganda</strong></td>
<td>Oral Presenter: Mackline Hope (Kampala, Uganda)</td>
</tr>
</tbody>
</table>

**Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments**

**Type: E-posters**

**Channel: E-posters (accessible on-demand)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP-17-761</td>
<td><strong>Screening and preventive interventions finding the correct balance</strong></td>
<td></td>
</tr>
<tr>
<td>EP-17-762</td>
<td><strong>Prevalence of TB infection among household contacts of persons with pulmonary TB in Mumbai, India</strong></td>
<td>Oral Presenter: Mangala Gomare (Mumbai, India)</td>
</tr>
<tr>
<td>EP-17-762</td>
<td><strong>Implementation of an integrated care strategy for children household contacts of patients with pulmonary TB Colombia, 2021–2022</strong></td>
<td>Oral Presenter: Dione Benjumea-Bedoya (Medellín, Colombia)</td>
</tr>
<tr>
<td>EP-17-763</td>
<td><strong>Efficacy of TB preventive therapy in a national cohort of people with HIV</strong></td>
<td>Oral Presenter: Nunurai Ruswa (Windhoek, Namibia)</td>
</tr>
<tr>
<td>EP-17-764</td>
<td><strong>Multidrug-resistant TB diagnosis to treatment gap in Cameroon: lessons from clinic audits in five regions</strong></td>
<td>Oral Presenter: Rogers Ajeh (Douala, Cameroon)</td>
</tr>
<tr>
<td>EP-17-765</td>
<td><strong>Operational implementation of 3-month rifampicin and isoniazid for household contacts in Indonesia</strong></td>
<td>Oral Presenter: Felisia Felisia (Sleman, Indonesia)</td>
</tr>
<tr>
<td>EP-17-766</td>
<td><strong>Comparison of yield from symptomatic W4SS screening and mass mobile X-ray in schoolchildren in Lagos, Nigeria</strong></td>
<td>Oral Presenter: Abiola Alege (Lagos, Nigeria)</td>
</tr>
</tbody>
</table>
EP-17-767  The negative and positive predictive value of interferon-γ release assays for the development of TB disease in a TST-positive population
Oral Presenter: Caro Damarjanan (Den Haag, Netherlands)

EP-17-768  Improving uptake of TB preventive therapy among contacts of TB patients in Nigeria
Oral Presenter: Obioma Chijioke-Akaniro (Abuja, Nigeria)

EP-17-769  Efficacy and safety of a new 1-month regimen of rifapentine plus isoniazid to prevent TB in Chinese silicosis patients
Oral Presenter: Qiaoling Ruan (Shanghai, China)

EP-17-770  Incidence of lymphadenitis following bacille Calmette–Guérin vaccination in North Indian children
Oral Presenter: S Rangesh (Chandigarh, India)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments
Type: E-posters
Channel: E-posters (accessible on-demand)

EP-18  Tuberculosis laboratory services: challenges and solutions

EP-18-771  TB-LAMP for the expansion of diagnostic access: planned and purposeful implementation
Oral Presenter: Nkiru Nwokoye (Abuja, Nigeria)

EP-18-772  Strengthening institutional capacity for improved TB diagnostics laboratory services in the Kyrgyz Republic
Oral Presenter: Gulmira Kalmamabetova (Bishkek, Kyrgyzstan)

Oral Presenter: Vidyanidhi Gumma (Delhi, India)

EP-18-774  Improving quantification of TB laboratory supplies by using standardised quantification tool in Ethiopia
Oral Presenter: Pawlos Reji (Addis Ababa, Ethiopia)
EP-18-775  TB diagnostic network assessment: a critical input to achieve TB goals and targets in Tanzania
Oral Presenter: Samwel Mulungu (Dar Es Salaam, Tanzania)

EP-18-776  Rapid drug susceptibility testing for fluoroquinolone resistance in rifampicin-resistant TB patients using the Xpert MTB/XDR assay
Oral Presenter: Faisal Masood Khanzada (Islamabad, Pakistan)

EP-18-777  National TB Programme strategy of switching to Xpert as the primary diagnostic test for rapid TB diagnosis in Uzbekistan
Oral Presenter: Rafis Rakhmatillin (Tashkent, Uzbekistan)

EP-18-778  Impact of Xpert site optimisation on diagnostic error rates in Nigeria
Oral Presenter: Shalom Balogun (Abuja, Nigeria)

EP-18-779  Xpert device module failure and underutilisation: major changes in Ethiopia’s Xpert MTB/RIF assay rollout
Oral Presenter: Endale Mengesha Goshu (Addis Ababa, Ethiopia)

EP-18-780  Gloom and boom: the real impact of COVID-19 on Xpert TB testing volumes
Oral Presenter: Brad Cunningham (Northampton, United States)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments
Type: E-posters
Channel: E-posters (accessible on-demand)

EP-19  TB diagnostics speed and availability

EP-19-781  Performance of the TB-LAMP assay for the rapid diagnosis of pulmonary TB in Tunisia
Oral Presenter: Imen Bouzouita (Ariana, Tunisia)

EP-19-782  Validating proficiency testing panels of the new Truenat™ TB assays in India using CDC’s dried tube specimen technology
Oral Presenter: Shipra Bhargava (New Delhi, India)
Oral Presenter: Valerie Flore Donkeng Donfack (Yaounde, Cameroon)

Oral Presenter: Nkiru Nwokoye (Abuja, Nigeria)

EP-19-785  Support package for Truenat™ MTB-RIF Dx assay implementation at the peripheral level
Oral Presenter: Erik Reisdorf (Rockville, MD, United States)

Oral Presenter: Rosa Bellido (Lima, Peru)

EP-19-787  Impact of gaps in accessing second-line line-probe assay testing on enrolment in drug-resistant treatment of confirmed cases with rifampicin resistance
Oral Presenter: Sharmin Islam (Dhaka, Bangladesh)

EP-19-788  Diagnostic performance of the GenoType MTBDRplus v2.0 line-probe assay in the detection of isoniazid-resistant M. tuberculosis in Ethiopia
Oral Presenter: Shewki Moga Siraj (Addis Ababa, Ethiopia)

EP-19-789  Alignment of care-seeking behaviour with diagnostic availability in health facilities in Nigeria
Oral Presenter: Bethrand Odume (Abuja, Nigeria)

EP-19-790  Impact of continuous mentorship of TB diagnostic and treatment units in the national Health Management Information System in Kampala, Wakiso and Mukono, Uganda
Oral Presenter: Hellen Namwanje (Kampala, Uganda)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments
Type: E-posters
Channel: E-posters (accessible on-demand)
EP-20 Access to rapid testing for TB

EP-20-791 Access to GeneXpert testing and yield of TB across different outpatient department settings in Ethiopia

Oral Presenter: Taye Letta (Addis Ababa, Ethiopia)

EP-20-792 Evidence of active TB among individuals with a trace result on Xpert Ultra during community-based TB screening in Kampala, Uganda

Oral Presenter: Mariam Nantale (Kampala, Uganda)

EP-20-793 Outcome of culture and DST on trace MTB, rifampicin-indeterminate Ultra results at Zimbabwe National Tuberculosis Reference Laboratory, January 2019–December 2021

Oral Presenter: Barbara Manyame-Murwira (Bulawayo, Zimbabwe)

EP-20-794 Role of repeat Xpert Ultra test after trace results: an experience from Vietnam

Oral Presenter: Cuong Duong (Hanoi, Vietnam)

EP-20-795 The simple one-step stool processing method for Xpert Ultra is robust: results from an optimisation study in Ethiopia

Oral Presenter: Bazezew Yenew (Addis Ababa, Ethiopia)


Oral Presenter: Imen Bouzouita (Ariana, Tunisia)

EP-20-797 Addressing the social determinants and consequences of TB (ASCOT): interim findings from the ASCOT pilot randomised-controlled trial in Nepal

Oral Presenter: Bhola Rai (Kathmandu, Nepal)

EP-20-798 Finding TB among HIV-positive clients: use of lateral flow urine lipoarabinomannan assay test kit to find missing TB cases

Oral Presenter: Ifiok Ekanim (Uyo, Nigeria)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)
Various lessons learnt from active case finding

Pooled testing of sputum with Xpert MTB/RIF and Xpert Ultra in TB active case-finding intervention in Lima, Peru

Oral Presenter: Yorka Alania (Lima, Peru)

Intensified TB case-finding using digital X-ray and CAD4TB among people living with HIV receiving care at health facilities in Uganda

Oral Presenter: Burua Aldo (Kampala, Uganda)

Finding missing TB cases using digital chest X-ray with computer-aided detection during TB screening in South Africa

Oral Presenter: Lynette Duckworth (Durban, South Africa)

Early TB case detection by community-based mobile X-ray screening and Xpert testing in Balochistan, Afghanistan

Oral Presenter: Ahmad Wali (Quetta, Pakistan)

Results from a contact investigation strategy piloting the use of an ultraportable radiography system in Ho Chi Minh City, Vietnam

Oral Presenter: Lan Anh Hoang (Ha Noi, Vietnam)

Programmatic approach to positively screened TB active case-finding participants with negative molecular confirmatory test

Oral Presenter: Bintari Dwihardiani (Yogyakarta, Indonesia)

Implementation of an electronic information channel for data exchange on TB cases in Uzbekistan

Oral Presenter: Usmonjon Mikhmanov (Tashkent, Uzbekistan)

Improved targeting of active case-finding in India using an index of individual vulnerability to TB

Oral Presenter: Akash Dey (New Delhi, India)

Programmatic implementation of contact investigation in eight African countries

Oral Presenter: Kobto Ghislain Koura (Paris, France)

Finding the missing child TB cases: using stool samples for Xpert Ultra testing among malnourished children in Kano State, Nigeria

Oral Presenter: AbdurRazaq Dikko (Kano, Nigeria)
Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

**EP-22**

**Imaging tuberculosis infection**

**EP-22-809** Artificial intelligence reading of chest X-rays to triage pulmonary TB at health facilities in Vietnam

Oral Presenter: Cuong Duong (Hanoi, Vietnam)

**EP-22-810** Computer-aided triaging of chest X-ray images to reduce radiologists’ workload during TB screening: a comparison of three softwares

Oral Presenter: Thang P. Dao (Ho Chi Minh City, Vietnam)

**EP-22-811** A Deep learning-based approach for automatic detection of pulmonary nodules on chest radiographs

Oral Presenter: Richa Pant (Pune, India)

**EP-22-812** Augmenting TB case-finding in the private sector involving artificial intelligence-enabled reading of chest X-ray images in Bhilwara and Nagaur, Rajasthan, India

Oral Presenter: Ashvini Vyas (Jaipur, India)

**EP-22-813** Utility of a social media platform to help chest X-ray interpretation in Cambodia

Oral Presenter: Chanthe Thor (Phnom Penh, Cambodia)


Oral Presenter: Heejun Shin (Seoul, Korea, Republic of)

**EP-22-815** Improving TB case detection through systematic screening using artificial intelligence computer-aided detection software for X-ray interpretation in Cambodia

Oral Presenter: Kimcheng Choun (Phnom Penh, Cambodia)

**EP-22-816** Inter-observer agreement of chest X-rays of household contacts

Oral Presenter: Mayara Lisboa Bastos (Montreal, Canada)

**EP-22-817** Comparison of CAD-reported chest X-ray findings of culture-confirmed pulmonary TB in persons with and without diabetes
Oral Presenter: Coralie Geric (Montreal, Canada)

**EP-22-818**
An artificial intelligence-based approach for automated assessment of chest CT severity scores in patients suspected of COVID-19 infection

Oral Presenter: Richa Pant (Pune, India)

**EP-22-819**
Implementation of a portable digital X-ray intervention in special populations in Kano and Katsina states, Nigeria

Oral Presenter: Mustapha Tukur (Kano, Nigeria)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

**EP-23**
Pathways to tuberculosis diagnosis and treatment

**EP-23-820**
Diagnosis of TB among suspected COVID-19 cases in Ghana

Oral Presenter: Theophilus Affum (Accra, Ghana)

**EP-23-821**
Workable strategies for active TB case-finding among goldminers in Ethiopia

Oral Presenter: Mengistu Kenea Wakjira (Addis Ababa, Ethiopia)

**EP-23-822**
Patient pathways and delays in diagnosis and treatment of TB in a peri-urban setting in Mozambique

Oral Presenter: Pedroso Nhassengo (Maputo, Mozambique)

**EP-23-823**
Impact of the COVID-19 pandemic on patients’ experiences of obtaining a TB diagnosis in Lima, Peru

Oral Presenter: Ana Karina Millones Gómez (Lima, Peru)

**EP-23-824**
Can point-of-care ultrasound support TB diagnosis in children? The MSF experience in Guinea-Bissau

Oral Presenter: Laura Moretó-Planas (Barcelona, Spain)

**EP-23-825**
Benefits of strengthening TB-HIV collaboration: a case study of General Hospital Oron, Nigeria
Oral Presenter: Ifiok Ekanim (Uyo, Nigeria)

**EP-23-826**Evaluating the impact of a radio campaign on TB testing and case notifications in Zambezia, Mozambique

Oral Presenter: Sonali Wayal (London, United Kingdom)

**EP-23-827**Electronic case-based surveillance system: improving drug-resistant TB reporting rates in Uganda

Oral Presenter: Hellen Namwanje (Kampala, Uganda)

**EP-23-828**Factors associated with the first consultation at private health providers at the onset of TB symptoms: a cross-sectional study in The Gambia

Oral Presenter: Olumuyiwa Owolabi (Banjul, Gambia)

**EP-23-829**Feasibility, acceptability and yield of systematic TB screening in children at primary health centres and district hospitals: a multi-country mixed-methods study

Oral Presenter: Naome Natukunda (Mbarara, Uganda)

---

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

**EP-24**Drugs, dosing and resistance

**EP-24-830**Re-evaluation of the critical concentration of newer and repurposed anti-TB drugs for the phenotype-based wild-type M. tuberculosis isolates in and around Chennai, India

Oral Presenter: Azger Dusthackeer (Chennai, India)

**EP-24-831**Characterisation of embB406 mutations and variable ethambutol resistance among M. tuberculosis isolates in Canada

Oral Presenter: Morgan Hiebert (Winnipeg, Canada)

**EP-24-832**Managing the implementation of active drug safety monitoring of new anti-tuberculosis drugs in Kazakhstan

Oral Presenter: Shynar Maretbayeva (Alma-Ata, Kazakhstan)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Oral Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP-24-833</td>
<td>Assessment of whole-genome sequencing for predicting drug resistance and transmission of TB</td>
<td>Kuang-Hung Liu (Taipei, Taiwan)</td>
</tr>
<tr>
<td>EP-24-834</td>
<td>Second-line drug resistance to fluoroquinolone among patients with rifampicin-resistant and multidrug-resistant TB in Nepal</td>
<td>Bhagwan Maharjan (Thimi, Bhaktapur, Nepal)</td>
</tr>
<tr>
<td>EP-24-835</td>
<td>MDR-TB data enhancement: role of data quality mentorship at MDR sites in Uganda</td>
<td>Hellen Namwanje (Kampala, Uganda)</td>
</tr>
<tr>
<td>EP-24-836</td>
<td>Pathogen-targeted next-generation sequencing (ptNGS) for rapid and accurate diagnosis of TB in children</td>
<td>Lichao Fan (Shenyang, China)</td>
</tr>
<tr>
<td>EP-24-838</td>
<td>Genotypic diversity and drug resistance of M. tuberculosis strains in Moldova</td>
<td>Elena Chesov (Chisinau, Moldova)</td>
</tr>
<tr>
<td>EP-24-839</td>
<td>Gender disparities in multidrug-resistant TB</td>
<td>Ameni Naaroura (Tunis, Tunisia)</td>
</tr>
</tbody>
</table>

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments
Type: E-posters
Channel: E-posters (accessible on-demand)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Oral Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP-25-840</td>
<td>A novel quantitative molecular assay for accurate diagnosis and monitoring response to antibiotic therapy of bacteria underlying COPD exacerbation</td>
<td>Natasha Walbaum (St Andrews, United Kingdom)</td>
</tr>
<tr>
<td>EP-25-841</td>
<td>Humoral response to human cytomegalovirus and risk of pulmonary TB in adolescents</td>
<td></td>
</tr>
</tbody>
</table>
Oral Presenter: Jeremi Swanepoel (Cape Town, South Africa)


Oral Presenter: Richard Nkusa (Masaka, Uganda)

EP-25-843  Usability and acceptability of the tuberculin skin test and interferon-γ release assays among groups at high risk of TB infection in Mexicali, Mexico

Oral Presenter: Amanda Brumwell (Seattle, United States)

EP-25-844  Comparison of positivity for TB infection and test concordance using two diagnostic tests among a prison population in Mexicali, Mexico

Oral Presenter: Amanda Brumwell (Seattle, United States)

EP-25-845  Introduction of external quality assessment for Truenat™ MTB-RIF at peripheral-level laboratories in Zimbabwe

Oral Presenter: Erik Reisdorf (Rockville, MD, United States)

EP-25-846  Concordance of TB infection diagnostic tests among two high-risk groups in Mexicali, Mexico

Oral Presenter: Amanda Brumwell (Seattle, United States)

EP-25-847  Impact of decentralising childhood TB diagnosis at primary health centre and district hospital levels on case detection in high TB burden countries

Oral Presenter: Eric Wobudeya (Uganda)

EP-25-848  Clinical profiles of urine LAM-positive children lacking microbiological confirmation in South Africa

Oral Presenter: Mark Fajans (Seattle, United States)

EP-25-849  Impact of monocytes differentiation pathways in M. tuberculosis complex lineages infection

Oral Presenter: Salem Mberkadji Ngana (The Gambia, Gambia)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters
Channel: E-posters (accessible on-demand)

**EP-26**

**Improved methods for TB case finding**

**EP-26-850**
Framework for implementation of intensified TB case-finding in health facilities: lessons from the KNCV Nigeria TB LON Project

Oral Presenter: Ogoamaka Chukwuogo (Abuja, Nigeria)

**EP-26-851**
Multi-sector forum as an advocacy vessel to increase local funding for TB programme in two cities in Indonesia

Oral Presenter: Jhon Sugiharto (Jakarta, Indonesia)

**EP-26-852**
Developing a predictive tool to identify and prioritise people with TB at risk of incurring catastrophic costs for social protection in Vietnam

Oral Presenter: Rachel Forse (Ha Noi, Vietnam)

**EP-26-853**
Exploring the role of the public–private mix sector in TB care in Afghanistan

Oral Presenter: Azizullah Hamim (Kabul, Afghanistan)

**EP-26-854**
TB cascade of care in Mozambique, 2020–2021

Oral Presenter: Algyl Abdula (Maputo, Mozambique)

**EP-26-855**

Oral Presenter: Ilueme Precious (Port Harcourt, Nigeria)

**EP-26-856**
Closing TB notification gaps through registration of hospitalised clients

Oral Presenter: Ntokozo Gama (Mbabane, Eswatini)

**EP-26-857**
TB contact screening and preventive therapy initiation in India

Oral Presenter: Nayana Siddalingaiah (Udupi, India)

**EP-26-858**
Improved TB case detection rate during COVID-19: experience from the National Tuberculosis Reference Laboratory, Bangladesh

Oral Presenter: Sharmin Islam (Dhaka, Bangladesh)

**EP-26-859**
Early implementation experience on the use of CAD-enabled ultra-portable X-ray machine for active TB case-finding in Oyo State, Nigeria

Oral Presenter: Jamiu Olabamiji (Lagos, Nigeria)
Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

EP-27  How tailored care can make a difference.
EP-27-860  Person-centred care for multidrug-resistant TB patients with alcohol use disorder
Oral Presenter: Rebecca E. Harrison (Minsk, Belarus)

EP-27-861  Implementation of patient support strategies for drug-resistant TB patients in palliative care at a MSF independent clinic, Mumbai, India
Oral Presenter: Santosh Jha (Mumbai, India)

EP-27-862  Orientation of clinicians at high-load health facilities improved TB case notification in Ethiopia
Oral Presenter: Berhanemeskal Assefa (Addis Ababa, Ethiopia)

EP-27-863  Provider attitudes towards ambulatory treatment and incentive payments: facilitating the transition towards patient-centred care in Kyrgyzstan
Oral Presenter: Samantha Huffman (Bishkek, Kyrgyzstan)

EP-27-864  Empowering TB patients with information using TB Aarogya Sathi, a mobile application for TB control in India
Oral Presenter: Sanjay Kumar Mattoo (Delhi, India)

EP-27-865  From a TB patient to a 'TB warrior': a case study from Kampala, Uganda
Oral Presenter: Kenneth Mutesasira (Kampala, Uganda)

EP-27-866  Gender disparities in drug-resistant TB treatment outcomes in KwaZulu-Natal, South Africa
Oral Presenter: Suzanne Staples (Durban, South Africa)

Oral Presenter: Thu-Anh Nguyen (Hanoi, Vietnam)
Intermediate results of implementing video-supported treatment at the USAID activity sites in Uzbekistan
Oral Presenter: Begimkul Kholikulov (Tashkent, Uzbekistan)

People-centred care during the war in Ukraine: how TB patients' needs have changed
Oral Presenter: Evgenia Geliukh (Kyiv, Ukraine)

TB treatment adherence among drug-susceptible TB persons using a medication monitor and differentiated care vs. standard of care in South Africa
Oral Presenter: Noriah Maraba (Johannesburg, South Africa)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments
Type: E-posters
Channel: E-posters (accessible on-demand)

Key affected populations and person-centred care

Increasing child TB patient-finding during the COVID-19 pandemic through a story-based social and behaviour change campaign in Bataan, The Philippines
Oral Presenter: Kristian Paul Soliven (Makati, Philippines)

Context-specific contact investigation what community-based organisations and healthcare workers bring to the fore in Kano State, Nigeria
Oral Presenter: Gideon Zephaniah (Kano, Nigeria)

Enhanced TB case-finding offset the anticipated reduction in TB case notifications due to conflict in Ethiopia
Oral Presenter: Taye Letta (Addis Ababa, Ethiopia)

A proud South African youth experience: screening, finding missing TB cases in communities and linkage to care
Oral Presenter: Shriya Misra (Durban, South Africa)

Building capacity of healthcare workers to achieve excellence in TB care and services: experiences from India
Oral Presenter: Abhijith Njarattil Parameswaran (New Delhi, India)
<table>
<thead>
<tr>
<th>EP-28-876</th>
<th>The role of 99DOTS digital adherence technology to support TB treatment adherence among adolescents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Presenter: Peter Wambi (Kampala, Uganda)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP-28-877</th>
<th>Feasibility and acceptability of the smart pill box with differentiated response to support person-centred TB care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Presenter: Amare Worku Tadesse (London, United Kingdom)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP-28-878</th>
<th>Best practice and challenges in improving TB treatment enrolment and adherence support for private health facilities: an experience from Indonesia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Presenter: Surya Windari (Jakarta, Indonesia)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Presenter: Jason Alacapa (Makati City, Philippines)</td>
<td></td>
</tr>
</tbody>
</table>

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

<table>
<thead>
<tr>
<th>EP-29</th>
<th>TB prevention, diagnosis, treatment and costs</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>EP-29-880</th>
<th>Automation of data entry and processing in laboratories using barcoding and laboratory management information system</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Presenter: Muneer Mammi Kutty (New Delhi, India)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP-29-881</th>
<th>Direct healthcare costs to achieve TB case detection and TB preventive treatment targets set by the 2018 UN High-Level Meeting on Tuberculosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Presenter: Srinath Satyanarayana (New Delhi, India)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP-29-882</th>
<th>Overcoming drug resistance in M. tuberculosis: AI-driven virtual screening to identify FDA-approved drugs as potential therapeutics for TB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Presenter: Mukta Sharma (Bengaluru, India)</td>
<td></td>
</tr>
</tbody>
</table>

|-----------|--------------------------------------------------------------------------------------------------|
Oral Presenter: Mariame Traore (Bamako, Mali)

EP-29-884 Improving TB monitoring, evaluation and surveillance using a virtual centre of excellence model

Oral Presenter: Nino Lomtadze (Tbilisi, Georgia)

EP-29-885 Scaling up TB preventive therapy in household contacts of all ages in Yogyakarta Province, Indonesia

Oral Presenter: Betty Nababan (Yogyakarta, Indonesia)

EP-29-886 Management of children and adolescents exposed to rifampicin-resistant TB in the household

Oral Presenter: Ivy Apolisi (Cape Town, South Africa)

EP-29-887 Incorporating sustainability in TB programming

Oral Presenter: Phoebe Nzombe (Harare, Zimbabwe)

EP-29-888 Effectiveness of using an interactive voice response system as a health training delivery platform: a report from South India

Oral Presenter: Raghini Ranganathan (Chennai, India)

EP-29-889 Cost and time-efficient approach for assessing baseline TB awareness in Indian youth: a digital targeted methodology

Oral Presenter: Niraj Sharma (New Delhi, India)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

EP-30 Knowledge is power!

EP-30-890 Overcoming stigma as a barrier to TB contact investigation: utility of the KNCV Nigeria spot-to-tent model

Oral Presenter: Ogoamaka Chukwuogo (Abuja, Nigeria)
EP-30-891  Health seeking behaviour, knowledge and stigma around TB: findings from a baseline study of a behaviour change intervention in specific vulnerable population groups in India
Oral Presenter: Atreyee Sinha (Bengaluru, India)

EP-30-892  TB stigma assessment in Mongolia
Oral Presenter: Tsogt Bazarragchaa (Ulaanbaatar, Mongolia)

19:24 – 19:32  EP-30-893  Developing and testing training tools to engage informal healthcare providers in TB prevention, care and support services: experiences from a project implemented in India
Oral Presenter: Vikas Panibatla (Hyderabad, India)

Oral Presenter: Sani Useni (FCT, Nigeria)

19:40 – 19:48  EP-30-895  TB Mukt Certificate (TB treatment completion certificate), a powerful tool to address social and self stigma
Oral Presenter: Prakash Sandur (Bangalore, India)

Oral Presenter: Gideon Zephaniah (Kano, Nigeria)

Oral Presenter: Maria Brunette (Columbus, United States)

20:04 – 20:12  EP-30-898  TB knowledge among private providers not engaged with the National TB Programme in urban Lagos, Nigeria
Oral Presenter: Victor Abiola Adepoju (Abuja, Nigeria)

20:12 – 20:20  EP-30-899  Building perspectives of field health practitioners and community leaders on vulnerability and gender to implement robust community engagement models for TB
Oral Presenter: Shramana Majumder (Bangalore, India)
Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

**EP-31**

**Not one size fits all!**

**EP-31-910**
Assessment of TB awareness and perceptions among four socio-economically disadvantaged communities in the Philippines

Oral Presenter: Christine Joy Candari (Makati, Philippines)

**EP-31-911**
Impact of community-based TB control activities in Bouake prisons in Cote d’Ivoire, January–June 2019 [Impact des activités communautaires de lutte contre la TB dans les prisons de Bouake en Cote d’Ivoire de Janvier a Juin 2019]

Oral Presenter: Abdoulaye Fougnigue Ouattara (Bouake, Cote D’Ivoire)

**EP-31-912**
Stigma, mental health and quality of life of people with TB in Nepal: a longitudinal, prospective cohort study

Oral Presenter: Kritika Dixit (Kathmandu, Nepal)

**EP-31-913**
A qualitative exploration of the psychosocial impact of TB in adolescents and young people

Oral Presenter: Patricia Moscibrodzki (Calgary, Canada)

**EP-31-914**
Understanding disease disclosure patterns of people with TB and its outcomes: findings from a longitudinal follow up study in Chennai, India

Oral Presenter: Karikalan Nagarajan (Chennai, India)

**EP-31-915**
Community-based care delivery improves retention in care and treatment completion among patients on TB treatment in a nomadic community in Uganda

Oral Presenter: Tadeo Nsubuga (Kampala, Uganda)

**EP-31-916**
Rapid assessment of the burden of depression and anxiety among TB patients through telephone
Oral Presenter: Atreyee Sinha (Bengaluru, India)

EP-31-917  Understanding differentiated preferences for non-adherence follow-up among TB patients across rural and urban India

Oral Presenter: Devika Kapadia (Mumbai, India)

EP-31-918  We are TB-free: branding local health workers as TB navigators in the Philippines

Oral Presenter: Nilo Yacat (Makati, Philippines)

EP-31-919  Residents of missionary centres, mine workers and prison inmates are key populations affected by TB in Ethiopia

Oral Presenter: Wogayehu G Tafesse (Addis Ababa, Ethiopia)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

EP-32  Programmatic issues in the cascade of care

EP-32-920  Improving programme monitoring through the TB Command Centre under the National TB Elimination Programme, India

Oral Presenter: Sanjay Kumar Mattoo (Delhi, India)

EP-32-921  Rapid efficiencies in policy adoption through policy influence plan and consultative engagements revolutionalise the TB preventive therapy landscape in Zimbabwe

Oral Presenter: Juliet Jokwiro (Harare, Zimbabwe)

EP-32-922  Early lessons of rolling out TB preventive therapy among household contacts of patients with pulmonary TB in India

Oral Presenter: Aakshi Kalra (Delhi, India)

EP-32-923  M. tuberculosis-specific multiple cytokine response in different TB infection status: an exploratory study

Oral Presenter: Lifan Zhang (Beijing, China)

EP-32-924  Why does the locale matter when implementing mHealth interventions in routine MDR-TB care?

Oral Presenter: Dorothy Drabarek (Sydney, Australia)
EP-32-925  Efficacy, adherence and safety of latent TB infection treatments: systematic review and network meta-analysis of randomised controlled trials

Oral Presenter: Dawit Getachew Assefa (Addis Ababa, Ethiopia)

EP-32-926  Predicting factors of latent TB infection in long-term care facilities in Taiwan, 2018–2021

Oral Presenter: Pin Hui Lee (Taipei, Taiwan)

EP-32-927  Beyond patient delay: navigating structural health system barriers to timely care and treatment in a TB-endemic setting in Papua New Guinea

Oral Presenter: Paula Jops (Sydney, Australia)

EP-32-928  Community-based contact screening to enhance uptake of TB preventive therapy in household contacts in Sidama and SNNP Regions, Ethiopia

Oral Presenter: Eshetu Abdissa (Addis Ababa, Ethiopia)

EP-32-929  Assessing and refining image analysis software to automate reading of objective home-based TB adherence tests

Oral Presenter: Kyle Goodwin (Seattle, United States)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

EP-33  Lung health across the life course and after TB

EP-33-930  Psychosocial sequelae following treatment for pulmonary TB: qualitative results from an international multi-stakeholder participatory workshop

Oral Presenter: Oluwatosin Nkereuwem (Fajara, Gambia)

EP-33-931  Factors associated with poor retention in the TB Sequel Study after successful completion of TB treatment

Oral Presenter: Denise Evans (Johannesburg, South Africa)

EP-33-932  Pulmonary function in survivors of severe pneumonia in early childhood: a cohort study in Uganda

Oral Presenter: Shawheen Rezaei (Boston, United States)
EP-33-933  Comparing alcohol consumption by sex during and after TB treatment: a longitudinal study of a South African cohort

Oral Presenter: Sarah E. Weber (Boston, United States)


Oral Presenter: Feiling Ai (Beijing, China)

EP-33-935  Diffusion impairment in asthma–COPD overlap: does it matter?

Oral Presenter: Gyanshankar Mishra (Nagpur, India)

EP-33-936  Clinical characteristics and management of children below 5 years admitted for very severe community-acquired pneumonia in Africa and South East Asia

Oral Presenter: Agathe de Lauzanne (Phnom Penh, Cambodia)

EP-33-937  Perspectives of post-TB healthcare delivery among healthcare workers in urban Blantyre, Malawi

Oral Presenter: Wezi Msukwa-Panje (Blantyre, Malawi)

EP-33-938  Characterising TB-related stigma and associated factors among patients in Uganda

Oral Presenter: Juliet Sekandi (Athens, United States)

EP-33-939  Effectiveness of the post-TB lung disease intervention in affected individuals in northern Tanzania

Oral Presenter: Florence J. Mtei (Kilimanjaro, Tanzania)


Oral Presenter: Sarah Matoi (Kilimanjaro, Tanzania)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)
EP-34 | Post TB lung health, case finding, DR-TB management
---|---
EP-34-941 | Cavitory lesions are associated with increased levels of matrix metalloproteinases after successful TB treatment
Oral Presenter: Argita Salindri (Atlanta, United States)

EP-34-942 | TB recurrence among individuals recently treated for TB in India
Oral Presenter: Madhusudan Barthwal (Pune, India)

Oral Presenter: Menonli Adjobimey (Cotonou, Benin)

Oral Presenter: Hauwa Usman Garba (Katsina, Nigeria)

EP-34-945 | Reaching the unreached: TB diagnosis in children in Madhesh Province of Nepal
Oral Presenter: Rajesh Sah (Makawanpur, Nepal)

EP-34-946 | Treatment outcomes among drug-resistant TB children below 10 years treated with newer drugs in Médecins Sans Frontières Clinic, Mumbai, India
Oral Presenter: Pramila Singh (Mumbai, India)

EP-34-947 | Scaling up paediatric DR-TB management in a high TB burden district in South Africa
Oral Presenter: Sipho Nyathie (Pretoria, South Africa)

EP-34-948 | Post-TB lung disease: community-based lung rehabilitation in Malawi
Oral Presenter: Bruce Matewere (Lilonwe, Malawi)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments
Type: E-posters
Channel: E-posters (accessible on-demand)

EP-35 | TB and comorbidities
Oral Presenter: Chin-Chung Shu (Taipei, Taiwan)

EP-35-950  The role of continuous cough sound detection for TB treatment monitoring among people living with and without HIV
Oral Presenter: Alex Kityamuwesi (Kampala, Uganda)

EP-35-951  The impact of TB on lung cancer mortality
Oral Presenter: Chin-Chung Shu (Taipei, Taiwan)

Oral Presenter: Ishita Aggarwal (Chicago, United States)

EP-35-953  Early experience of integrated diabetes model of care in drug-resistant TB treatment at a nodal DR-TB centre, Mumbai, India
Oral Presenter: Sejal Tambah (Mumbai, India)

EP-35-954  Identifying patient-driven factors limiting TB preventive therapy uptake among adults with advanced HIV disease
Oral Presenter: Jane Gakuru (Kampala, Uganda)

EP-35-955  Risk factors and complications in TB patients hospitalised in the Pulmonology Department, Fann University Hospital Centre, Dakar, Senegal, from 2017 to 2019
Oral Presenter: Maimouna FAFA Cisse (Dakar, Senegal)

EP-35-956  Risk factors and treatment outcomes of active TB in patients diagnosed with diabetes mellitus: a retrospective matched case-control study
Oral Presenter: Trirong Choosongdet (Bangkok, Thailand)

EP-35-957  Intersectionality of malnutrition, diabetes and TB: experiences from the private sector in Chennai, India
Oral Presenter: Shruthi Basavardhya Sahukar (Chennai, India)

EP-35-958  The yield of chest X-ray based vs. symptom-based TB screening among patients with diabetes mellitus in public health facilities in Addis Ababa, Ethiopia
Oral Presenter: Chaltu Jiru (Addis Ababa, Ethiopia)
Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

EP-36 Global Examples of Tobacco Industry Interference

EP-36-959 Effective implementation of the WHO Framework Convention on Tobacco Control Article 17 in Mysuru District of Karnataka, India

Oral Presenter: Jael Thomas (Bengaluru, India)

EP-36-960 How household nutrition has been impacted by tobacco consumption in India: a state-level analysis

Oral Presenter: Sajda Khatoon (Kolkata, India)

EP-36-961 Understanding the reasons behind bidi workers’ protests in Bangladesh: a qualitative investigation

Oral Presenter: Md Hasan Shahriar (Dhaka, Bangladesh)

EP-36-962 Effective mitigation of educational institution-targeted tobacco industry interference: success, challenges and learnings of Karnataka, India

Oral Presenter: Prabhakara. (New Delhi, India)

EP-36-963 Corrupt tactics of the tobacco industry in Bangladesh

Oral Presenter: Samiul Hassan Shajib (Dhaka, Bangladesh)

EP-36-964 Tobacco consumption in West Bengal, India: a district-level comparative analysis using Demographic and Health Survey data

Oral Presenter: Paramita Bhattacharya (Kolkata, India)

EP-36-965 End-line compliance survey for tobacco advertising, promotion and sponsorship in eight districts of Uttarakhand, India

Oral Presenter: Yogesh Bahurupi (Rishikesh, India)

EP-36-966 The tobacco industry’s insidious tactics to reach children in India: the Conrad Challenge, 2021

Oral Presenter: Shivam Kapoor (New Delhi, India)
Assessing compliance with health warnings on tobacco packs marketed around 100 yards of educational institutions in an Eastern state of India

Oral Presenter: Nancy Satpathy (Bhubaneswar, India)

Do non-smokers live longer? A comparison of life expectancy of male smokers and non-smokers in India

Oral Presenter: Paramita Bhattacharya (Kolkata, India)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

Tobacco, nicotine, cannabis products and health effects

Estimating the proportion of Chinese lung cancer deaths due to smoking using three methods, 2000-2019

Oral Presenter: Feiling Ai (Beijing, China)

Beyond hashtags and likes: an exploratory study of electronic cigarettes-related social media posts in India

Oral Presenter: Shivam Kapoor (New Delhi, India)

The association between exposure to second-hand smoke and diseases in the Chinese population: a systematic review

Oral Presenter: Yutong Wang (Beijing, China)

Tobacco smoking in the early months of the COVID-19 pandemic among online social media users in Russia

Oral Presenter: Artyom Gil (Moscow, Russian Federation)

Getting high on hookah: correlates of smoking marijuana using waterpipe among US adults

Oral Presenter: Mohammad Ebrahimi Kalan (Chapel Hill, United States)

Smoking cessation intervention for TB patients in routine health service in Benin and Burkina-Faso: preliminary results from CesTA_TB pilot study
Oral Presenter: Attannon Arnauld Fiogbe (Cotonou, Benin)

EP-37-976 Designated smoking areas or dining cars? An observation assessment of trains in Bangladesh

Oral Presenter: Preethi Kannan (Baltimore, United States)

EP-37-977 Determinants of cigarette smoking and smoking intensity among women of reproductive age in Nigeria

Oral Presenter: Daniel Ogbuabor (Enugu, Nigeria)

EP-37-978 Smokeless tobacco as a risk factor for type 2 diabetes mellitus in South East Asia Region: systematic review and meta-analysis

Oral Presenter: Harshawardhan Sawane (Pune, India)

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

EP-38 Tobacco legislation and compliance

EP-38-979 Compliance assessment of the Cigarette and Other Tobacco Products Act in educational institutions in the Surguja District of Chhattisgarh, India

Oral Presenter: Sanjana Agrawal (Raipur, India)


Oral Presenter: Reiner Lorenzo Tamayo (Manila, Philippines)


Oral Presenter: Yulin Shi (Beijing, China)

EP-38-982 Compliance with smoke-free policies in public venues from 2018 to 2021 in Qingdao, China

Oral Presenter: Qinghua Nian (Baltimore, United States)

EP-38-983 Compliance monitoring of smoking prohibition under Section 4 of COTPA in the Surguja District of Chhattisgarh, India
Oral Presenter: Shikhar Sharma (Raipur, India)

**EP-38-984** Prevalence and compliance of designated smoking areas in hospitality venues and transport in Dhaka, Bangladesh

Oral Presenter: Sejal Saraf (Baltimore, United States)

**EP-38-985** Tobacco industry interference through corporate social responsibility using the State’s Education Department in rural Bengaluru, Karnataka, India

Oral Presenter: Jael Thomas (Bengaluru, India)

**EP-38-986** Perceptions of and reasons for transitions between tobacco products: findings from four waves of the International Tobacco Control Bangladesh Surveys

Oral Presenter: Daniel Tzu-Hsuan Chen (London, United Kingdom)

**EP-38-987** Bibliometric analysis of scientific publications on tobacco endgame during the period 2011–2021

Oral Presenter: Nidhi Jaswal (Chandigarh, India)


Oral Presenter: Suranji Dahanayake (York, United Kingdom)

---

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: E-posters

Channel: E-posters (accessible on-demand)

**EP-39** Community-based interventions to improve health for all

**EP-39-989** Defeating childhood TB: advocacy for a positive national policy and preparedness for childhood TB programming in 10 countries

Oral Presenter: David Ruiz Villafranca (Geneva, Switzerland)

**EP-39-990** Civil society and government against COVID-19: a comprehensive health equity promotion strategy by Partners In Health and the Ministry of Health in Chiapas, Mexico

Oral Presenter: Sebastian Gonzalez (Angel Albino Corzo, Mexico)
| EP-39-991 | Convergence approach to engage and empower village councils (Gram Panchayats) to improve public health and create TB-free villages in India |
| EP-39-992 | Strengthening TB survivor-led networks through structured leadership training: experiential learning from India |
| EP-39-994 | Community contribution to TB active case-finding |
| EP-39-995 | South-to-South collective learnings and challenges of communities working on TB stigma, discrimination and human rights |
| EP-39-996 | Identifying gender-related barriers in accessing TB diagnostic and treatment services in Kazakhstan, Tajikistan and Uzbekistan |

**Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments**

**Type: E-posters**

**Channel: E-posters (accessible on-demand)**
| EP-40-999 | TB services coping with COVID-19  
Challenges in TB treatment provision during the COVID-19 pandemic: perspectives from patients and health workers  
Oral Presenter: Juliet Nampala (Kampala, Uganda) |
| EP-40-1000 | A COVID-19 screening strategy based on the use of rapid antigen tests in healthcare facilities in Niger  
Oral Presenter: Franck Lamontagne (Paris, France) |
| EP-40-1002 | Addressing COVID-19 and other communicable diseases among internally displaced persons in Poltava, Ukraine  
Oral Presenter: Roman Rodyna (Kyiv, Ukraine) |
| EP-40-1003 | Multi-disease integrated outreaches to bridge the gap in TB and COVID-19 case detection in Bauchi State, Nigeria  
Oral Presenter: Amos Omoniyi (Abuja, Nigeria) |
Oral Presenter: Alaine Umubyeyi Nyaruhirira (Pretoria, South Africa) |
| EP-40-1005 | Community-based integrated screening and testing for TB and COVID-19 in Nelson Mandela Bay District, South Africa  
Oral Presenter: Freck Dikgale (Pretoria, South Africa) |
Oral Presenter: Ruby Maka Shrestha (Dhulikhel, Nepal) |
| EP-40-1007 | The pandemic is not the great equalizer: front-line labour and the work of rationing in COVID-19 critical care  
Oral Presenter: Neelima Navuluri (Durham, United States) |
Oral Presenter: Ubong Okon (Nigeria) |
<table>
<thead>
<tr>
<th>Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type: E-posters</td>
</tr>
<tr>
<td>Channel: E-posters (accessible on-demand)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP-41</th>
<th>COVID-19 a challenge for chest disease services</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP-41-1009</td>
<td>Lessons learnt from the COVID-19 pandemic: a Brazilian patients’ perspective</td>
</tr>
<tr>
<td>Oral Presenter: Carla Almeida (Porto Alegre, Brazil)</td>
<td></td>
</tr>
<tr>
<td>EP-41-1010</td>
<td>Gait speed is a promising functional performance measure in post-COVID patients</td>
</tr>
<tr>
<td>Oral Presenter: Asli Gorek Dilektasli (Turkey)</td>
<td></td>
</tr>
<tr>
<td>EP-41-1011</td>
<td>The impact of the COVID-19 pandemic on essential health, TB and HIV services in Free State Province, South Africa</td>
</tr>
<tr>
<td>Oral Presenter: Christo Heunis (Bloemfontein, South Africa)</td>
<td></td>
</tr>
<tr>
<td>EP-41-1012</td>
<td>Performance characteristics and operational feasibility assessment of a CRISPR-based Tata MD™ Check diagnostic test for COVID-19</td>
</tr>
<tr>
<td>Oral Presenter: Shubhada Shenai (Delhi, India)</td>
<td></td>
</tr>
<tr>
<td>EP-41-1013</td>
<td>Evaluation of a strategy combining medical triage and SARS-CoV-2 antigen rapid diagnostic tests to improve the diagnosis of COVID-19 in Mali</td>
</tr>
<tr>
<td>Oral Presenter: Guillaume Breton (Paris, France)</td>
<td></td>
</tr>
<tr>
<td>Oral Presenter: Javier Cabrera-Sanchez (Lima, Peru)</td>
<td></td>
</tr>
<tr>
<td>EP-41-1015</td>
<td>Post-hospitalisation lung function outcomes in patients with symptomatic COVID-19 disease from a tertiary facility, South Africa</td>
</tr>
<tr>
<td>Oral Presenter: Nicole Glover (Johannesburg, South Africa)</td>
<td></td>
</tr>
<tr>
<td>EP-41-1016</td>
<td>High COVID-19 seroprevalence at Ugandan TB clinics underlines the need to protect vulnerable populations</td>
</tr>
<tr>
<td>Oral Presenter: Brian Otaalo (Kampala, Uganda)</td>
<td></td>
</tr>
<tr>
<td>EP-41-1017</td>
<td>Implementation of bi-directional screening of COVID-19 and TB in community posts in Mozambique</td>
</tr>
<tr>
<td>Oral Presenter: Elzier Mavume Mangunyane (Maputo, Mozambique)</td>
<td></td>
</tr>
</tbody>
</table>
Reducing cost and time spent in screening, triaging and prioritising patients for COVID-19 and TB using the Swaasa AI Platform

Oral Presenter: Narayana Rao Sripada (Hyderabad, India)
Satellite session programme

Tuesday, November 8, 2022

Track: A4: Imaging and image analysis for diagnostics

Type: Satellite session

Channel 4

09:45 – 10:45

Advances in deployment of digital chest X-ray AI for tuberculosis screening and the road ahead

Chair: Amit Kharat (India)

Organised by: DeepTek Inc

Digital Chest X Ray as a diagnostic tool is a key component for TB screening. AI applications on Digital Chest X Ray for TB screening is an important aspect to ensure patients are not lost for follow up and instant triage results are available at the site of patient screening. This ensures point of care diagnostics which can potentially result in better care delivery in high risk and vulnerable populations. AI based screening alone may not be sufficient unless there is an end to end solution which captures key patient metrics, documents AI output, sputum sample collection, facilitates review, audit by experts and provides powerful analytics which can drive meaningful impact at the grass root level by giving deep insights. The expert panelist will share their experience on how these tools are impacting workflows at ground zero and how key policies are helping augment drive for TB elimination.

09:45 – 09:50

Introduction

Speaker: Amit Kharat (India)

09:50 – 09:59

Role of AI solutions in Active case finding in TB

Speaker: Suma Shivshankar (India)

09:59 – 10:08

Tamil Nadu's Experience in utilising the AI Solutions under programmatic conditions.

Speaker: Asha Frederick (India)

10:08 – 10:17

Mitigation of Delayed Care Seeking for TB screening using Mobile Diagnostic Units (MDUs)

Speaker: Sanskriti Goel (New Delhi, India)
10:17 – 10:26  Artificial Intelligence application for Screening Tuberculosis in Remote Healthcare setting – Lessons learnt and Way forward

Speaker: P S Balu (India)

10:26 – 10:35  Diagnosis of tuberculosis on chest radiographs - Reviewing the nuances!

Speaker: Bhavin Jankharia (India)

Track: B3: Clinical trials and operational research for new treatments for TB (for adults and children)

Type: Satellite session

Channel 3

18:15 – 19:45  Accelerating the development of new TB drugs and regimens

Chair: Debra Hanna (United States)

Chair: David Barros-Aguirre (London, United Kingdom)

UNITE4TB is a public-private partnership with representation from academic institutions, SMEs, public organizations, and pharmaceutical companies. The PAN-TB collaboration is a consortium of philanthropic, non-profit and private sector organizations that aims to accelerate the Phase 2 development of novel “pan-TB” drug regimens for the treatment of TB. These organizations are working on programs to deliver novel phase 2 clinical trials that will accelerate the development of new TB drugs and regimens. The regimens are designed to have little to no drug resistance and an improved safety and tolerability profile, relative to existing options. This session will describe both organizations, their composition, structure and governance. Objectives of the clinical programs will be discussed, focusing on coordination between the two groups, to maximize impact of these programs. These innovative collaborations are establishing a new partnership model to expedite TB clinical research.

18:15 – 18:20  Live introduction

18:20 – 18:32  U4TB study design

Speaker: Martin Boeree (Netherlands)

18:32 – 18:44  Perspective from the Joint Development Team

Speaker: Ramesh Dass (United Kingdom)
18:44 – 18:56
Clinical perspective
Speaker: David Holtzman (United States)

18:56 – 19:08
Biostatistics and Endpoints
Speaker: Patrick Phillips (United States)

19:08 – 19:20
Regulatory perspective on regimen development
Speaker: Karin Rombout (Belgium)

19:20 – 19:45
Live Q&A

Track: B7: Identification and management of TB infection
Type: Satellite session
Channel 4

18:15 – 19:45
Innovations to end TB infection while living with COVID-19
Chair: Vladyslav Nikolayevskyy (United Kingdom)

This session will focus on innovative laboratory tools for TB infection screening and their rollout in high TB incidence settings in the context of the End TB Strategy and re-prioritization of TB services while living with COVID-19. Speakers will discuss various aspects of TB infection screening and TB prevention as a part of living with COVID-19 concept including cost effectiveness and performance of the innovative QIAreach QFT assay, focusing on resource constrained setting that can benefit most from implementation of affordable and scalable solutions.

18:15 – 18:25
Live introduction, welcome and opening remarks. Introductory presentation
Speaker: Vladyslav Nikolayevskyy (United Kingdom)

18:25 – 18:35
Programmatic and global health aspects
Speaker: Marc Destito (Switzerland)

18:35 – 18:55
QIAreach QFT: clinical performance and results of early field studies
Speaker: Kwame Shanaube (Lusaka, Zambia)

18:55 – 19:15
Cost effectiveness of TB infection screening
Diagnosing tuberculosis is inherently challenging given that traditional sample types are difficult to collect, transport and process. Yet, without finding and diagnosing patients sooner, progress to control and eradicate TB will be elusive. Vulnerable populations such as children are often unable to produce a raw sputum necessary for conventional molecular diagnosis. To address these challenges and accelerate TB eradication, alternative sample types are necessary. In 2021, the World Health Organization has published diagnostic guidelines for a number of more sensitive molecular platforms. Through a panel discussion moderated by Roche Diagnostic Solutions, we explore how dorsal tongue swabs may enable more patients to be tested and treated with WHO approved molecular systems to benefit a broader population.

**Organised by: Roche**

18:15 – 18:20
**Introduction**

18:20 – 18:43
**Panel Discussion: Alternative sample type use cases**

Speaker: Anura David (South Africa)

18:43 – 19:03
**Panel Discussion: Future of TB diagnostics**

Speaker: Matilu Mwau (Kenya)

19:03 – 19:25
**Panel Discussion: Future of TB diagnostics**

Speaker: Adam Penn-Nicholson (Switzerland)

19:25 – 19:45
**Live Q&A**
Wednesday, November 9, 2022

Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: Satellite session

Channel 2

18:15 – 19:45

**TB diagnostic tools: leveraging COVID-19 innovations | FIND and NDWG Annual Symposium**

Chair: Daniela Maria Cirillo (Milan, Italy)

Chair: Camilla Rodrigues (India)

Organised by: FIND and the New Diagnostics Working Group (NDWG) of the Stop TB Partnership

Tuberculosis (TB) diagnostics that are non-sputum based, rapid, low-cost, and user-friendly are crucial to find the “missing millions”. In this session by FIND, the global alliance for diagnostics, and the Stop TB Partnership’s New Diagnostics Working Group (NDWG), the latest advancement in TB diagnostics research and development (R&D) will be explored. You will be engaged by presentations on the TB diagnostics pipeline, including sequencing, and TB technology pitches.

**List of speakers** -

**Presentation 4:** Tony Xu (USA), Alexander Kay (USA), Linda Xie (USA), Ellen H Mitchell (Belgium), Khalil Amoka Sani (Nigeria)

**Presentation 5:** Marc Matthews (South Africa), Xavier Ding (Switzerland), Chris Novak (USA)

18:15 – 18:20

**Live introduction**

18:20 – 18:30

**The TB diagnostics pipeline**

Speaker: Morten Ruhwald (Geneva, Switzerland)

18:30 – 18:40

**Evidence on oral swab analysis for TB detection**

Speaker: E. Chandler Church (United States)

18:40 – 18:50

**Use of targeted next generation sequencing for drug-resistant TB detection – Updates from Seq&Treat**

Speaker: Anita Suresh (Singapore)
18:50 – 19:10  
**Novel TB diagnostic tests**

Speaker: Tony Hu (United States)  
Speaker: Alexander Kay (Houston, United States)  
Speaker: Linda Xie (United States)  
Speaker: Ellen H Mitchell (Belgium)  
Khalil Amoka Sani (Nigeria)

19:10 – 19:20  
**TB technology pitch**

Speaker: Marc Matthews (South Africa)  
Speaker: Xavier Ding (Switzerland)  
Speaker: Christopher Novak (United States)

19:20 – 19:45  
**Live Q&A**

Track: C2: Care and treatment of TB (drug-sensitive and drug-resistant TB)  
Type: Satellite session  
Channel 3

18:15 – 19:45  
**Taking stock of digital adherence technologies: evidence synthesis and the path forward**

Chair: Amera Khan (Switzerland)  
Chair: Juliet Sekandi (Athens, United States)

Organised by: Tufts, McGill, and London School of Hygiene and Tropical Medicine supported by the Bill and Melinda Gates Foundation

In last decade, digital adherence technologies (DATs) are being increasingly used as part of tuberculosis (TB) care globally. This session will present recent evidence regarding DATs to facilitate discussion regarding the path forward for these technologies. We will disseminate preliminary findings of two systematic reviews, which aim to understand the impact of DATs on TB treatment outcomes and the implementation of DATs in
routine care. Preliminary findings will be presented from the multi-site ASCENT study and recent randomized trials of digital pillboxes conducted in China and South Africa. Finally, colleagues from the Chinese Center for Disease Control and Prevention and South Africa’s national TB program will discuss their experiences implementing DATs for TB care in those settings.

18:15 – 18:20
Live introduction

18:20 – 18:32
Effectiveness, cost-effectiveness, and accuracy of TB digital adherence technologies: evidence from systematic reviews
Speaker: Mona Salaheldin Mohamed (Canada)

18:32 – 18:44
Implementation of TB digital adherence technologies: findings of a systematic review using the RE-AIM framework
Speaker: Shruti Bahukudumbi (United States)

18:44 – 18:56
Lessons from recent implementation studies and pragmatic trials evaluating digital adherence technologies
Speaker: Katherine Fielding (United Kingdom)

18:56 – 19:08
Medication Event Reminder Monitors – the implementation experience in China
Speaker: Zhao Yanlin (China)

19:08 – 19:20
Health care provider reflections on using digital adherence technologies to care for people with TB
Speaker: David Sello Mavimbela (South Africa)

19:20 – 19:45
Live Q&A

Track: C8: Global and local policies and politics, including funding and accountability
Type: Satellite session
Channel 4

18:15 – 19:45
Improving the use of data tools and analytics for TB program planning
Chair: Kathy Fiekert (United Kingdom)
Chair: Jennifer Harris (United States)
Organised by: CDC Foundation

In addition to routine surveillance systems, there are numerous additional activities and tools that have been developed to assist countries in the collection and use of TB-related data like prevalence surveys, drug resistance surveys, inventory studies, patient pathway analyses, and the people-centered framework. While these activities provide important information, implementation of such activities can place a burden on Ministries of Health and partners and may not occur in an optimized and efficient manner. This session will highlight key findings from a project which documented the use and usefulness of these (supplemental) data-related activities at global and country level and the resulting recommendations for the optimization of data generation, review, and analysis efforts. Data was collected through literature review, key informant interviews, indicator mapping and a survey of NTPs. Following the presentation of findings, a panel representing country NTP programs and key partners will discuss the implications of these findings.

18:15 – 18:20  Live introduction
18:20 – 18:30  A mixed-methods approach to assess the use and usefulness of supplemental TB data activities

Speaker: Jennifer Harris (United States)

18:30 – 18:45  Key findings from the TB Data Optimization Project: Global perspectives

Speaker: Eveline Klinkenberg (Netherlands)

18:45 – 19:05  Key findings from the TB Data Optimization project: Country perspectives

Speaker: Rachel Fiorillo (United States)

19:05 – 19:30  Live panel discussion: Potential Implications of findings from the TB Data Optimization project: perspectives of National TB Programs and global partners

Speaker: Daniel Chin (United States)

19:30 – 19:45  Live Q&A

Track: C7: Access to quality TB care and services

Type: Satellite session

Channel 5
18:15 – 19:45  Implementation of Global EQA for Xpert and Truenat - lessons learned and value evaluation

Chair: Dean Sher (South Africa)
Chair: Anest Reyneke (South Africa)

Organised by: SmartSpot Quality

Describe the design and implementation of a Global EQA for Xpert and Truenat and review implementation, performance and lessons learned from Ghana, Cambodia, Zimbabwe, Namibia and India.

18:15 – 18:20  Live introduction

18:20 – 18:33  The role of quality in tuberculosis diagnosis and how EQAs will play a crucial role in maintaining the confidence on the performance of the lab

Speaker: Praveen Kamdasmy (India)

18:33 – 18:46  Xpert TB and HIV EQA implementation in Namibia

Speaker: Douglas Chiwara (Namibia)

18:46 – 18:59  Xpert TB - Ghana shares its experience, focus on funding challenges

Speaker: Felix Sorvor (Ghana)

18:59 – 19:12  Truenat TB - Zimbabwe shares its experience, focus on central EQA management

Speaker: Hebert Mutunzi (Zimbabwe)

19:12 – 19:25  Truenat TB - Cambodia shares its experience, focus on the value of training

Speaker: Chanthe Thor (Phnom Penh, Cambodia)

19:25 – 19:45  Live Q&A

Thursday, November 10, 2022
Track: A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments

Type: Satellite session

Channel 2

09:45 – 10:45

**DR-TB in Central Asia. Responding to the challenge**

Chair: Sevim Ahmedov (United States)

Organised by: USAID

This satellite session will focus on giving better visibility of challenges and solutions proposed by the USAID Eliminating Tuberculosis in Central Asia, the current epidemiology of DRTB, and the cascade of care implemented in the region, starting from the case finding, then diagnosis and treatment.

The topics to present are the fresh epidemiology data (it could be data on TB prevalence among migrants based on results of the active case finding, results of DRTB prevalence based on the regional Drug susceptibility testing data or prevalent mutations patterns), diagnostic pathways including XDR Xpert and molecular diagnostic methods, and we could present data on different treatment regimens implemented in the region. Other potentially interesting topics proposed for this session is patient-centered activities aiming to improve uptake and adherence to treatment, stigma and gender barriers, and key populations.

09:45 – 09:52

**Introduction**

Speaker: Sevim Ahmedov (United States)

09:52 – 10:06

**Gender-Related Barriers and Delays in Accessing Tuberculosis Diagnostic and Treatment Services: results of the assessment in Tajikistan, Uzbekistan, and Kazakhstan**

Speaker: Jamilya Ismoilova (Tajikistan)

10:06 – 10:19

**Emerging resistance against new TB drugs: how laboratory networks could mitigate the threat**

Speaker: Uladzimir Antonenka (Germany)

10:19 – 10:32

**TB laboratory network in the Central Asian region**

Speaker: Dzmitry Sinitski (Germany)

10:32 – 10:45

**Implementation of the new treatment regimens in the region**

Speaker: Oleksandr Telnov (Tashkent, Switzerland)
Track: B1: TB diagnostics – Operational and clinical studies

Type: Satellite session

Channel 4

18:15 – 19:45

SMART4TB: An Ambitious Initiative to Contribute to Ending TB Through Research, Capacity-Strengthening, Community Ownership, and Policy

Chair: Richard Chaisson (United States)

Chair: Payam Nahid (United States)

Organised by: Johns Hopkins University and USAID

The mission of the USAID-funded SMART4TB Consortium is to design and implement research studies in partnership with local partners that will identify effective person-centered methods for finding, treating, and preventing TB; to strengthen local capacity to conduct high-quality research; and to engage communities to build demand for new interventions, drive policy change, and improve implementation to reach the End TB targets. This session will describe the bold agenda set forth by the Consortium to leverage an extraordinary investment by USAID to help achieve the END TB goals and to engage with the TB community regarding additional research priorities.

Agenda to be confirmed